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ABSTRACT 
Depth-Sensitive Optical Spectroscopy for Noninvasive Diagnosis of Oral Neoplasia 
by 
Richard Alan Schwarz 
Oral cancer is the 11th most common cancer in the world. Cancers of the oral 
cavity and oropharynx account for more than 7,500 deaths each year in the United States 
alone. Major advances have been made in the management of oral cancer through the 
combined use of surgery, radiotherapy and chemotherapy, improving the quality of life 
for many patients; however, these advances have not led to a significant increase in 
survival rates, primarily because diagnosis often occurs at a late stage when treatment is 
more difficult and less successful. Accurate, objective, noninvasive methods for early 
diagnosis of oral neoplasia are needed. 
Here a method is presented to noninvasively evaluate oral lesions using depth-
sensitive optical spectroscopy (DSOS). A ball lens coupled fiber-optic probe was 
developed to enable preferential targeting of different depth regions in the oral mucosa. 
Clinical studies of the diagnostic performance of DSOS in 157 subjects were carried out 
in collaboration with the University of Texas M. D. Anderson Cancer Center. An overall 
sensitivity of 90% and specificity of 89% were obtained for nonkeratinized oral tissue 
relative to histopathology. Based on these results a compact, portable version of the 
clinical DSOS device with real-time automated diagnostic capability was developed. The 
portable device was tested in 47 subjects and a sensitivity of 82% and specificity of 83% 
were obtained for nonkeratinized oral tissue. 
The diagnostic potential of multimodal platforms incorporating DSOS was 
explored through two pilot studies. A pilot study of DSOS in combination with widefield 
imaging was carried out in 29 oral cancer patients, resulting in a combined sensitivity of 
94% and specificity of 69%. Widefield imaging and spectroscopy performed slightly 
better in combination than each method performed independently. A pilot study of 
DSOS in combination with the optical contrast agents 2-NBDG, EGF-Alexa 647, and 
proflavine was carried out in resected tissue specimens from 15 oral cancer patients. 
Improved contrast between neoplastic and healthy tissue was observed using 2-NBDG 
and EGF-Alexa 647. 
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1. INTRODUCTION 
1.1 Objective and Specific Aims 
The objective of this research is to develop a portable, noninvasive, depth-sensitive, 
point-probe spectroscopic device for diagnosis of oral neoplasia and evaluate its 
diagnostic potential in clinical studies. The specific aims are as follows: 
Specific Aim 1: Construct a compact, portable depth-sensitive optical spectroscopy 
(DSOS) device for detection of oral neoplasia, and evaluate its operating characteristics 
using optical calibration standards. 
Specific Aim 2: Evaluate the diagnostic performance of the portable DSOS device 
through clinical studies in populations with a range of neoplastic lesions (dysplasia and 
cancer) and benign lesions common in the at-risk population. A clinical study will be 
performed in a high-prevalence patient population at M.D. Anderson Cancer Center 
(target accrual 70 subjects) and a pilot study will be performed in an at-risk population 
(target accrual 25 subjects). 
Specific Aim 3: Carry out two pilot studies to evaluate the diagnostic potential of 
multimodal optical platforms using DSOS in combination with other diagnostic 
techniques: a pilot study combining fluorescence imaging and DSOS, and a pilot study 
combining molecular targeted contrast agents and DSOS. 
The intent is to provide a portable DSOS device that can be implemented as a 
diagnostic aid in high-prevalence patient populations, and potentially as a screening aid 
in primary care dental and medical environments in which an expert clinical observer is 
not available. Knowledge gained through this research will facilitate integration of new 
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diagnostic technologies to optimize oral cancer screening and surveillance in diverse 
patient populations. 
1.2 Overview 
This dissertation describes the development of a technique for depth-sensitive optical 
spectroscopy (DSOS) for diagnosis of oral neoplasia, the implementation and clinical 
evaluation of DSOS, and the combination of DSOS with other diagnostic methods. The 
dissertation is organized as follows. 
Chapter 1 lists the specific aims of the research and provides a brief overview of 
the topics and clinical studies to be discussed. 
Chapter 2 provides background information on oral cancer, premalignant lesions, 
methods for detection and diagnosis, and optical diagnostic techniques. Imaging and 
spectroscopic techniques for diagnosis of oral precancer are reviewed. 
Chapter 3 describes the design and development of a ball lens coupled fiber optic 
probe for in vivo depth-sensitive optical spectroscopy (DSOS) of oral tissue. This basic 
probe design is used in all versions of the clinical spectroscopy instruments described in 
subsequent chapters. 
Chapter 4 describes the clinical implementation of DSOS. Autofluorescence and 
diffuse reflectance spectra of oral epithelial tissue are measured in vivo using a clinical 
DSOS instrument. Procedures for calibration and data processing are described. 
Chapter 5 describes a clinical study of the diagnostic performance of DSOS in 
124 subjects measured in vivo, including 60 oral cancer patients and 64 healthy 
volunteers. The development and training of an automated diagnostic algorithm are 
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described. Diagnostic performance is evaluated in a training set and in a validation set. 
Optimum features for diagnostic classification are identified. 
Chapter 6 reports the results of a validation study of the DSOS method and 
algorithm described in Chapter 5, performed using a subset of the illumination 
configurations and probe depth channels used previously. Measurements in vivo of an 
additional 33 subjects, including 20 oral cancer patients and 13 normal volunteers, form a 
second validation set. Diagnostic performance is compared to earlier results. 
Chapter 7 describes the design and construction of a compact, portable DSOS 
device as outlined in Specific Aim 1. The results of the clinical studies described in 
Chapters 4-6 are critically important in the design of the portable device. The operating 
characteristics of the portable instrument are evaluated using optical calibration 
standards. The implementation of software for real-time diagnosis is described. 
Chapter 8 presents clinical studies of the portable DSOS device as outlined in 
Specific Aim 2. Similarities and differences between the earlier DSOS instrument and 
the portable DSOS device are described. The algorithm previously developed in 
Chapter 5 is used to classify measured sites. Results of in vivo measurements of 47 
subjects, including 16 oral cancer patients, 11 high-risk subjects, and 20 healthy 
volunteers, are presented. 
Chapter 9 describes a pilot study combining widefield fluorescence imaging with 
DSOS for multimodal diagnosis, as outlined in Specific Aim 3. Results of in vivo 
measurements of 29 oral cancer patients are presented and methods for combining the 
data from both instruments are explored. 
Chapter 10 describes a pilot study combining DSOS with optical contrast agents 
for multimodal diagnosis, as outlined in Specific Aim 3. Results of measurements of 
resected tissue specimens from 15 oral cancer patients are described. 
Chapter 11 summarizes the results of the various studies and concludes with a 
discussion of the status of DSOS for diagnosis of oral neoplasia. Chapter 12 lists 
references cited. 
1.3 List of clinical studies 
Table 1 lists the clinical studies that are discussed in this dissertation, the specific aim 
each study is associated with, the measurement device(s) used, target accrual, actual 
accrual, and the chapter in which each study is described. 
Table 1, List of clinical studies. 
Clinical Specific 
Study Aim Measurement Device(s) Target Accrual Actual Accrual Chapter 
A - DSOS - 124 patients & vols 5 
B - DSOS - 33 patients & vols 6 
C 2 Portable DSOS 70 patients 16 patients 8 
D 2 Portable DSOS 25 hi risk subj 20 vols + 11 hi risk subj 8 
E 3 DSOS + Widefield Imaging 10-15 patients 29 patients 9 
F 3 DSOS + Contrast Agents 10-15 patients 15 patients 10 
Clinical Study A represents prior work, discussed here because it was the study in 
which the DSOS clinical method and algorithm were developed. Clinical Study B is a 
subsequent validation study of DSOS; it was not called out in the specific aims but is 
included here because it was done in parallel with the construction of the portable DSOS 
system and bears directly on the design of that system. 
Clinical Studies C and D are studies of the portable DSOS system associated with 
Specific Aim 2. The construction of the portable DSOS device was completed on 
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schedule in April 2009. Due to a six-month delay in protocol approval, clinical study C 
did not begin until November 2009; accrual to date is therefore lower than expected at 16 
patients. The six month time period was used to develop real-time analysis software as 
described in Chapter 7 and to construct a second portable DSOS device. Similarly, due 
to a delay in the startup of the collaboration with the University of Texas Dental Branch, 
Clinical Study D proceeded initially with measurements of healthy volunteers at Rice 
University, and is now continuing with measurements of high risk subjects at the UT 
Dental Branch. To date 20 healthy volunteers and 11 high risk subjects have been 
accrued on Clinical Study D. 
Clinical Studies E and F are studies of multimodal diagnostic platforms associated 
with Specific Aim 3. Accrual on Clinical Study E was 29 patients and accrual on 
Clinical Study F was 15 patients. 
2. BACKGROUND 
2.1 Motivation and significance 
Oral cancer is the 11th most common cancer in the world. An estimated 390,000 new 
cases are diagnosed each year worldwide, with the highest incidence rates in India, 
Pakistan, Australia, France, Brazil, and South Africa (1). Cancers of the oral cavity and 
oropharynx are annually responsible for more than 7,500 deaths in the United States and 
an estimated 127,000 deaths worldwide (2, 3). Risk factors include advanced age 
(persons 60 years or older are at greatest risk); use of tobacco, alcohol, betel quid, areca 
nut and paan; immunological compromise; unhealthy diet; and infection with the human 
papilloma virus (HPV), particularly HPV-16 (4, 5). Oral cancer affects men more 
frequently than women, with the male:female ratio of occurrence varying from 2:1 to 
15:1 depending on the anatomic site (1). The tongue is the most common site for the 
development of oral cancer, followed by the floor of mouth. In Southeast Asia, however, 
oral cancer most commonly arises from the buccal mucosa due to the use of betel nut (6). 
Methods for management of oral cancer have improved significantly in the past 
thirty years, including the combined use of surgery, radiotherapy, and chemotherapy (7). 
Despite these advances, there 
has been little change in patient 
survival rates (8). In the United 
States, patients diagnosed with 
oral or oropharyngeal cancer 
have an overall five-year 
survival rate of 59% relative to 
100 -r 
80 
60 
40 
20 
0 4 
Regional Distant 
Fig. 1. Five-year oral cancer survival rates (%) in the United 
States, by stage of cancer at the time of diagnosis (2). The 
overall survival rate is 59%. 
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people of the same age group, gender, and ethnicity who do not have cancer (2). Patients 
with early lesions have better chances for cure and less treatment associated morbidity; 
yet oral cancer is often diagnosed at an advanced stage, when treatment is more difficult, 
more expensive and less successful compared to earlier interventions (4, 6). Figure 1 
shows five-year oral cancer survival rates in the United States by stage of cancer 
(localized, regional, or distant) at the time of diagnosis. The drastic difference in survival 
rates for early vs. late diagnosis indicates that early detection of neoplastic changes may 
be the best and most cost-effective means to improve survival and quality of life for 
patients (9). A simple, automated method to enable healthcare workers to screen high 
risk individuals for suspicious oral lesions and to evaluate the risk of malignant 
conversion is needed. 
2.2 Oral premalignant lesions and malignant progression 
Clinically visible lesions that have the potential for conversion to malignancy are called 
oral premalignant lesions (OPLs). OPLs may be white (leukoplakia), red (erythroplasia, 
erythroplakia), or white with a red component (erythroleukoplakia). The term 
leukoplakia is used to describe a clinical white patch or plaque on the oral mucosa that 
cannot be scraped off and cannot be classified clinically or microscopically as another 
disease (10). Leukoplakia (shown in Figure 2a) is benign by definition but has a rate of 
malignant transformation estimated at 1-25% (11-15). Similarly, the term erythroplakia 
describes a lesion of the oral mucosa that presents as bright red velvety plaques that 
cannot be characterized clinically or pathologically as another condition (16). 
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Erythroplakia (Figure 2b) is less common than leukoplakia but carries a higher risk of 
malignant conversion (10). 
The risk of malignant progression in OPLs is typically evaluated by invasive 
biopsy, hematoxylin and eosin staining, and pathologic evaluation for neoplasia 
(dysplasia or cancer). The purpose of histopathologic examination is to exclude any 
definable benign condition and to establish the degree of epithelial dysplasia or invasive 
carcinoma, if present (17). OPLs with severe dysplasia (also called carcinoma in situ, or 
CIS) are likely to progress to cancer. However, most leukoplakia lesions have 
mild/moderate dysplasia, or no dysplasia, and are therefore at much lower risk for 
malignant conversion. For this reason the risk of malignant progression is extremely 
difficult to determine by visual inspection alone. 
Furthermore, the oral cavity is susceptible to a wide variety of benign lesions that 
can mimic the appearance of OPLs. Three examples are listed here. Oral lichen planus 
(Figure 2c) is a T-cell-mediated inflammatory oral mucosal disease that affects 1-2% of 
the adult population (18). Lichen planus is considered benign, although suggestions that 
it is associated with an increased risk of malignant transformation remain a source of 
controversy (19-21). Pemphigus vulgaris (Figure 2d) is an autoimmune mucous 
membrane disease that causes blisters, erosions, and ulcers on the oral mucosa (22, 23). 
While pemphigus vulgaris is a serious disease, it is not a premalignant oral lesion. 
Geographic tongue is a benign condition marked by smooth, maplike, erythematous 
patches on the dorsal tongue (24). It involves atrophy of the papillae of the tongue 
surrounded by a white hyperkeratotic rim (25). These and many other benign conditions 
make the task of visual evaluation of oral lesions difficult even for experienced clinicians. 
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(a) Leukoplakia (b) Erythroplakia 
(c) Lichen planus (d) Pemphigus vulgaris 
Fig. 2. Top row: Oral premalignant lesions (a) leukoplakia and (b) erythroplakia. Bottom row: 
benign oral lesions (c) lichen planus and (d) pemphigus vulgaris. 
2.3 Current and emerging methods for screening and diagnosis 
As illustrated in Figure 3, studies of methods for oral cancer diagnosis tend to take place 
in one of two clinical settings: screening studies in low-prevalence general populations, 
in which an expert observer's diagnosis is the gold standard; or diagnostic studies in 
high-prevalence referral populations, in which histopathology is the primary gold 
standard. Screening studies typically compare the performance of a non-expert observer, 
such as a health worker or general dentist, to that of an expert observer such as an oral 
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cancer specialist. Diagnostic studies typically compare the performance of an expert 
observer or a diagnostic aid in a high-risk population to a gold standard that is based on 
histopathology for a large fraction of cases. 
Population 
Typical 
observer and 
gold standard 
Primary desired 
characteristic of 
test 
SCREENING SETTING DIAGNOSTIC SETTING 
General population: 
Low prevalence Screen 
positive 
Referral population: 
High prevalence 
Non-expert observer 
(dentist, family practitioner, 
health worker) 
Gold standard: Expert 
observer's diagnosis 
Expert observer 
(oral cancer 
specialist) 
Gold standard: Biopsy 
and histopathology 
High specificity 
(to rule out disease) 
High sensitivity 
(to identify disease) 
Fig. 3. Screening and diagnostic clinical settings. 
The performance of visual oral examination in the screening setting has been 
systematically reviewed by Downer et al (26). Downer's meta-analysis resulted in a 
weighted pooled sensitivity of 85% and a specificity of 97%. Other reports of the 
performance of visual oral screening include Sankaranarayanan et al (sensitivity 77%, 
specificity 76%), Ramadas et al (sensitivity 82%, specificity 85%), and Nagao et al 
(sensitivity 92%, specificity 64%) (27-29). When these studies are included along with 
the eight studies cited by Downer, the weighted pooled sensitivity and specificity for the 
screening setting are, respectively, 80% and 82% (Figure 4a). Studies involving toluidine 
blue staining in high-risk referral populations can provide information about the 
performance of visual examination by an expert observer in a diagnostic setting in which 
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histopathology is the gold standard. Gray et al (30) identified fourteen studies that 
assessed the use of toluidine blue as an adjunct to visual diagnosis of oral cancer. 
Figure 4b shows the sensitivity and specificity for the studies cited by Gray. From these 
studies the weighted and pooled sensitivity and specificity of "enhanced" visual exam in 
the diagnostic setting are 87% and 75%. 
(a) Visual Examination / SCREENING SETTING (b) Visual Exam with Toluidine Blue/DIAGNOSTIC SETTING 
0.3 
0.2 
0.1 
0 
^ Meta-analysis in Downer 2004 
A Low-prevalence studies cited in Downer 2004 
• High-prevalence studies cited in Downer 2004 
O Other studies 
• Weighted pooled values including other studies 
0.4 0.6 
1-Specificity 
0.8 
• Weighted pooled values from Gray 2000 
O Studies cited in Gray 2000 
0.4 0.6 
1-Specificity 
Fig. 4. Reported sensitivity and specificity of visual examination (a) in a screening setting and (b) with 
toluidine blue staining in a diagnostic setting. 
A number of other new techniques have emerged to improve early detection and 
diagnosis: the OralCDx BrushTest™ (OralCDx Laboratories, Inc.), the ViziLite Plus 
oral lesion identification system (Zila Pharmaceuticals, Inc.), and the VELscope™ (LED 
Dental, Inc.). The performance of these techniques has been reviewed by Lingen et al 
(31). For the OralCDx test, reported performance varies from nearly perfect (sensitivity 
100%), specificity 93%) to worthless (sensitivity 52%, specificity 29%) (32-35). Two 
studies have reported that the ViziLite system has a high sensitivity (100%) but an 
extremely low specificity (14%» and 0%) (36, 37). Promising results have been obtained 
in an early pilot study with the VELscope™ (sensitivity 98%>, specificity 100%) (38). As 
noted by Lingen (31), these techniques show promise but none has been proven 
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definitively to provide better sensitivity and specificity than conventional oral 
examination. Meanwhile, there remains an urgent need for effective diagnostic aids, as a 
significant fraction of dentists and health care workers do not feel adequately trained to 
perform oral cancer screening and diagnosis (39-41). 
2.4 Optical detection and diagnosis 
The development and progression of oral neoplasia are associated with a variety of 
changes in tissue optical properties. These changes arise from alterations in the 
concentration of fluorophores such as reduced nicotinamide adenine dinucleotide 
(NADH), flavin adenine dinucleotide (FAD), and keratin; changes in fluorescent collagen 
crosslinks in the underlying stroma; changes in tissue scattering due to alterations in cell 
morphology; changes in hemoglobin absorption due to increased microvascularization; 
and changes in the thickness of the epithelial layer (38, 42-50). The morphological and 
biochemical changes that take place in the epithelium and supporting stroma during 
disease progression are depth-dependent in nature (Figure 5). Early dysplastic changes 
V':-
-
Fig. 5. Histopathology image showing depth-dependent changes in oral tissue with the development of 
cancer. Right side of image shows dysplasia, with layered structure of epithelium and supporting 
stroma still intact. Left side of image shows cancer with associated breakdown of layered structure. 
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such as increasing nuclear size and density, increasing pleomorphism, and increasing 
metabolic activity occur in the epithelium (51, 52). Thus the epithelial layer (from the 
tissue surface to a typical depth of 300-500 microns in the oral cavity) is critical for 
diagnosis of precancer. 
A variety of optical techniques including spectroscopy, widefield imaging, and 
high-resolution imaging can be used to detect neoplastic changes. As early as 1924 
Policard used a Wood lamp to observe red fluorescence from necrotic rat sarcomas (53). 
In the 1950s and 1960s the fluorescence properties of cellular macromolecules and intact 
cells were studied, and the use of fluorescence to characterize oxidation-reduction 
changes in cells was demonstrated (54-56). In the 1980s Alfano et al measured 
differences in the spectral profiles of malignant and normal human tissues (57). The late 
1980s and 1990s saw increasingly widespread applications of optics to detection of 
precancer and cancer, with the development and application of spectroscopic methods 
(43, 58-61), imaging methods (62, 63), and combinations of both techniques (64, 65). 
Since 2000 there has been an explosion of interest in optical diagnosis, with increasingly 
sophisticated and complex optical instrumentation and diagnostic algorithms for 
spectroscopy (47, 66-78), imaging (38, 79-90), and multimodal methods (52, 91, 92). A 
number of review articles surveying this work have been published (9, 31, 93-97). 
Despite advances in instrumentation and modeling, interpretation of 
spectroscopic measurements made from intact tissue is difficult. The precise mechanisms 
underlying the observed changes in tissue autofluorescence are not well understood (84). 
As neoplastic lesions develop, the optical properties of both the epithelium and stroma 
change, often in different ways. Fiber probes that can localize spectroscopic information 
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by depth to distinguish epithelial and stromal optical signatures may improve the ability 
of spectroscopy to noninvasively evaluate progression of precancerous changes. The 
ability to target the epithelial layer, where early precancerous changes occur, is of 
particular interest. Chapter 3 describes a novel probe design for depth-sensitive optical 
spectroscopy that has been developed for this purpose. 
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3. BALL LENS COUPLED FIBER-OPTIC PROBE FOR DEPTH-RESOLVED 
SPECTROSCOPY OF EPITHELIAL TISSUE3 
"The contents of this chapter have been published in the following journal article: Schwarz RA, Arifler D, 
Chang SK, Pavlova I, Hussain IA, Mack V, Knight B, Richards-Kortum R. Ball lens coupled fiber optic 
probe for depth-resolved spectroscopy of epithelial tissue. Opt Lett. 2005;30:1159-1161. 
Abstract: A ball lens coupled fiber optic probe design is described for 
depth-resolved measurements of the fluorescence and reflectance 
properties of epithelial tissue. The performance of the probe is 
characterized using a reflectance target, fluorescence targets, and a two-
layer tissue phantom consisting of fluorescent microspheres suspended in 
collagen. Localization of the signal to within 300 microns of the probe tip 
is observed using reflectance and fluorescence targets in air. Differential 
enhancement of the fluorescence signal from the top layer of the two-layer 
tissue phantom is observed. 
Optical spectroscopy is emerging as an effective diagnostic technique for noninvasive 
detection of cancers and precancers that originate in the epithelial lining of organs such as 
the uterine cervix, the oral cavity, the urinary bladder, and the esophagus (98). The 
progression of precancer in these tissues produces morphologic and biochemical changes 
in the epithelium and supporting stroma. These changes include alterations in epithelial 
cell morphology and metabolic activity, changes in stromal protein morphology and 
crosslinking, and increasing stromal angiogenesis. As a result, the concentration and 
distribution of endogenous fluorophores such as reduced nicotinamide adenine 
dinucleotide (NADH), flavin adenine dinucleotide (FAD), keratin, tryptophan, and 
collagen crosslinks, and absorbers such as hemoglobin, are altered with the progression 
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of precancer (46). Thus knowledge of the depth-dependent distribution of chromophores 
may have important diagnostic significance. 
Endogenous chromophores can be detected noninvasively in vivo using fiber optic 
fluorescence and reflectance spectroscopy. Many fiber optic probe designs collect the 
integrated signal from both the epithelium (which is typically on the order of 300 um 
thick) and the underlying stroma. In these systems, sophisticated analysis strategies are 
required to deconvolve spectroscopic data to yield quantitative concentrations of 
chromophores, and little information about depth related changes is obtained. Fiber 
probes that can localize spectroscopic information by depth to distinguish epithelial and 
stromal optical signatures should improve the ability of spectroscopy to noninvasively 
evaluate progression of precancerous changes. 
A variety of probe designs for obtaining localized or depth-resolved spectroscopic 
data have been reported (99, 100). Single-fiber probe configurations, in which the same 
fiber is used for illumination and collection, are sensitive to light scattering from 
superficial tissue regions (101, 102). However, the use of single-fiber probes for optical 
measurements is limited by lower signal to noise ratios due to autofluorescence generated 
by impurities in the fiber core, and by specular reflection from fiber surfaces. With 
multiple-fiber probes, many different configurations are possible. Straight-fiber 
geometries with different source-detector separations allow some depth discrimination; 
however, in epithelial tissue the signal from the stroma tends to dominate, even at 
minimum source-detector separation (103). Angled illumination and collection fibers can 
be used to target specific depth regions (104, 105). Targeting the epithelial layer, 
however, requires steep angles that may be impractical for clinical probe designs. Other 
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strategies include variation of the diameter of the illumination and collection fibers and 
variation of the probe-to-tissue distance (106). 
Spherical tips and ball lenses have been used for a variety of purposes in optical 
probes for biomedical applications. Spherical tips have been employed to improve light 
delivery in photodynamic therapy (107). On-axis configurations using ball lenses and 
half-ball lenses have been described (100). A ball lens probe with a central illumination 
fiber surrounded by collection fibers was used for signal enhancement in Raman 
spectroscopy of tissue (108). 
In this Letter we describe the design and characterization of a ball lens coupled, 
multiple fiber, contact probe for depth-resolved fluorescence and reflectance 
spectroscopy of epithelial tissue. Different source-detector separations used in 
combination with a sapphire ball lens provide a variable geometric overlap between the 
illumination and collection regions, allowing depth discrimination. The probe design is 
illustrated in Figure 6a. The illumination and collection fibers have a core diameter of 
200 um and a numerical aperture of 0.22. The fiber ends are separated from the sapphire 
ball lens by a 0.5 mm air gap. The collection fiber is positioned on the central axis of the 
ball lens and two illumination fibers are symmetrically positioned off-axis. 
The angle at which the illumination paths intersect the collection region grows 
steeper with increasing source-detector separation and with decreasing ball lens diameter. 
As shown in Figure 6b, a ray traveling in air that enters the ball lens parallel to the probe 
axis at a displacement d from the centerline experiences a total angular deviation 0 as it 
passes through the lens and exits into tissue: 
6 = sin"1 - 2 sin" 
f
 d ^ 
\RnLj 
+ sin ' 
f
 d ^ 
yRnT i 
(1) 
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where d is the displacement from centerline, R and ni are the radius and refractive index 
of the ball lens, and nr is the refractive index of the tissue. Depth localization of the 
detected signal is determined by the overlap of the angled illumination rays and the 
collection region. Wavelength alone may also have an effect on the penetration depth, a 
factor which is not included in this model. Maximum sensitivity to the superficial tissue 
region is achieved when the illumination paths intersect the detection cone at the distal 
surface of the ball lens, then diverge rapidly. The diverging illumination beams are 
visible in Figure 7, which is a photograph of the ball lens coupled probe illuminating a 
quartz cuvette containing the fluorescent dye Rhodamine. 
Illumination 
fiber 
Collection 
fiber 
Ball lens 
(2 mm dia.) 
Illumination 
fiber 
(a) 
d - H 
(b) 
Fig. 6. (a) Ball lens coupled probe, showing illumination ray paths (solid lines) and collection 
region (dashed lines). A typical epithelial thickness of 300 um is shown for reference, (b) Angular 
deviation of a ray incident parallel to the probe axis. 
The performance of the ball lens coupled probe design was characterized 
experimentally with a 2-mm diameter ball lens using center-to-center source-detector 
separations of 500 um and 750 um. The ball lens was supplied by Edmund Industrial 
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Optics (Barrington, NJ). The experimental setup included a Xenon light source (ISA Inc., 
Edison, NJ); bandpass filters (Chroma Technology Corp., Rockingham, VT); the ball lens 
coupled probe; an imaging spectrograph (Chromex 250is); and a TE cooled CCD detector 
(DV420-BU, Andor Technology). 
Experiments to evaluate depth 
localization were conducted using 
a reflectance target at a variable 
distance, fluorescence targets at a 
variable distance, and a two-layer 
tissue phantom in contact with 
the probe. 
For the experiments involving targets at a variable distance, a thin reflective or 
fluorescent target was placed near the tip of the probe (in air) and the intensity of the 
detected reflectance or fluorescence signal was measured as a function of probe-to-target 
distance. The reflectance target was a 125 um thick sheet of white business paper 
(Southworth P403C). The fluorescence targets were single-layer tissue phantoms of 400 
urn nominal thickness, consisting of fluorescent polystyrene microspheres (Bangs 
Laboratories, Fishers, IN) embedded in collagen gels. The procedure used for the 
preparation of the collagen gels has been previously described (109). Three types of 
fluorescent microspheres were used, with the following excitation/emission peak 
wavelengths, diameters, and concentrations: (a) 370nm/425nm, 1.89 jam diameter, 
1.2 x 109 spheres/mL; (b) 450 nm/490 nm, 2.72 um diameter, 5.7 x 108 spheres/mL; (c) 
633-650 nm/680 nm, 5.49 jam diameter, 5.0 x 107 spheres/mL. The scattering parameters 
Fig. 7. Photograph of the ball lens coupled probe 
illuminating a cuvette containing the fluorescent dye 
Rhodamine. 
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of each tissue phantom were calculated at the corresponding excitation wavelength using 
Mie theory. The contribution of collagen to the total scattering and fluorescence is not 
significant due to its low concentration in the gel. The calculated values roughly 
approximate the scattering parameters of epithelial tissue (110): (a) us=79 cm"1, g=0.93; 
(b) u,=57 cm"1, g=0.90; (c) us=30 cm"1, g=0.92. 
Results obtained with the reflectance target are displayed in Figure 8. For the 750 
urn source-detector separation, the normalized intensity drops to half-maximum at an 
average probe-to-target distance of 136 um, and to 10% of maximum at an average 
distance of 274 um. For the 500 um source-detector separation, the normalized intensity 
drops to half-maximum at an average distance of 340 um, and to 10% of maximum at an 
average distance of 565 um. Similar results were obtained with the single-layer 
fluorescence targets (not shown). 
Reflectance Data With 2-mm Ball Lens 
i; 370 nm 
i; 450 nm 
i; 633 nm 
i; 370 nm 
i; 450 nm 
i; 633 nm 
0 200 400 600 800 1000 
Distance to Target (um) 
Fig. 8. Normalized reflectance signal as a function of probe-to-target distance. Source-detector 
separation and illumination wavelength are noted. Half-maximum intensity occurs at an average 
distance of 136 um (for 750 um separation) or 340 um (for 500 um separation). 
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The two-layer tissue phantom consisted of two stacked layers of fluorescent 
microspheres suspended in collagen, each 400 um thick and prepared identically to the 
single-layer phantoms (a) and (b) described above. The probe was placed in contact with 
the tissue phantom and fluorescence emission spectra were obtained at 370 nm and 450 
nm excitation sequentially. Excitation at 370 nm preferentially excites fluorescence in 
the top layer, and some residual fluorescence in the bottom layer, while 450 nm 
excitation preferentially excites fluorophores in the bottom layer. These measurements 
were performed with a straight-fiber probe (no ball lens; single illumination fiber with 
adjacent collection fiber at 250 um source-detector spacing), and with the ball lens 
coupled probe configuration selected for optimum depth localization (two illumination 
fibers with 2-mm diameter ball lens and 750 um source-detector separation). Excitation 
power values in the straight-fiber configuration were 0.30 uW (370 nm) and 2.4 uW (450 
nm), and in the ball lens configuration 0.45 uW (370 nm) and 3.4 p,W (450 nm). The 
exposure time was 1 second in all cases. To facilitate comparison, all two-layer phantom 
fluorescence spectra were background corrected and divided by the corresponding 
excitation energy. 
Figures 9 and 10 show the detected fluorescence signal at 370 nm and 450 nm 
excitation from the two-layer phantom. Relative to the straight-fiber probe configuration 
(Figure 9), the ball lens probe configuration (Figure 10) collects 3.8 times as much 
fluorescence signal from the top layer and 0.74 times as much fluorescence signal from 
the bottom layer. In the straight-fiber case, the 370 nm excited fluorescence spectrum 
displays a "shoulder" due to the fact that the bottom layer does produce some 
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fluorescence at 370 nm excitation. This contribution from the lower layer is significantly 
reduced by the use of the ball lens coupled probe. 
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Fig. 9. Two-layer tissue phantom fluorescence data: straight fiber probe at minimum source-
detector separation (250 um), corrected for excitation energy. 
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Fig. 10. Two-layer tissue phantom fluorescence data: ball lens coupled probe with 2-mm diameter 
ball lens and 750 um source-detector separation, corrected for excitation energy. 
23 
These preliminary results indicate that the ball lens coupled fiber optic probe has 
the potential to enable depth-resolved measurements of the reflectance and fluorescence 
properties of tissue. The depth profile of the probe is controllable through the selection 
of source-detector fiber spacing and ball lens diameter. The geometry described here can 
be extended to concentric rings of illumination fibers to increase the signal to noise ratio. 
The ability to selectively target the epithelium may improve the performance of optical 
spectroscopy as a diagnostic tool for detection of cancers that originate in epithelial 
tissue. 
The authors gratefully acknowledge support from NCI Grant No. R01 CA095604. 
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4. AUTOFLUORESCENCE AND DIFFUSE REFLECTANCE SPECTROSCOPY OF 
ORAL EPITHELIAL TISSUE USING A DEPTH-SENSITIVE FIBER-OPTIC PROBEb 
bThe contents of this chapter have been published in the following journal article: Schwarz RA, Gao W, 
Daye D, Williams MD, Richards-Kortum R, Gillenwater AM. Autofluorescence and diffuse reflectance 
spectroscopy of oral epithelial tissue using a depth-sensitive fiber-optic probe. Appl Opt. 2008;47:825-834. 
Abstract: Optical spectroscopy can provide useful diagnostic information about 
the morphological and biochemical changes related to the progression of 
precancer in epithelial tissue. As precancerous lesions develop, the optical 
properties of both the superficial epithelium and underlying stroma are altered; 
measuring spectral data as a function of depth has the potential to improve 
diagnostic performance. We describe a clinical spectroscopy system with a 
depth-sensitive, ball lens coupled fiber-optic probe for noninvasive in vivo 
measurement of oral autofluorescence and diffuse reflectance spectra. We report 
results of spectroscopic measurements from oral sites in normal volunteers and in 
patients with neoplastic lesions of the oral mucosa; results indicate that the 
addition of depth selectivity can enhance the detection of optical changes 
associated with precancer. 
4.1 Introduction 
Cancers of the oral cavity and oropharynx are annually responsible for more than 7,500 
deaths in the United States and an estimated 127,000 deaths worldwide (2, 3). In the 
United States, patients diagnosed with oral or oropharyngeal cancer have a five-year 
survival rate of 59% relative to people of the same age group, gender, and ethnicity who 
do not have cancer (2). This survival rate has changed little over the past thirty years, in 
part because most patients present with disease that is already at an advanced stage (8). 
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Better methods for early detection and diagnosis of oral cancer are needed to improve 
patient outcomes. 
Standard clinical practice for diagnosis of oral cancer consists of visual inspection 
followed by invasive biopsy and histologic examination of any sites that appear 
abnormal. However, visual identification of the more subtle changes associated with 
early lesions can be difficult even for experienced clinicians. Most clinically apparent 
oral lesions, such as candidiasis and aphthous ulcers, are benign; other lesions, such as 
leukoplakia, are associated with a risk of malignant progression that is difficult to judge 
by appearance alone. Furthermore, especially in patients with chronic exposure to 
carcinogens, histologic and genetic damage may exist even in areas in which the mucosa 
appears normal (82). 
A variety of technologies designed to aid the clinician in detecting and diagnosing 
oral neoplasia are under development (9). Optical spectroscopy is a noninvasive 
technique whose potential to facilitate diagnosis of oral lesions has been demonstrated by 
a number of groups (58, 60, 65-68, 72). Loss of auto fluorescence in the blue-green region 
of the spectrum is thought to be diagnostically significant, and according to recent reports 
may be associated with subclinical genetic alterations in the cancer risk field (82); but the 
nature of this association has not been explained. 
The development and progression of oral neoplasia has been reported to be 
associated with a variety of changes in tissue optical properties, including changes in the 
concentration of fluorophores such as reduced nicotinamide adenine dinucleotide 
(NADH), flavin adenine dinucleotide (FAD), and keratin; changes in fluorescent collagen 
crosslinks in the underlying stroma; changes in tissue scattering due to alterations in cell 
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morphology; changes in hemoglobin absorption due to increased microvascularization; 
and changes in the thickness of the epithelial layer (38, 42, 43, 47). While fluorescence 
microscopy studies of excised fresh tissue provide insight into the spatial dependence of 
optical property changes that accompany neoplasia (111, 112), it is more difficult to 
interpret spectroscopic measurements made from intact tissue. The precise mechanisms 
underlying the observed changes in tissue autofluorescence are not well understood (84). 
As neoplastic lesions develop, the morphological and biochemical properties of both the 
epithelium and stroma change, often in very different ways. If tissue spectra are acquired 
in vivo using an optical system which simply integrates optical signals arising from 
different depths, then optical changes arising in the epithelium and stroma may produce 
dissimilar or even opposing contributions to spectra measured from intact tissue. While a 
variety of mathematical models have been developed to analyze measured tissue spectra 
and deconvolve optical changes which occur in the epithelium and stroma, most of these 
models include many variables that describe multiple competing effects, and typically 
require prior knowledge or assumptions regarding some input parameters such as the 
depth-dependent distribution of specific chromophores in the tissue (113-116). Results 
generated by these models, such as concentrations of fluorophores in tissue in vivo, are 
difficult to validate. 
These issues must be addressed as optical spectroscopy and spectroscopic 
imaging move increasingly into clinical use for detection and diagnosis of oral lesions. 
The use of a depth-sensitive spectroscopy device that is capable of selectively targeting 
the epithelium or stroma may provide a means of overcoming some of these limitations. 
The ability to disentangle the changes in optical properties which arise in the epithelium 
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and stroma may prove useful in improving the diagnostic ability of optical spectroscopy, 
particularly for the detection of early neoplastic lesions which originate in the epithelium. 
A number of probe designs and techniques intended to target specific sampling 
regions in tissue have been reported (100). Oblique-incidence illumination and/or 
collection geometries using angled fibers have been used to target superficial tissue 
regions (104, 117, 118). Variations in fiber size, illumination-collection fiber separation, 
and probe-sample spacing have been shown to influence sensitivity to different 
fluorophore layers in turbid media (119). Differential path-length spectroscopy has been 
demonstrated as a technique for preferential detection of photons scattered from shallow 
depths (120). 
We have previously described the design of a ball lens coupled fiber-optic probe 
for depth-resolved spectroscopy and validated its performance in tissue phantoms (121). 
In this paper we present a clinical spectroscopy system based on this depth-sensitive 
probe, designed for noninvasive in vivo measurement of autofluorescence and diffuse 
reflectance spectra of oral mucosa. We present representative spectral measurements of 
oral sites in healthy normal volunteers and in patients with neoplastic lesions of the oral 
mucosa. Results indicate that the addition of depth selectivity can enhance the detection 
of optical changes associated with precancer. 
4.2 Materials and Methods 
4.2.1 Instrumentation 
A schematic diagram and photograph of the clinical spectroscopy system are shown 
in Figure 11. The device is housed in a mobile cart 0.6 m x 0.8 m x 1.3 m in size. The 
light source is a 75 W Xenon arc lamp (Photon Technology International, Birmingham, 
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NJ). Two filter wheels (Sutter Instrument Company, Novato, CA) containing bandpass 
filters (Chroma Technology Corporation, Rockingham, VT) allow selection of twelve 
different excitation wavelengths between 300 nm and 470 nm for fluorescence 
measurements, or broadband light at various illumination levels for reflectance 
measurements. The full-width half-maximum transmission bandwidth for the 
fluorescence excitation filters is 7 nm. Exposure time is controlled by a shutter (Vincent 
Associates, Rochester, NY) located in the illumination pathway. Excitation light is 
coupled into one of four illumination channels in the fiber optic probe, selected by means 
of a motorized translation stage (Parker Hannifin Corporation, Cleveland, OH). 
Illumination power is measured using two power meters (Newport Corporation, Irvine, 
CA). One power meter is used for direct measurements of probe output during system 
calibration; the other is permanently coupled to sampling fibers in the probe to monitor 
the illumination power and exposure time during the tissue measurement. 
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Figure 12 shows a photograph of the fiber optic probe and a diagram of the 
arrangement of illumination and detection fibers at its distal end. The design concept of 
the ball lens coupled probe has been previously described (121). The clinical probe 
described here contains four channels that are identified in terms of their depth response 
characteristics: a "shallow" 
channel, a "medium" depth 
channel, and two "deep" 
channels. In the shallow channel 4.2 mm 
and the medium channel, light is 
delivered to the tissue and 
collected through a 2-mm 
diameter sapphire ball lens. The 
ball lens is mounted in a 
stainless steel outer disk at the 
distal tip of the probe. The 
fibers for the shallow and 
medium channels terminate in a 
stainless steel inner disk, which 
is located just inside the probe 
tip and is separated from the ball 
lens by a 0.50-mm air gap. The 
shallow channel contains 14 
illumination fibers arranged in a 
Shallow Ilium 
Medium Ilium 
Deep Collect 
Deep Ilium 
Shallow and 
Medium Collect 
Deep Collect 
Deep Ilium 
Ball Lens 
/ 
Fig. 12. Diagram and photograph of the clinical ball lens 
coupled fiber-optic probe. 
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circle of radius 0.72 mm. The medium channel contains 6 illumination fibers arranged in 
a concentric circle of radius 0.36 mm. A single collection fiber, serving both the shallow 
and medium channels, is located at the center of both circles. The shallow and medium 
channels collect signal preferentially from different depths beneath the same location on 
the tissue surface. The fibers for the two deep channels terminate in the outer disk 
adjacent to the ball lens, with one channel on each side of the ball lens. The two deep 
channels are identical to each other in design. Each contains two illumination fibers and 
one adjacent collection fiber, all in direct contact with the tissue. The deep channels 
interrogate tissue sites located approximately 1.4 mm on either side of the site 
interrogated by the shallow and medium channels. All optical fibers (Polymicro 
Technologies, Phoenix, AZ) have a 200 um core diameter and a numerical aperture of 
0.22. 
Upon illumination of the tissue, detected light (autofluorescence or diffuse 
reflectance) returns through the collection channels of the probe and emerges from fibers 
arranged in a vertical stack. The collected light passes through a filter wheel containing 
longpass filters and is directed onto the entrance slit of an imaging spectrograph (Horiba 
Jobin Yvon, Longjumeau, France). A TE-cooled CCD camera (Andor Technology, 
Belfast, Northern Ireland) located at the exit port of the spectrograph collects an image 
which contains the spectrum of collected light from each fiber in the stack. 
All system instrumentation is controlled by Labview software (National 
Instruments Corporation, Austin, TX). The measurement sequence is fully automated 
and a single measurement takes approximately 90 seconds. During a measurement the 
instrument collects 52 individual spectra: fluorescence spectra at twelve different 
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excitation wavelengths in the range 300-470 nm and one broadband diffuse reflectance 
spectrum, through each of the four depth-selective probe channels. Background spectra, 
with the illumination source blocked, are also collected during the measurement. 
4.2.2 Measurement and Modeling of Probe Depth Response 
To measure the depth response of the clinical probe, a single side of a microscope 
slide was coated with a thin (<15 urn) uniform layer of green fluorescent paint for use as 
a test target. The response of each probe channel to the fluorescent target was measured 
as a function of distance from the probe tip to the target. This experiment was first 
performed in air and was then repeated with the probe and target fully immersed in water, 
to better simulate the refractive index change that would be encountered when the probe 
is in contact with tissue. 
The measurements described above provide only an approximation of the actual 
depth response of the probe in tissue, since tissue is a highly scattering medium compared 
to air or water. Monte Carlo simulations were performed to evaluate the effect of 
scattering on depth response. A previously reported Monte Carlo model (122) was 
modified to simulate the clinical ball lens probe geometry and the experimental 
conditions corresponding to the depth response measurement using a fluorescent target 
immersed in water. Simulations were performed with a range of scattering coefficients 
assigned to the medium: nonscattering ((j,s = 0 cm"1), moderate scattering (|j,s = 47 cm"), 
and high scattering (u^ = 224 cm"1). Results of the simulations were compared to 
measured data. 
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4.2.3 In Vivo Spectral Measurements 
Protocols were approved by the Institutional Review Boards at the University of 
Texas M.D. Anderson Cancer Center (MDACC) and Rice University. Sites within the 
oral cavity of patients with oral lesions and normal volunteers were measured using the 
device. For each patient, spectroscopic measurements were acquired from several sites, 
including clinically suspicious lesions selected by the clinician and at least one 
contralateral, clinically normal appearing site. At each measurement site, the probe was 
placed in gentle contact with the mucosal surface of the tissue for the duration of the 
spectroscopic measurement. The procedure was performed in a darkened room to 
minimize variability and artifact from exposure to ambient light. Wavelength calibration, 
power calibration, and standards measurements were performed immediately before or 
after the patient measurements. After the spectroscopic measurements were completed, 
biopsies were collected from the corresponding tissue sites for histologic examination, 
subject to prior patient consent and the discretion of the clinician. Histologic results were 
reviewed by a study pathologist. For normal volunteers, the same procedure was 
followed for spectroscopic measurements; clinical appearance of measured sites was 
noted but no biopsies were performed. 
4.2.4 Calibration and Data Processing 
Wavelength calibration was performed using a mercury-argon calibration lamp 
(Ocean Optics, Dunedin, FL). Standards measured daily included two positive 
fluorescence standards (Rhodamine B in ethylene glycol, 2 mg/L and 8 g/L); two 
negative fluorescence standards (frosted surface of a quartz cuvette and deionized 
ultrafiltered water); and a positive reflectance standard (Teflon). The spectrum of a 
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calibrated tungsten halogen light source (Ocean Optics) was obtained and used to correct 
measured spectra for non-uniform spectral variations in the throughput of the detection 
system. 
Measured spectra were processed using Matlab (The Math Works, Natick, MA). 
A median filter was first applied to remove single-pixel outliers and a Savitzky-Golay 
filter was used to remove high-frequency noise. Each tissue fluorescence measurement 
was normalized by the illumination energy delivered to the tissue and corrected for 
variations in the spectral transmission characteristics of the detection system. Diffuse 
reflectance spectra of tissue were divided by the corresponding diffuse reflectance spectra 
of the Teflon reflectance standard to obtain the ratio of tissue reflectance to this standard. 
4.3 Results 
4.3.1 Probe Depth Response Data 
The measured depth response of the shallow channel, medium channel, and a 
representative deep channel of the clinical ball lens coupled probe are shown in Figures 
13a and 13b. The normalized fluorescence intensity is plotted as a function of distance 
from the probe tip to the fluorescent target. The probe tip is formed by the distal surface 
of the ball lens, which extends 0.43 mm beyond the surface of the outer disk where the 
deep channel fibers terminate. Therefore when the probe tip is in contact with a 
noncompliant surface such as the microscope slide used in this measurement, the shallow 
and medium channels are in direct contact with the target but the deep channels are 
recessed by 0.43 mm. The data shown were measured using an excitation wavelength of 
400 nm; measurements obtained at other excitation wavelengths were similar. Figure 13a 
shows results obtained with the probe and target in air. In the shallow channel, the 
34 
fluorescence intensity drops to 10% of 
its peak value within 320 um of the 
probe tip. Figure 13b shows the same 
measurement performed with both the 
probe and target immersed in water. In 
this case the depth response curve 
broadens and shifts slightly deeper 
due to the reduced refraction of 
illumination rays at the probe-water 
interface. This is a better indication of 
the depth response that would be 
expected with the probe in contact 
with tissue. In water, the fluorescence 
intensity in the shallow channel drops 
to 10% of its peak value within 550 
um of the probe tip. 
Figure 13c shows the 
measured depth response for the 
shallow channel in water compared to 
the Monte Carlo simulated depth 
response for the shallow channel. 
Monte Carlo results are shown for 
three different cases: a nonscattering 
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Fig. 13. Measured depth response of the probe and 
comparison with simulations: (a) measured depth 
response in air; (b) measured depth response in water; 
(c) measured depth response in water vs. Monte Carlo 
simulated depth response for nonscattering, 
moderately scattering, and highly scattering media 
(shallow channel only). 
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medium (\xs = 0 cm"1), a moderately scattering medium (|xs = 47 cm"1); and a highly 
scattering medium (|is = 224 cm"1). The Monte Carlo result in the nonscattering case is 
roughly comparable to the measured depth response in water. The simulations indicate 
that as scattering increases, the depth response is confined to shallower depths. This is 
consistent with results reported by Pfefer et al from a Monte Carlo simulation of a similar 
oblique-incidence illumination geometry, in which increasing attenuation was found to 
decrease the probing depth (118). We conclude from these modeling results that the 
measured depth response in water provides a rough approximation of the depth response 
in tissue but tends to overestimate the actual probing depth. 
4.3.2 In Vivo Spectral Data 
Using this system, we obtained spectroscopic measurements from 188 sites in 39 
patients with lesions of the oral mucosa and from 140 sites in 32 normal volunteers. 
Figure 14 shows a representative example of spectra collected from a single site on the 
lateral tongue in a normal volunteer. The data shown are fluorescence emission spectra 
collected at three excitation wavelengths (330 nm, 350 nm, and 400 nm) and reflectance 
spectra collected using white light illumination. Data from the shallow channel and a 
deep channel of the probe are shown for comparison. The spectra shown represent eight 
of the fifty-two spectra that are collected in a given spectroscopic measurement. The 
reflectance spectra and several of the fluorescence spectra shown exhibit a valley at 420 
nm, which is attributed to the presence of the absorber hemoglobin which has a peak 
absorption at this location. Fluorescence and reflectance spectra acquired through the 
deep channel of the probe show a substantially increased contribution of hemoglobin 
absorption than do measurements made through the shallow channel. Since blood 
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vessels are expected to be present in the stroma but not in the epithelium, this is a good 
indication that the fraction of signal collected from the epithelium is greater for the 
shallow channel than for the deep channels. 
Figure 15 shows representative fluorescence emission spectra collected from 
normal, dysplastic, and cancerous sites of the buccal mucosa in a single oral cancer 
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patient at 350 nm excitation, using the shallow channel (15a) and a deep channel (15b) of 
the probe. Figures 15c and 15d show the same spectra normalized to their peak intensity 
values for comparison. Spectra measured using both the shallow and deep channels 
indicate progressively lower fluorescence intensity from the dysplastic and cancerous 
tissue sites compared to the normal site. The spectrum of the normal site collected 
through the deep channel shows a strong absorption at 420 nm that is absent in the 
corresponding shallow channel spectrum; again, this is consistent with the presence of 
hemoglobin in the stroma but not in the epithelium. In the shallow channel, it is 
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interesting to note that there is a shift to longer peak wavelengths in the fluorescence 
spectra of the abnormal sites with respect to the normal site. Since the shallow channel 
enhances signal collection from the epithelium, this wavelength shift is consistent with 
increased relative contributions of NADH and FAD to the fluorescence spectra in the 
epithelial layer of the abnormal tissue sites (111, 112). 
Figure 16 shows representative fluorescence emission spectra collected from 
normal, dysplastic, and cancerous sites in the lateral tongue in a single oral cancer patient 
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at 350 nm excitation, using the shallow channel (16a) and a deep channel (16b) of the 
probe. Figures 16c and 16d show the same spectra normalized to their peak intensity 
values for comparison. The spectra show trends similar to those observed in Figure 15. 
Lower fluorescence intensity is observed from the dysplastic and cancerous sites 
compared to the normal site in both the shallow channel and deep channel spectra. 
Hemoglobin absorption is more evident in the spectra measured through the deep 
channel. In the shallow channel there is a pronounced wavelength shift in the spectra of 
the abnormal sites compared to the spectrum of the normal site. In this case a wavelength 
shift is also apparent in the deep channel spectra. 
4.4 Discussion 
Previous reports have documented the potential of fluorescence and reflectance 
spectroscopy for noninvasive diagnosis of early oral cancer and precancer. However, to 
be effective clinically, diagnostic technologies need to have high specificity, as well as 
sensitivity, in order to avoid unnecessary patient interventions. Recent advances in the 
understanding of the alterations in tissue optical properties during carcinoma 
development have identified distinct differences between the epithelium and the 
underlying stroma (111). This suggests that separate interrogation of epithelial and 
stromal layers may improve the ability to distinguish dysplasia and carcinoma from 
normal mucosa and benign conditions. 
The spectroscopy system described in this report allows in vivo measurements of 
oral fluorescence and diffuse reflectance spectra at different depths within the tissue. The 
depth response measurements shown in Figure 13 indicate how well the depth-sensitive 
clinical probe performs. The measurements taken with the probe immersed in water, 
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Figure 13b, provide an estimate of the depth sensitivity of the probe for tissue 
measurements, though the actual probing depth may be slightly shallower due to 
scattering in tissue In the oral cavity the thickness of the epithelial layer is typically on 
the order of 300-500 um, varying with the specific tissue type. Figure 13b indicates that 
the shallow channel is strongly weighted towards the epithelial layer (the first 300-500 
um), but does not completely exclude signal from the stroma. The degree to which the 
interrogated region is confined to the epithelium depends on the epithelial thickness and 
therefore on tissue type within the oral cavity. The medium channel collects signal from 
a broad region that includes both epithelium and stroma, extending from the tissue 
surface to depths greater than 1 mm. The deep channels primarily interrogate the stroma 
but do include a small component of signal from the epithelium. 
The most prominent general feature observed in our in vivo data collected to date 
is a progressive overall reduction in blue-green fluorescence intensity in dysplastic and 
cancerous tissue compared to normal tissue, as illustrated in Figures 15a,b and 16a,b. 
This trend is evident across a wide range of excitation wavelengths from 330 nm to 470 
nm, though not at 300 nm or 310 nm excitation. The reduction in fluorescence intensity 
in dysplasia and carcinoma is observed in all oral tissue types measured and in all depth 
channels of the probe (shallow, medium, and deep), indicating that alterations in both 
epithelium and stroma are involved. We believe the most likely contributing factors to 
this reduction in fluorescence intensity are the breakdown of collagen crosslinks in the 
stroma, thickening of the epithelium, increased epithelial scattering, loss of keratin in the 
epithelium, and increased hemoglobin absorption associated with increased 
microvascular density throughout the epithelial-stromal region (38, 123, 124). 
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A second general feature observed in the data is a progressive shift of the blue-
green fluorescence peak to longer wavelengths in dysplastic and cancerous tissue 
compared to normal tissue, as shown in Figures 15c and 16c. This trend also appears 
across a range of excitation wavelengths, most notably in the 330-390 nm range and 
somewhat less consistently in the 400-470 nm range. It is mostly seen in the shallow and 
medium channels, and less clearly observed in the deep channels; this may be because 
hemoglobin absorption distorts the shape of the normal spectra measured using the deep 
channels, as seen in Figure 15d, making the wavelength shift less readily apparent. The 
origin of the wavelength shift is not known but it may be associated with loss of 
fluorophores that emit at shorter wavelengths, such as keratin and collagen, and increased 
relative contributions to the fluorescence signal from NADH and FAD. 
The reduction in blue-green fluorescence intensity and the associated wavelength 
shift that we observe in our data are consistent with results reported in the literature for in 
vivo oral measurements. In a previous study (without a ball lens coupled probe), our 
group found a reduction in blue-green fluorescence intensity and a wavelength shift in 
cancerous tissue compared to normal tissue, with excitation wavelengths of 365 nm, 337 
nm, and 410 nm (43). Badizadegan et al reported a similar progressive reduction in 
fluorescence intensity and wavelength shift in dysplastic and cancerous oral tissue 
compared to normal tissue, with an excitation wavelength of 337 nm (66). De Veld et al 
found a progressive decrease in blue-green fluorescence intensity in dysplastic and tumor 
tissue compared to healthy tissue at 405 nm excitation, but also found a decrease in the 
fluorescence intensity of benign lesion sites compared to healthy tissue (67). This raises 
the concern that this parameter may not provide sufficient specificity to distinguish 
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dysplastic and cancerous lesions from benign lesions. Since inflammatory lesions 
predominantly affect the stroma, whereas dysplasia also produces alterations in the 
epithelium, spectral data separately derived from these layers may provide novel 
parameters to distinguish these clinical entities. 
Our initial results indicate that the clinical ball lens coupled probe functions as 
designed and provides depth-sensitive in vivo spectral data. The shallow channel of the 
probe appears to minimize the effect of hemoglobin absorption on the fluorescence 
spectrum. It remains to be seen whether the removal of the hemoglobin absorption leads 
to significantly improved diagnostic performance; whether the probe can be used to 
identify different trends in fluorescence associated with fluorophores located in the 
epithelium and stroma; how diagnostic performance is affected by inter- and intra-patient 
variability; and whether benign and malignant lesions can be distinguished. 
In summary, we have described a clinical spectroscopy system with a depth-
sensitive fiber-optic probe for noninvasive in vivo measurement of oral sites in healthy 
subjects and in patients with lesions of the oral mucosa. Differences have been observed 
in intensity, peak emission wavelength, and shape of the fluorescence spectra of normal 
and abnormal tissue sites. Depth-sensitive spectral measurements have been successfully 
demonstrated in vivo. The ability to obtain spectra from different depths at a single 
measurement site, and to distinguish between epithelial and stromal spectral signatures, 
may improve the diagnostic capability of point probe optical spectroscopy systems. 
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5. NONINVASIVE EVALUATION OF ORAL LESIONS USING DEPTH-SENSITIVE 
OPTICAL SPECTROSCOPY0 
cThe contents of this chapter have been published in the following journal article: Schwarz RA, Gao W, 
Weber CR, Kurachi C, Lee JJ, El-Naggar AK, Richards-Kortum R, Gillenwater AM. Noninvasive 
evaluation of oral lesions using depth-sensitive optical spectroscopy. Cancer 2009;115:1669-1679. 
Abstract: 
Background: Optical spectroscopy is a noninvasive technique with potential applications 
for diagnosis of oral dysplasia and early cancer. In this study we evaluated the diagnostic 
performance of a depth-sensitive optical spectroscopy (DSOS) system for distinguishing 
dysplasia and carcinoma from non-neoplastic oral mucosa. 
Methods: Patients with oral lesions and volunteers without any oral abnormalities were 
recruited to participate. Autofluorescence and diffuse reflectance spectra of selected oral 
sites were measured using the DSOS system. 424 oral sites in 124 subjects were 
measured and analyzed, including 154 sites in 60 patients with oral lesions and 270 sites 
in 64 normal volunteers. Measured optical spectra were used to develop computer-based 
algorithms to identify the presence of dysplasia or cancer. Sensitivity and specificity 
were calculated using a gold standard of histopathology for patient sites and clinical 
impression for normal volunteer sites. 
Results: Differences in oral spectra were observed in: (1) neoplastic vs. non-neoplastic 
sites, (2) keratinized vs. non-keratinized tissue, and (3) shallow vs. deep depths within 
oral tissue. Algorithms based on spectra from 310 non-keratinized anatomic sites 
(buccal, tongue, floor of mouth, and lip) yielded an area under the receiver operating 
characteristic (ROC) curve of 0.96 in the training set and 0.93 in the validation set. 
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Conclusions: The ability to selectively target epithelial and shallow stromal depth 
regions appears diagnostically useful. For non-keratinized oral sites the sensitivity and 
specificity of this objective diagnostic technique are comparable to that of clinical 
diagnosis by expert observers. Thus DSOS has potential to augment oral cancer screening 
efforts in community settings. 
5.1 Introduction 
Oral cancer ranks as the 1 l l most common cancer in the world, with 390,000 new cases 
estimated to occur annually worldwide (1). In the United States, cancers of the oral 
cavity and pharynx are predicted to account for over 35,000 new cases and more than 
7,500 deaths this year (2). Despite advances in treatment methods, the five-year survival 
rate for oral cancer has not increased substantially during the past several decades (8). 
Treatment is more effective in patients with early disease; however, most patients present 
with advanced tumors for which treatment is less successful and may cause severe 
deficits in speech, swallowing, facial appearance and quality of life (6). Detection and 
diagnosis of early neoplastic changes may be the best way to improve patient outcomes. 
During carcinogenesis in the oral cavity, structural and biochemical changes in 
both the epithelium and stroma alter the optical properties of dysplastic and cancerous 
tissue. Increased nuclear size and nuclear to cytoplasmic ratio, increased 
microvascularization, degradation of stromal collagen, and changes in the concentration 
of mitochondrial fluorophores such as reduced nicotinamide adenine dinucleotide 
(NADH) and flavin adenine dinucleotide (FAD) lead to changes in optical scattering, 
absorption, and autofluorescence characteristics within the tissue (38, 42, 43, 47). A 
number of groups have reported that these alterations can be detected using spectroscopic 
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techniques (58, 60, 65-68, 72). Optical spectroscopy may therefore be a useful 
noninvasive and objective clinical tool to help improve early detection and diagnosis of 
oral neoplasia. 
In current practice, oral premalignant lesions and cancer are diagnosed by visual 
inspection and palpation, identification of areas that appear clinically abnormal, and 
invasive biopsy and histologic examination of the removed tissue. However, visual 
identification of early lesions can be difficult even for experienced clinicians (9), and 
many less experienced examiners such as community dentists, primary care physicians, 
and health care workers feel insufficiently trained to perform this important task (39). To 
address the challenge of early detection and diagnosis of oral cancer, several alternative 
diagnostic techniques and visualization aids for examining the oral cavity have recently 
become commercially available. These include the OralCDx BrushTest™ (OralCDx 
Laboratories, Inc., Suffern, NY), an oral brush cytology test; ViziLite Plus (Zila 
Pharmaceuticals, Inc., Phoenix, AZ), a direct tissue visualization technique using acetic 
acid and a blue light source; and the VELscope™ (LED Dental, Inc., White Rock, BC, 
Canada), a handheld device for direct visualization of tissue fluorescence. 
Clinical studies to evaluate the performance of new diagnostic aids for oral 
precancer and cancer have been reviewed and critiqued elsewhere (31, 94). While 
promising results have been reported for several diagnostic technologies including optical 
spectroscopy, none has been definitively proven to improve diagnostic yields over 
conventional oral examination (31). Auto fluorescence spectroscopy has been reported to 
be accurate for distinguishing malignant tumors from healthy oral mucosa, but less 
reliable for distinguishing between benign lesions, such as inflammation, and dysplastic 
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or malignant lesions (94). Indeed, the presence of inflammation may be a complicating 
factor in spectroscopic diagnosis of oral lesions; reduced autofluorescence due to 
inflammation may be difficult to distinguish from reduced autofluorescence due to 
neoplasia (51). Since inflammation primarily affects the stroma while dysplastic changes 
occur in the epithelium, depth-sensitive spectral data, particularly that obtained from 
more superficial layers, may provide more useful information for discriminating benign 
inflammatory lesions from dysplastic or malignant lesions. 
We have previously reported the development of a clinical spectroscopy system 
with a depth-sensitive, ball lens coupled fiber-optic probe for noninvasive in vivo 
measurement of oral autofluorescence and diffuse reflectance spectra (125). Here we 
describe results obtained using this depth-sensitive optical spectroscopy (DSOS) system 
to measure oral sites in 124 subjects. The goal of this study was to investigate three 
questions regarding depth-sensitive optical spectroscopy: (1) whether spectral 
differences are observed in the signal collected from different depth regions; (2) whether 
the ability to collect signal from different depth regions enhances diagnostic 
performance; and (3) how the diagnostic performance of depth-sensitive spectroscopy 
compares to other diagnostic methods. 
5.2 Materials and Methods 
5.2.1 Study Population 
This study, conducted at the University of Texas M.D. Anderson Cancer Center 
(UTMDACC) and Rice University, was approved by the Institutional Review Boards at 
both institutions. Patients with lesions of the oral mucosa and normal volunteers 18 years 
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or older were recruited to participate. Persons with previous squamous cell carcinoma of 
the oral cavity, previous radiation therapy to the head and neck region, chemotherapy 
within the previous 6 months, use of smokeless tobacco, or current oral cavity lesions 
were excluded from the normal volunteer pool. Written informed consent was obtained 
from all subjects. 
5.2.2 Protocol 
Spectroscopic measurements of patients were performed at UTMDACC in the operating 
room immediately prior to surgery, or in the clinic. Measurements of normal volunteers 
were performed at UTMDACC and Rice University. No oral rinse or other prior 
preparation of the oral cavity was required. The oral cavity was inspected by 
conventional visual examination. Several sites in each subject were selected by the 
clinician for spectroscopic measurement, including clinically suspicious lesions if present 
and at least one contralateral site with a normal clinical appearance. The clinical 
appearance of each measured site was categorized by a single expert observer as Normal, 
Abnormal Low Risk, Abnormal High 
Risk, or Cancer. Seven expert observers 
took part in the study, with two of the 
participating experts providing over 
96% of the clinical evaluations. The 
probe was placed in gentle contact with 
the mucosal surface and held in place by 
the clinician for the duration of the 
measurement (Figure 17). Spectroscopic measurements were performed in a darkened 
Fig. 17. Spectroscopic probe in contact with a 
measurement site. 
49 
room to minimize the effects of ambient light. The measurements were collected over a 
period of 21 months with measurements of normal volunteers and patients interspersed 
throughout that time period. 
The spectroscopic instrumentation used in this study, including the depth-
sensitive fiber-optic probe, methods used for calibration and data processing, and 
examples of measured spectra from individual sites have been described previously 
(125). Briefly, autofluorescence spectra at twelve excitation wavelengths ranging from 
300-470 nm and a diffuse reflectance spectrum under white light illumination were 
collected through each of four probe channels with different depth responses, for a total 
of 52 spectra collected in each 90-second measurement. The shallow channel has a depth 
response weighted towards the epithelial tissue layer; the medium channel interrogates 
both epithelium and shallow stroma; and the two deep channels collect signal primarily 
from the stroma (125). Wavelength calibration, power calibration, and standards 
measurements were performed daily before or after patient measurements. The probe 
was disinfected before and after each patient with Cidex® OPA (Advanced Sterilization 
Products, Johnson & Johnson Gateway, LLC). 
Upon completion of the optical measurements, tissue specimens were collected 
from the measured sites for histopathologic evaluation. Usually, 4 mm punch biopsies 
were performed immediately following spectroscopy; however, in some cases, measured 
sites within a region of tissue to be resected were marked and later identified on the 
resected tissue. Specimens were placed in fixative and analyzed by the study pathologist. 
The study pathologist's diagnoses were categorized as Normal/Benign, Mild Dysplasia, 
Moderate to Severe Dysplasia, or Cancer. For histologic diagnosis, Normal/Benign was 
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defined as normal, hyperkeratosis, hyperplasia, and/or inflammation without dysplasia or 
with only focal mild dysplasia. There were no benign tumors in the study. In normal 
volunteers biopsies were not performed but the clinical appearance of measured sites was 
noted. 
5.2.3 Data Analysis 
A quality control check was performed for each spectroscopic measurement before 
analyzing the data. Measurements for which one or more spectra were missing or 
otherwise unsatisfactory due to instrument malfunction or flawed measurement 
conditions (such as excessive ambient light) were excluded from the analysis. Each 
measurement site was assigned either a "hard" or "soft" gold standard diagnosis 
following the terminology used by Lingen et al (31). For patient sites, the diagnosis 
assigned by the study pathologist was used as the "hard" gold standard. For normal 
volunteer sites, a "soft" gold standard of Normal/Benign was used based on expert 
clinical impression. All measurements that passed the quality control check and had a 
corresponding gold standard diagnosis were included in the data set. 
Data were separated into training and validation sets, with all spectroscopic 
measurements from a single patient randomly assigned to either the training set or the 
validation set. The training set was used to define a set of spectral features; to reduce the 
data to a diagnostically relevant subset of the spectral features; and to develop a 
diagnostic classification algorithm to classify tissue sites based on the identified subset of 
spectral features. The algorithm was developed using linear discriminant analysis with 
automated forward stepwise feature selection. For all calculations of sensitivity and 
specificity, a binary diagnosis of Normal to Mild Dysplasia (negative) vs. Moderate 
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Dysplasia to Cancer (positive) was used. Equal prior probabilities were assigned for 
positive and negative diagnosis categories. The algorithm was used to calculate the 
posterior probability of disease for each measurement. In cases where a tissue site was 
measured more than once, the highest posterior probability from the measurements at that 
site was used. Diagnostic predictions were made as the threshold was varied from 0 to 1 
to generate a receiver operating characteristic (ROC) curve. The classification algorithm 
was chosen to maximize the area under the ROC curve in the training set. For the final 
algorithm, an arbitrary limit of six spectral features was imposed to reduce the risk of 
overtraining. This limit was chosen in part because it is unlikely that more than six 
endogenous biological fluorophores and chromophores make major contributions to the 
measured signal (38, 42, 43, 47). An operating point on the ROC curve, corresponding to 
a specific threshold, was established using the training set data. The algorithm and 
threshold were then applied to the validation set to evaluate the diagnostic performance 
of spectroscopy with respect to the gold standard. 
5.3 Results 
Table 2 summarizes the numbers of subjects, oral sites, and spectroscopic measurements 
involved in the study. A total of 695 in vivo measurements of oral tissue were collected 
from 515 sites in 139 subjects. Of the 695 measurements performed, 676 (97%) passed 
the quality control check. There were 405 measurements of sites in patients that passed 
the quality control check; of these, 281 (69%) had a corresponding biopsy available from 
the same tissue site that produced a valid histopathology diagnosis (a "hard" gold 
standard). There were 271 measurements of sites in normal volunteers that passed the 
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quality control check. Of these, all were considered to have a "soft" gold standard of 
Normal/Benign based on expert clinical impression, including four sites at which 
inflammation was noted. The final data set consisted of 552 measurements from 424 
sites in 124 subjects. 
Table 2. Oral Tissue Measurements In Vivo of the Study Populations 
Performed Subjects 
Sites 
Measurements 
Patients 
73 
232 
411 
Normal 
volunteers 
66 
283 
284 
Total 
139 
515 
695 
Passed quality control check Subjects 
Sites 
Measurements 
73 
231 
405 
64 
270 
271 
137 
501 
676 
Passed quality control check, with Subjects 
valid histopathology diagnosis Sites 
Measurements 
60 
154 
281 
0* 
0* 
0* 
60 
154 
281 
Final data set for analysis Subjects 
Sites 
Measurements 
60 
154 
281 
64 
270 
271 
124 
424 
552 
Subset: Subjects represented** 31 
Non-keratinized tissue, training set Sites 70 
Measurements 131 
38 
121 
122 
69 
191 
253 
Subset: Subjects represented** 21 
Non4<eratinized tissue, validation set Sites 45 
Measurements 81 
25 
74 
74 
46 
119 
155 
Subset: 
Keratinized tissue 
Subjects represented** 17 
Sites 39 
Measurements 69 
47 
75 
75 
64 
114 
144 
* No biopsies were taken in normal volunteers. 
** Some subjects are represented in both the keratinized subset and a non-keratinized subset. 
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Table 3 shows a comparison between the conventional pathologic and expert 
clinical diagnosis for sites in patients. The clinical impression category Abnormal Low 
Risk includes sites described clinically as inflammation, lichen planus, or scar tissue. 
The clinical impression category Abnormal High Risk includes sites described clinically 
as leukoplakia, erythroplasia, pre-cancer, dysplasia, or verrucous lesion. In Table 3, with 
clinical impression categories grouped as Normal to Abnormal Low Risk vs. Abnormal 
High Risk to Cancer, and histopathologic categories grouped as Normal to Mild 
Dysplasia vs. Moderate Dysplasia to Cancer, expert clinical diagnosis of all patient sites 
correlated with pathologic diagnosis with a sensitivity of 94% and a specificity of 74%. 
Table 3. Histopathology vs. Clinical Diagnosis of Measured Oral Sites in Patients 
Expert clinical impression 
Abnormal Abnormal 
Data Set Histopathology diagnosis Normal low risk high risk Cancer Total 
All sites in Normal / benign 53 4 
patients Mild dysplasia 9 1 
Moderate or severe dysplasia 4 0 
Cancer 0 0 
Total 66 5 
Non-keratinized Normal / benign 20 1 
tissue, training Mild dysplasia 7 0 
set, sites in Moderate or severe dysplasia 1 0 
patients Cancer 0 0 
Total 28 1 
Non-keratinized Normal / benign 17 2 
tissue, validation Mild dysplasia 1 1 
set, sites in Moderate or severe dysplasia 1 0 
patients Cancer 0 0 
Total 19 3 
Keratinized Normal / benign 16 1 
tissue, sites in Mild dysplasia 1 0 
patients Moderate or severe dysplasia 2 0 
Cancer 0 0 
Total 19 1 
6 
8 
11 
4 
29 
3 
3 
5 
2 
13 
2 
2 
3 
0 
7 
1 
3 
3 
2 
9 
3 
7 
4 
40 
54 
0 
4 
4 
20 
28 
1 
2 
0 
13 
16 
2 
1 
0 
7 
10 
66 
25 
19 
44 
154 
24 
14 
10 
22 
70 
22 
6 
4 
13 
45 
20 
5 
5 
9 
39 
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Anatomic sites measured include buccal mucosa, tongue (predominantly lateral 
tongue), floor of mouth, lip, gingiva, and palate (predominantly hard palate). The spectra 
of normal gingiva and palate sites were observed to differ from the spectra of other 
normal anatomic sites in both intensity and variability. Based on these observations, and 
on the results of a separate recent study in which fluorescence microscopy indicated 
differences in gingiva and palate compared to other oral sites (51), the 424 sites were 
divided into two groups for analysis: non-keratinized tissues including buccal, tongue, 
floor of mouth, and lip (310 sites), and keratinized tissues including gingiva and palate 
(114 sites). The two groups were analyzed separately and a different classification 
algorithm was developed for each group. 
Figure 18 shows average spectra collected at 350 nm excitation from non-
keratinized tissues for each diagnostic category. The figure illustrates the progressive 
reduction in blue-green fluorescence intensity that is observed in dysplastic and 
cancerous oral tissue compared to normal tissue. This loss of fluorescence has been 
reported by many investigators and serves as the basis for the operation of the VELscope 
(38). The reduced fluorescence associated with neoplasia was observed across a wide 
range of excitation wavelengths from 330 nm to 470 nm in this study. 
As Figure 18 indicates, spectral differences were observed in the signal collected 
from different depth regions through the separate probe channels. The greatest depth-
dependent differences occurred in fluorescence measurements at 330-350 nm excitation 
and in diffuse reflectance measurements. At 350 nm excitation at shallow depths, the 
average fluorescence spectra from normal and dysplastic sites have smooth, rounded 
peaks, while in cancer sites the peak emission wavelength is shifted to the right (red 
55 
shifted) and a valley begins to appear in the 420 nm region. At medium depths, the 420-
nm valley is evident in the spectra from moderate/severe dysplasia sites as well. Finally, 
in the deep channel measurements the 420-nm valley appears prominently in all the 
spectra regardless of diagnosis. 
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Fig, 18. Average spectra of non-keratinized tissue by diagnosis, illustrating differences in data 
obtained at different depths. Left column: fluorescence spectra at 350 nm excitation; arrows indicate 
absorption of fluorescent light by hemoglobin. Right column: reflectance spectra with white light 
illumination. Top, middle, and bottom: shallow, medium, and deep probe channels, respectively. An 
asterisk (*) next to a diagnostic category indicates that differences in the mean intensities of normal 
tissue and that diagnostic category were statistically significant (two-tailed Student's Mest, 
P < 0.05 / 6, correcting for 6 comparisons per panel). Peak fluorescence intensity in the 390-650 nm 
region and reflectance intensity ratio at 420 nm were used in the statistical comparisons. 
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Depth-dependent differences in spectral shape are also evident in the reflectance 
data shown in Figure 18. The slope of the reflectance spectrum in the 500-650 nm region 
is relatively flat in the shallow and medium depth data, but increases in measurements 
from deeper regions. Greater differences in intensity between the diagnostic categories 
of Normal to Mild Dysplasia and Moderate Dysplasia to Cancer are observed in shallow 
and medium depth reflectance measurements than in deep reflectance measurements. 
Note, however, that the general trend of decreasing fluorescence intensity and reflectance 
intensity with disease progression is observed in all measured depth regions. 
A total of 160 distinct spectral features of interest were defined from the 
measured spectra, including such quantities as peak emission intensity and peak emission 
wavelength at each excitation wavelength and depth channel. A subset of diagnostically 
useful features was identified in two steps. In the first step, the 160 features were 
examined and reduced to an intermediate subset of features. The diagnostic performance 
of each individual feature was first evaluated independently using data from the training 
set and features were ranked accordingly. Spectra and classification results associated 
with high-performing individual features were inspected. Features which were derived 
from spectra that appeared qualitatively similar and which produced similar classification 
results (similar sensitivity and specificity, and misclassified mostly the same sites) were 
considered to be correlated. For correlated features, a representative feature with optimal 
individual performance was included and the other correlated features were excluded. 
For non-keratinized tissues, the data were reduced to an intermediate subset of 16 
features associated with fluorescence at 380 nm excitation, fluorescence at 470 nm 
excitation, and reflectance, all using the shallow and medium channels. For keratinized 
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tissues, the data were reduced to an intermediate subset of 36 features including 
fluorescence at 300-330 nm excitation, fluorescence at 470 nm excitation, and 
reflectance, using the shallow, medium, and deep channels. In the second step, the 
intermediate set of features was used as input for algorithm development. An algorithm 
was developed using linear discriminant analysis with automated forward stepwise 
feature selection, resulting in a final set of 6 features chosen to maximize the area under 
the ROC curve. 
Table 4 summarizes the set of optimal spectral features selected for diagnostic 
classification of non-keratinized tissues. The 380 nm/472 nm fluorescence 
excitation/emission combination using the medium depth channel proved to be the most 
diagnostically useful single feature for non-keratinized tissues. This is consistent with 
results reported by Heintzelman et al (69). The six features in the set selected for non-
keratinized tissues were all associated with fluorescence at 380 nm excitation or diffuse 
reflectance; five were obtained using the medium depth channel and one was obtained 
using the shallow channel. For keratinized tissues, diffuse reflectance spectra obtained 
using the medium and deep channels were optimal for diagnostic classification; 
fluorescence spectra at 300-330 and 470 nm excitation, obtained using the shallow, 
medium, and deep channels, were of secondary importance. 
Table 4. Feature Set for Diagnostic Classification of Non-Keratinized Sites of the Oral Cavity 
Depth 
# Spectral feature channel 
1 Fluorescence: 380 nm excitation, 472 nm emission Medium 
2 Reflectance: 650 nm / 500 nm intensity ratio Medium 
3 Reflectance: 500 nm / 420 nm intensity ratio Medium 
4 Reflectance: 500 nm intensity Medium 
5 Fluorescence: 380 nm excitation, 478 nm/458 nm emission intensity ratio Medium 
6 Reflectance: 420 nm intensity Shallow 
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Figure 19 shows the diagnostic performance of depth-sensitive spectroscopy for 
non-keratinized tissues. In the posterior probability plots, the data value on the vertical 
axis represents the posterior probability of disease at each site according to spectroscopy, 
and the horizontal lines indicate thresholds established for a positive result. The area 
under the ROC curve was 0.96 in the training set and 0.93 in the validation set. Using the 
training set data, Threshold #1 was selected as the operating point. Using Threshold #1, 
the sensitivity and specificity, respectively, were 94% and 90% in the training set (191 
sites in 69 subjects), and 82% and 87% in the validation set (119 sites in 46 subjects). 
For comparison, Threshold #2 is also shown as an alternate operating point. Using 
Threshold #2, the sensitivity and specificity, respectively, were 100% and 77%) in the 
training set, and 100% and 73% in the validation set. 
Fig. 19a and 19c also show the diagnostic performance of clinical impression as 
judged by an expert observer. Note that the data set for clinical impression is a smaller 
subset of the data set for spectroscopy; only sites in patients were included in calculations 
of sensitivity and specificity of clinical impression, because in normal volunteers the gold 
standard itself is based on clinical impression. For clinical impression, a binary grouping 
of Normal to Abnormal Low Risk (negative) vs. Abnormal High Risk to Cancer 
(positive) was used. For non-keratinized sites in patients, expert clinical impression had 
a sensitivity of 97% and a specificity of 74% within the training set (70 sites in 31 
patients), and a sensitivity of 94% and a specificity of 75% within the validation set (45 
sites in 21 patients). 
Fig. 19b and 19d compare the performance of depth-sensitive spectroscopy and 
expert clinical impression at individual sites. In the training set, spectroscopy (using 
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Threshold #1) misclassified 2 of 32 positive sites and clinical impression misclassified 1 
of 32 positive sites, with 1 site misclassified by both; and spectroscopy misclassified 16 
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Fig. 19. Diagnostic classification results. Left column: Non-keratinized training set (191 sites in 69 
subjects). Right column: non-keratinized validation set (119 sites in 46 subjects). Top row: ROC 
curves for depth-sensitive spectroscopy; sensitivity and specificity values for clinical impression; and 
sensitivity and specificity values reported in the literature. Bottom row: Posterior probability values 
corresponding to the plotted ROC curves. Sensitivity and specificity of spectroscopy in the 
keratinized set (114 sites in 64 subjects) are also shown in (a), n: number of subjects. AUC: area 
under ROC curve. 
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of 159 negative sites and clinical impression misclassified 10 of 38 negative sites, with 8 
sites misclassified by both. In the validation set, spectroscopy misclassified 3 of 17 
positive sites and clinical impression misclassified 1 of 17 positive sites, with 1 site 
misclassified by both; and spectroscopy misclassified 13 of 102 negative sites and 
clinical impression misclassified 7 of 28 negative sites, with 5 sites misclassified by both. 
Also shown in Fig. 19a and 19c are sensitivity and specificity values reported in the 
literature (38, 43, 47, 69, 126-131) for spectroscopy and imaging studies based on 
measurements of blue-green autofluorescence and/or diffuse reflectance. Values reported 
from a single data set or from a training set are shown in Fig. 19a. Values reported from 
an independent validation set are shown in Fig. 19c. 
For keratinized tissue, there were insufficient sites for analysis using separate 
training and validation sets. Five-fold cross-validation was used instead to evaluate the 
diagnostic performance of depth-resolved spectroscopy. In the cross-validation set of 
114 keratinized sites, the area under the ROC curve was 0.76; at a selected operating 
point the sensitivity was 79% and the specificity was 80%, as shown in Fig. 19a. 
5.4 Discussion 
Our results demonstrate the diagnostic potential of optical spectroscopy for objectively 
and noninvasively distinguishing dysplastic and cancerous oral sites from benign lesions 
and normal mucosa. Further, these findings support the use of a depth-sensitive 
spectroscopy system to enhance diagnostic performance of optical spectroscopy. 
The first question addressed by this study is whether spectral differences are 
observed in the signal collected from different depths in oral tissue. As shown in 
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Figure 18, spectra collected using the shallow, medium, and deep channels of the depth-
sensitive probe have distinctive characteristics. Fluorescence spectra collected from 
deeper in the tissue display a different spectral shape than spectra collected from 
superficial tissue, including a more pronounced valley in the 420 nm wavelength region. 
This depth-dependent variation in fluorescence spectral shape is attributed partly to 
hemoglobin, which is present within vascular spaces in the stromal layer and absorbs a 
portion of the emitted fluorescence; this is particularly noticeable at 330-350 nm 
excitation where the peak fluorescence emission lies near the hemoglobin peak 
absorption wavelength of 420 nm. The depth-dependent distribution of fluorophores in 
the tissue also plays a role, with epithelial fluorophores such as NADH contributing 
primarily to the signal measured from shallow depths, and stromal fluorophores such as 
collagen contributing primarily to the signal measured from deeper regions. Depth-
dependent variations are also observed in the reflectance spectra. While the characteristic 
hemoglobin absorption spectrum is evident in the reflectance spectra from all depth 
channels, the reflectance spectra from shallow and medium depths show greater intensity 
differences among diagnostic categories than those from deeper in the tissue. This 
suggests that the shallow and medium channels may be more sensitive than the deep 
channels to alterations in the optical scattering properties of the epithelium, where early 
changes in nuclear size and nuclear to cytoplasmic ratio occur. 
The second question is whether signal collection from different depth regions 
enhances diagnostic performance. In this study, the ability to collect and analyze data 
from specific depth channels did prove to be diagnostically useful. For non-keratinized 
tissue, optimum diagnostic performance was achieved using only spectra from shallow 
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and medium depths. It is interesting that the medium depth channel, which interrogates 
epithelial and shallow stromal regions, provided the best diagnostic performance of any 
channel alone. It provided slightly better discrimination between normal and abnormal 
sites than the shallow channel, which is strongly weighted towards the epithelial layer 
and minimizes the effects of hemoglobin absorption. The medium channel also 
outperformed the deep channels, which primarily interrogate stromal regions and are 
strongly affected by hemoglobin absorption. Thus, it appears that the most diagnostically 
significant tissue alterations detected by optical spectroscopy occur in the deeper portion 
of the epithelium and in the shallow region of the stroma. These diagnostically important 
alterations are likely to include changes in nuclear size and nuclear to cytoplasmic ratio in 
the epithelium, and increased hemoglobin absorption and breakdown of collagen 
crosslinks in the shallow stroma (38, 42, 43, 47). This region is also critically important 
for identification of dysplasia and invasive carcinoma using standard histopathologic 
evaluation. Indeed, pathologic grading of dysplasia is also imperfect and subject to 
interobserver variability (132). 
The third question addressed by this study is how the performance of depth-
sensitive optical spectroscopy compares to that published for other diagnostic methods 
for distinguishing neoplastic from non-neoplastic oral mucosa. A wide range of 
sensitivity and specificity values for various oral cancer detection techniques has been 
reported in the literature using a variety of study designs and subject populations. The 
OralCDx test has been reported to perform as well as 100% sensitivity and 93% 
specificity (32), and as poorly as 71% sensitivity and 32% specificity (34). Two studies 
have reported that the ViziLite system has a high sensitivity (100%) but extremely low 
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specificity (0-14%) (36, 37). A single pilot study of the VELscope reported a sensitivity 
of 98% and a specificity of 100% (38). 
In this study of depth-sensitive optical spectroscopy, we report a sensitivity of 
94% and a specificity of 90% in the training set and a sensitivity of 82% and a specificity 
of 87%) in the validation set. As Figure 19a indicates, the results obtained for the training 
set are comparable to results reported in the literature for other spectroscopy and imaging 
studies using either a training set or a single data set. Spectroscopy and imaging studies 
that include an independent validation set are infrequent. Heintzelman reported a 
sensitivity of 100% and a specificity of 98% in an independent validation set of 281 sites 
in 56 subjects, but only 4 of the sites were abnormal (69). Majumder reported a 
sensitivity of 95% and a specificity of 96% in a validation set derived from measurements 
of 29 subjects (127); however, as noted by de Veld et al (94), the analysis included a 
preprocessing step that introduced information regarding lesion type. Here we report a 
sensitivity of 82% and a specificity of 87% in a validation set of 119 sites, 17 of which 
are abnormal, in 46 subjects. 
The diagnostic performance of DSOS in non-keratinized sites approaches that of 
expert clinical diagnosis (Figure 19), and the two methods tend to err on many of the 
same sites. This suggests that this objective technique may improve the ability of 
clinicians to diagnose early oral neoplasia, regardless of their experience, especially 
given the fact that this particular study population was quite a difficult one; it included 
many patients with extensive field cancerization as well as individuals who had received 
previous surgery and/or radiation treatment. The diagnostic performance of DSOS in 
keratinized sites (gingiva and hard palate) is lower than in non-keratinized sites, and 
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different algorithms appear to be needed to obtain optimal performance in keratinized 
tissue. Although the majority of cancers in the oral cavity arise in non-keratinized tissue 
(more than 80%) (2), this is an important consideration for future study. 
The context of this study should be considered when interpreting its results. A 
large fraction of the study population consisted of patients with oral cancer or a history of 
oral cancer. The diagnostic performance of expert clinical impression in this study is 
likely to have been inflated due to the fact that participating patients had all been referred 
to a tertiary care cancer center, many with previous biopsies indicating dysplasia or 
invasive carcinoma. Further work is needed to characterize the performance of DSOS in 
a community setting with a more general population, in which most patients have no 
disease or inflammatory disease. 
Overall, the results of this study indicate that depth-sensitive optical spectroscopy 
can be a useful technique for noninvasive evaluation of oral lesions, especially in 
situations in which the oral screening examination is performed by a community dentist 
or health care worker rather than an expert clinical observer. In practice it is anticipated 
that the depth-sensitive point probe system would be paired with a widefield imaging 
device (87); the imaging device would identify regions of interest and the depth-sensitive 
point probe would be used for noninvasive evaluation of those sites. The identification of 
diagnostic algorithms based on a limited number of excitation wavelengths and depth 
channels should enable fabrication of simplified DSOS devices that are portable and 
comparatively inexpensive. This should facilitate transition of these noninvasive and 
objective techniques from the laboratory to community and low-resource settings, where 
they are needed most to aid diagnosis of oral dysplasia and cancer. 
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Additional data: The Appendix contains plots of average spectra for all excitation 
wavelengths and all depth channels at sites measured in this study, broken down by gold 
standard diagnosis (normal, mild dysplasia, moderate/severe dysplasia, or cancer) and by 
tissue type (nonkeratinized or keratinized). It also shows plots of posterior probability vs. 
parameter value for each parameter varied individually in the classification algorithm for 
nonkeratinized tissue. 
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6. VALIDATION STUDY OF DEPTH-SENSITIVE SPECTROSCOPY METHOD 
AND ALGORITHM USING A REDUCED SET OF SPECTRAL DATA 
6.1 Introduction 
Chapter 5 described a clinical study of depth-sensitive optical spectroscopy (DSOS) in 
which spectra were collected using 13 different illumination configurations and four 
depth channels, for a total of 52 spectra per measurement. Algorithms were developed 
for diagnostic classification of nonkeratinized and keratinized tissue sites. The algorithm 
for nonkeratinized tissue was developed using a training set and tested using a separate 
validation set. The algorithm for keratinized tissue was developed and tested using cross-
validation. 
This chapter describes a followup study in which spectra were collected with the 
same DSOS device, this time using only a small subset of the illumination wavelengths 
and depth channels described in Chapter 5. The subset of wavelength and depth channel 
combinations used here included those specifically required in the algorithm for 
nonkeratinized tissue. The purpose of this study was threefold: first, to validate the 
performance of the algorithm for nonkeratinized tissue in another independent validation 
set; second, to determine what diagnostic performance could be obtained in keratinized 
tissue using the reduced set of wavelength and depth channel combinations; and third, to 
establish the basis for the design of a new, compact, portable DSOS device to be 
described in Chapter 7. 
6.2 Materials and Methods 
Procedures for clinical measurements, calibration, data analysis, and comparison with 
histopathology were the same as those described in Chapter 5. The DSOS device 
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described in Chapters 4 and 5 was used in this study, except that only eight spectra 
(instead of 52) were collected per measurement. The time required for a single 
measurement was correspondingly reduced from -90 seconds to ~15 seconds. The eight 
spectra were collected using four different illumination configurations (380 nm 
excitation, 390 nm excitation, 470 nm excitation, and white light illumination) and two 
different probe channels (shallow and medium depth channels). The choices of 380 nm, 
white light, medium depth channel, and shallow depth channel were made based on the 
spectral features needed for the algorithm for nonkeratinized tissue. The choices of 
390 nm and 470 nm were made because those wavelengths were also under consideration 
for inclusion in the portable DSOS system. 
6.3 Results 
Table 5 summarizes the numbers of subjects, oral sites, and spectroscopic measurements 
involved in this validation study. During the 10-month period from December 2007 to 
September 2008, a total of 368 in vivo measurements of oral tissue were collected from 
265 sites in 44 subjects. Of the 368 measurements performed, 351 (95%) passed the 
quality control check. There were 212 measurements of sites in patients that passed the 
quality control check; of these, 89 (42%) were from sites not on a clinical margin with a 
corresponding biopsy that produced a valid histopathology diagnosis (a "hard" gold 
standard). Sites that spanned an apparent clinical margin, which were measured 
separately as part of a margin study, were excluded from consideration here due to the 
need for different procedures to account for two potentially distinct disease states in both 
the measured data and the tissue sample. There were 139 measurements of sites in 
normal volunteers that passed the quality control check. Of these, all were considered to 
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have a "soft" gold standard of Normal/Benign based on expert clinical impression. The 
final data set consisted of 228 measurements from 184 sites in 33 subjects. 
Table 5. Oral Tissue Measurements In Vivo: Validation Study with Reduced Spectral Data 
Performed 
Passed quality control check 
Passed quality control check, non-
margin site with valid histopathology 
diagnosis 
Final data set for analysis 
Subset: 
Non-keratinized tissue, 
validation set #2 
Subset: 
Keratinized tissue, 
data set #2 
Subjects 
Sites 
Measurements 
Subjects 
Sites 
Measurements 
Subjects 
Sites 
Measurements 
Subjects 
Sites 
Measurements 
Subjects represented** 
Sites 
Measurements 
Subjects represented** 
Sites 
Measurements 
Patients 
31 
117 
220 
31 
116 
212 
20 
45 
89 
20 
45 
89 
16 
32 
64 
7 
13 
25 
Normal 
volunteers 
13 
148 
148 
13 
139 
139 
0* 
0* 
0* 
13 
139 
139 
13 
98 
98 
13 
41 
41 
Total 
44 
265 
368 
44 
255 
351 
20 
45 
89 
33 
184 
228 
29 
130 
162 
20 
54 
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* No biopsies were taken in normal volunteers. 
** Some subjects are represented in both the keratinized subset and a non-keratinized subset. 
Table 6 shows a comparison between the conventional pathologic and expert 
clinical diagnosis for sites in patients. In Table 6, with clinical impression categories 
grouped as Normal to Abnormal Low Risk vs. Abnormal High Risk to Cancer, and 
histopathologic categories grouped as Normal to Mild Dysplasia vs. Moderate Dysplasia 
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to Cancer, expert clinical diagnosis of all patient sites correlated with pathologic 
diagnosis with a sensitivity of 88% and a specificity of 64%. 
Table 6. Histopathology vs. Clinical Diagnosis: Validation Study with Reduced Spectral Data 
Data Set 
All sites in 
patients 
Non-keratinized 
tissue, validation 
set #2, sites in 
patients 
Keratinized 
tissue, data set 
#2, sites in 
patients 
Histopathology diagnosis 
Normal / benign 
Mild dysplasia 
Moderate or severe dysplasia 
Cancer 
Total 
Normal / benign 
Mild dysplasia 
Moderate or severe dysplasia 
Cancer 
Total 
Normal / benign 
Mild dysplasia 
Moderate or severe dysplasia 
Cancer 
Total 
Normal 
13 
4 
2 
0 
19 
11 
3 
1 
0 
15 
2 
1 
1 
0 
4 
Expert clinical impression 
Abnormal 
low risk 
1 
0 
0 
0 
1 
0 
0 
0 
0 
0 
1 
0 
0 
0 
1 
Abnormal 
high risk 
4 
3 
3 
0 
10 
4 
3 
3 
0 
10 
0 
0 
0 
0 
0 
Cancer 
2 
1 
1 
11 
15 
0 
0 
0 
7 
7 
2 
1 
1 
4 
8 
Total 
20 
8 
6 
11 
45 
15 
6 
4 
7 
32 
5 
2 
2 
4 
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Nonkeratinized sites were classified by direct application of the nonkeratinized 
algorithm previously developed in Chapter 5, without modification. This was possible 
because the reduced spectral data collected for each site still included the spectral 
features necessary for the nonkeratinized algorithm. For keratinized sites, the full range 
of spectral data used in the keratinized cross-validation algorithm in Chapter 5 was not 
available here. Instead, two methods for classifying keratinized sites were evaluated: (1) 
cross-validation using the combined keratinized data sets #1 and #2, with spectral 
features limited to only those available in keratinized data set #2; and (2) direct 
application of the nonkeratinized algorithm previously developed in Chapter 5, without 
modification, to keratinized data set #2. 
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Figure 20 shows the diagnostic performance of DSOS in nonkeratinized tissue in 
this validation study (Fig. 20c), as well as diagnostic performance previously obtained in 
the nonkeratinized training set (Fig. 20a) and in nonkeratinized validation set #1 
(Fig. 20b) for comparison. In this validation study a sensitivity of 91% and a specificity 
of 89% were obtained for diagnostic classification of 130 nonkeratinized tissue sites. In 
the patient-only nonkeratinized subset (32 sites), a sensitivity of 91% and a specificity of 
67% were obtained. 
(a) Nonker Training Set: 
Patient Sites 70, Volunteer Sites 121 
Training set ROC, nonkeratinized oral tissue 
• Training set, nonkeratirtized patients only 
O Screening: Weighted pooled visual examination 
D Referral: Weighted pooled visual examination 
0.2 0.4 0.6 
1-Specificity 
I • Diagnosis negative; clinical Impression negative | 
(d) Nonker Validation Set 2, Normal 
Volunteer Sites, Sp = 94% 
(b) Nonker Validation Set 1: 
Patient Sites 45, Volunteer Sites 74 
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Figure 20. Top row: ROC curves for spectroscopy algorithms in nonkeratinized tissue in (a) the training 
set, (b) validation set 1, and (c) validation set 2 in which a reduced set of spectral data were collected. 
Sensitivity and specificity values are shown for all subjects and for patients only. The estimated sensitivity 
and specificity of visual examination in screening and referral populations (see Chapter 2) are shown for 
comparison. Bottom row: Scatter plots of posterior probability for (d) sites in normal volunteers and (e) 
sites in patients in nonkeratinized validation set 2. 
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Table 7 shows the diagnostic performance of the two different methods that were 
evaluated for classifying keratinized tissue in this study. Using cross-validation in the 
combined keratinized data sets #1 and #2, with spectral features limited to those available 
in keratinized data set #2, a sensitivity of 50% and a specificity of 54% were obtained 
within keratinized data set #2 itself. (Overall sensitivity and specificity in the combined 
data sets #1 and #2 were 70% and 64%, respectively, in this case.) Using the 
nonkeratinized algorithm applied directly to keratinized data set #2, a sensitivity of 67% 
and a specificity of 75% were obtained. 
Table 7. Diagnostic performance in keratinized data set #2 (54 sites, including 6 positive sites). 
Analysis method Sensitivity Specificity 
Cross-validation using combined keratinized data sets 50% 54% 
#1 and #2; spectral features restricted to those available 
in keratinized data set #2 
Direct application of nonkeratinized algorithm to keratinized 67% 75% 
data set #2 without modification 
Finally, Table 8 summarizes the diagnostic performance of DSOS in the entire 
data set. Combining the data sets described in Chapters 5 and 6, a total of 780 
measurements from 608 sites in 157 patients were analyzed and classified. For all 608 
sites analyzed, the overall sensitivity was 86% and the overall specificity was 86%. For 
the 440 nonkeratinized sites, sensitivity and specificity were 90% and 89%), respectively. 
For the 168 keratinized sites, sensitivity and specificity were 75% and 78%), respectively. 
Table 8 also indicates the analysis method used and the diagnostic performance obtained 
within specific subsets of the data. 
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Table 8. Summary of diagnostic performance of DSOS in the combined data set. 
Data set 
All sites 
Nonkeratinized sites 
Keratinized sites 
Number 
of sites 
608 
440 
168 
Analysis method 
See below 
See below 
See below 
Sensitivity 
86% 
90% 
75% 
Specificity 
86% 
89% 
78% 
Nonkeratinized training set 
Nonkeratinized validation set 1 
Nonkeratinized validation set 2 
Keratinized data set 1 
Keratinized data set 2 
191 
119 
130 
114 
54 
Nonkeratinized algorithm 
Nonkeratinized algorithm 
Nonkeratinized algorithm 
Cross validation in ker data set 1 
Nonkeratinized algorithm 
94% 
82% 
91% 
79% 
67% 
90% 
87% 
89% 
80% 
75% 
6.4 Discussion 
This study succeeded in validating the spectroscopy method and algorithm for 
nonkeratinized tissue. For nonkeratinized sites the sensitivity and specificity were both 
approximately 90%, and were in fact higher than in the previous validation set. This 
confirmed that the correct set of illumination wavelengths and depth channels for 
nonkeratinized tissue had been selected for inclusion in the reduced data set. 
For keratinized tissue, diagnostic performance was relatively low. However, the 
nonkeratinized algorithm actually performed better in keratinized data set #2 than 
retraining using cross-validation on the combination of keratinized data sets #1 and #2. 
(Retraining on keratinized data set #2 alone was avoided due to the small size of this data 
set.) This appears to be consistent with earlier observations that there is considerable 
variability within the keratinized data sets, making classification more difficult. These 
results generally confirm that keratinized sites are more difficult to classify than 
nonkeratinized sites, but suggest that the possibility of using an algorithm for keratinized 
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tissue that is somewhat similar to the nonkeratinized algorithm (perhaps with a similar or 
identical subset of spectral data) should not necessarily be ruled out. Further 
measurements and data analysis are needed to optimize an algorithm for keratinized 
tissue. 
The use of a small subset of illumination configurations and depth channels in this 
study laid the foundation for the development of the compact, portable DSOS system 
described in the next chapter. This study showed that a reduced set of measurement 
configurations could result in substantially faster data collection and simplified analysis, 
both of which are important for the development of real-time diagnostic techniques, 
without sacrificing performance. Based on these results it was decided that the portable 
DSOS system would measure four spectra per measurement: fluorescence spectra at 385 
nm excitation through the shallow and medium depth channels, and reflectance spectra 
with white light illumination through the shallow and medium depth channels. The 
development of the portable DSOS system is described in the following chapter. 
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7. DESIGN, CONSTRUCTION, AND EVALUATION OF A PORTABLE DEVICE 
FOR DEPTH-SENSITIVE OPTICAL SPECTROSCOPY 
7.1 Design 
This chapter describes the design and construction of a compact, portable depth-sensitive 
optical spectroscopy (DSOS) device for detection of oral neoplasia and the evaluation of 
its operating characteristics using optical calibration standards, as outlined in Specific 
Aim 1. 
The clinical studies described in Chapters 4-6 provided detailed information about 
fluorescence and reflectance spectra of oral tissue at multiple wavelengths and different 
depths below the mucosal surface. This complexity was necessary to determine the 
parameters that provide best discrimination between normal and abnormal mucosa as 
well as abnormal/benign from abnormal neoplastic mucosa. The next step toward 
translation into clinical practice is to use these findings to develop simple systems 
optimized to provide the highest sensitivity and specificity, and diagnostic algorithms for 
automated real time risk characterization. 
The set of six spectral features found to be optimal for diagnostic classification of 
nonkeratinized oral tissue were shown in Table 4 in Chapter 5. All six features are 
associated with reflectance using white light illumination or fluorescence using 380 nm 
illumination, and all were obtained using the medium or shallow depth channels of the 
fiber optic probe. The design of the portable DSOS system is therefore based on these 
illumination wavelengths and depth channels. 
The portable DSOS system was designed with several novel features to facilitate 
use in community based clinical trials: 1) compact size and light weight for easy 
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portability; 2) a fiber probe to interrogate and collect spectral data preferentially from the 
epithelial and shallow stromal mucosal layers; 3) inexpensive LED (light emitting diode) 
light sources capable of exciting tissue fluorescence and broadband reflectance; 4) a 
laptop computer for system control and data storage; 5) a limited number of excitation 
wavelengths for rapid data collection; 6) a modular design making it possible to change 
which spectral features are interrogated simply by selecting different illumination LEDs 
and appropriate long pass filters; and 7) software to perform immediate data processing 
and classification so that a diagnostic result can be generated in real time following each 
measurement. 
7.2 Instrumentation 
Figure 21 shows a diagram of the portable DSOS instrument. Light is delivered to the 
tissue via a ball-lens coupled fiber probe that is placed in contact with the tissue. The 
probe contains two illumination 
channels: a shallow channel to 
target the epithelium, and a 
medium channel to target the 
basal epithelium and shallow 
stroma. The probe design is 
identical to that described in 
Chapter 4 except that the deep 
channels are omitted. Reflectance measurements using white light illumination, and 
fluorescence measurements using 385 nm narrowband illumination, are collected through 
each of the two depth channels. The use of a limited set of depth channels and 
Depth 
Channel 
#1 
Depth 
Channel 
#2 
385 nm 
LED 
White 
LED 
385 nm 
LED 
White 
LED 
Fiber Optic 
Spectrometer 
Depth-Selective 
Fiber Optic 
Probe 
Fig. 21. Diagram of the modular portable DSOS system. 
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illumination wavelengths simplifies probe construction and enables rapid data 
acquisition, while still enabling depth selectivity and measurement of key diagnostic 
features. 
Table 9 provides a summary of the LED light sources used in the portable DSOS 
system. Illumination for reflectance is provided by a two white LEDs (General Electric 
Vio High Power White), each with a 330 nm longpass filter in the illumination path to 
eliminate deep UV wavelengths. Illumination for fluorescence is provided by two 
385 nm narrow band LEDs (Nichia NCSU034A), each with a 385-nm bandpass filter 
(11 nm full-width half-maximum spectral width) in the illumination path to eliminate the 
"tails" of the illumination spectrum. 
Table 9. Characteristics of LED light sources for the portable DSOS device. 
Typical luminous flux (lm) or 
LED light source Emission wavelength radiometric power (mW) 
Nichia NCSU034A 385nm(peak) 310 mW @ 500 mA 
GE Vio High Power White LED 4W Emitter 405nm-660nm 138 lm @ 350 mA 
To eliminate the need for a filter wheel or moving parts, light from each LED is 
coupled directly into the illumination fibers of the corresponding depth channel of the 
probe. Light collected from the tissue is delivered to a miniature spectrometer (Ocean 
Optics USB2000+). The spectrometer is used to measure reflected light collected with 
white light illumination and fluorescent light collected at 385 nm excitation. A single 
405-nm longpass filter in the detection pathway blocks scattered excitation light for 
fluorescence measurements without affecting reflectance measurements in the 
wavelength region of interest. Again, this eliminates the need for a filter wheel or 
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moving parts on the detection side of the optical path. Table 10 lists the major 
components of the portable DSOS device. The total parts cost for components is 
approximately $9,230. 
Table 10. Major components of the portable DSOS device. 
Component Cost 
White LED x2, GE Vio white 4W emitter 
385 nm LED x2, Nichia NCSU034A 
Spectrometer, Ocean Optics USB2000+ 
Hardware for spectrometer interface, data acquisition and control 
Software for spectrometer data acquisition (Ocean Optics SpectraSuite) 
Depth sensitive fiber optic probe 
Laptop computer, Dell Latitude D630C 
Optical filters: 385 nm bandpass x2, 330 nm longpass x2, 405 longpass xl 
Mechanical housing, mounts, and fixtures 
Labview software for instrument control 
Matlab software for data processing and diagnostic classification 
Total cost of components 
(L 
(L 
$30 
$200 
$3,300 
$400 
$200 
$1,300 
$1,900 
$1,200 
$700 
icensed) 
icensed) 
$9,230 
Figure 22 shows a photograph of the portable DSOS device. It is 14" x 8" x 10" 
in size. The device itself weighs 14 pounds and the laptop computer weighs 6 pounds. 
This is drastically smaller and lighter than the earlier DSOS system described in Chapters 
4-6. The instrument collects 5 spectra per measurement (reflectance medium depth, 
reflectance shallow depth, fluorescence medium depth, fluorescence shallow depth, and 
background) with a total measurement time of 5 seconds. Data collection is fully 
automated and is controlled by custom Labview software. Data processing, data analysis, 
and real-time diagnostic classification are performed by custom Matlab software. Data 
processing and analysis consist of the following steps: 
1. Processing of spectroscopic data to yield a calibrated optical spectrum. 
Measured spectral data are wavelength calibrated, background subtracted, and 
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modified by appropriate correction factors to account for variations in 
illumination intensity and system throughput. 
2. Extraction of optical parameters required for diagnostic algorithm. Once data 
have been appropriately processed, the required input parameters to the diagnostic 
algorithm are extracted. 
3. Application of diagnostic algorithm to calculate posterior probability of disease. 
The diagnostic algorithm (based on linear discriminant analysis) is applied to 
calculate the probability that the interrogated site contains dysplasia or cancer. 
4. Diagnostic prediction. A threshold is applied to determine a diagnostic 
prediction, which is available within approximately 8 seconds of the completion 
of the measurement. 
Construction of the portable DSOS device was completed in April 2009. A second 
portable DSOS device is under construction. A photograph of two members of the 
clinical research group illustrating the use of the portable device is shown in Figure 23. 
Fig. 22. Portable depth-sensitive optical spectroscopy device. 
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Fig. 23. Two members of the clinical research team illustrate the measurement procedure using the 
portable depth-sensitive optical spectroscopy device. 
7.3 Calibration and evaluation 
Calibration measurements were performed on the portable DSOS device to ensure proper 
instrument performance and accuracy. Probe output power was measured using an 
optical power meter (Newport 1835-C or 4832-C) and the measured spectra were 
corrected for illumination energy. A background spectrum was subtracted from each 
tissue measurement to minimize the effects of ambient light. Wavelength calibration and 
spectral resolution were measured using a mercury-argon calibration lamp (Ocean Optics 
HG-1). The wavelength-dependent throughput of the system was measured using a 
tungsten calibration lamp (Ocean Optics LS-l-CAL) and these measurements were used 
to develop a correction factor that was applied to measured spectra during data 
processing. 
Measurements of optical calibration standards were performed before or after 
clinical measurements. Calibration standards included two positive fluorescence 
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standards (the fluorescent dye Rhodamine 610 in 8 g/L and 2 mg/L concentrations); two 
negative fluorescence standards (the ground surface of a fused silica cuvette, and filtered 
water); one positive reflectance standard (a highly reflective white Teflon sample); and a 
negative standard for both fluorescence and reflectance (a measurement of no target in a 
darkened room). Only spectra measured from the Teflon and water standards were used 
directly in data processing; tissue spectra were divided by an average Teflon spectrum, 
with or without a correction for the water spectrum, to generate a reflectance ratio. The 
other calibration standards were used as reference spectra to track system performance. 
Figure 24 shows the mercury-argon calibration lamp spectrum measured using the 
portable DSOS device. The measured spectral resolution of the instrument (full width at 
half maximum intensity of the mercury-argon spectral lines) is 8 nm. This is comparable 
to the anticipated spectral resolution of 5-7 nm, and is sufficient for measuring the 
spectral features of interest for the diagnostic algorithm. 
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Fig. 24. Mercury-argon calibration lamp spectrum measured using the portable DSOS device. 
Measured spectral resolution is 8 nm. 
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Figure 25 shows the probe output power measured over time for the two 
reflectance illumination channels (Fig. 25 a) and the two fluorescence illumination 
channels (Fig. 25b). The power values shown represent 23 independent measurements 
performed over a 6-month time period from October 2009 to March 2010. The 
discontinuity in the reflectance power data at measurements 11-12 represents an optical 
realignment of the system prior to the initial move to the clinic. Measurements 1-11 were 
performed in a laboratory environment with a Newport 1835-C power meter; 
measurements 12-23 were performed in a clinical environment with a Newport 4832-C 
power meter. Greater variation is observed in measurements 12-17 because procedures 
for properly fixturing the probe in the clinical environment were being worked out during 
this time period. The power values shown were used along with the exposure time to 
calculate the illumination energy, which was used as a correction factor for the measured 
data. 
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Fig. 26. (a,b): Fluorescence spectra measured from two negative fluorescence standards: (a) frosted 
fused silica cuvette surface and (b) filtered water. Fluorescence spectrum measured from a positive 
fluorescence standard: (c) a cuvette containing 8 g/L Rhodamine 610 dye. Fluorescence spectrum 
measured from oral tissue in vivo: (d) a buccal site in a healthy volunteer. All spectra shown were 
measured using the medium depth channel. S/N=250 for a typical measurement of healthy oral tissue. 
Figure 26 shows examples of fluorescence spectra measured from a frosted fused 
silica cuvette surface used as a negative fluorescence standard (Fig. 26a); from a sample 
of filtered water used as a negative fluorescence standard (Fig. 26b); from a cuvette 
containing 8 g/L Rhodamine 610 dye used as a positive fluorescence standard (Fig. 26c); 
and from a typical oral site in a healthy volunteer for comparison (Fig 26d). All 
measurements shown in Fig. 26 were performed using the medium depth channel. Note 
that the depth-sensitive nature of the probe significantly reduces the fluorescence signal 
of the Rhodamine 610 dye measured through the cuvette wall in (c); otherwise it would 
be many times greater than the tissue fluorescence shown in (d). The typical signal-to-
noise ratio for a measurement of healthy oral mucosa (Fig. 26d) is S/N=250. 
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Two different methods were considered for analyzing reflectance spectra 
collected by the portable DSOS device, as discussed further in Chapter 8. In the first 
method (Tissue/Teflon), the tissue spectrum was divided by the average spectrum of 
Teflon (a positive reflectance standard) to generate a reflectance ratio spectrum. This is 
identical to the analysis procedure described in Chapters 4 and 5. In the second method 
[(Tissue - Water)/Teflon], the average spectrum of water (a negative reflectance 
standard) was subtracted from the tissue spectrum, and the result was divided by the 
average spectrum of Teflon to generate a "water-corrected" reflectance ratio spectrum. 
The second method was considered as a possible way to account for variations from one 
probe to another in back reflections from the ball lens within the probe tip. Water is an 
appropriate negative reflectance standard for this purpose because its refractive index is 
close to that of tissue. 
Figure 27 illustrates the Tissue/Teflon method for analyzing reflectance spectra, 
using measured data from a water sample (negative reflectance standard) and from a 
tissue site (floor of mouth, cancer). The reflectance spectrum measured from the target is 
divided by the average reflectance spectrum from the Teflon standard to generate a 
reflectance ratio. Note that reflectance signal is observed even from the negative water 
standard. This is because a fraction of the illumination light is reflected within the probe 
tip/ball lens assembly itself back into the collection fiber, and is not excluded by an 
emission filter (as in the case of fluorescence). The fraction of reflected light is greater 
when the probe tip is in air, and smaller when the probe tip is immersed in water or in 
contact with tissue due to better index matching between the ball lens and the external 
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environment. The fraction of reflected light may vary from one probe to another due to 
slight differences in positioning of the fibers relative to the ball lens. 
Figure 28 illustrates the (Tissue - Water)/Teflon method for analyzing reflectance 
spectra, using the same measured data as in Figure 27. In this case the average water 
spectrum is subtracted from the spectrum of the target, and the difference is divided by 
the average reflectance spectrum of Teflon. The resulting water-corrected reflectance 
ratio eliminates the residual signal from the negative water standard. 
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Fig. 28. (Tissue - Water)/Teflon method for analysis of reflectance spectra. Left column: Water 
sample used as a negative standard. Right column: Tissue site (floor of mouth, cancer). Top: 
Reflectance spectrum from the target. Upper middle: Reflectance spectrum of the target after 
subtracting average water spectrum. Lower middle: Average spectrum of Teflon. Bottom: 
Reflectance ratio, (Tissue - Water)/Teflon. All spectra shown were measured using the medium 
depth channel. Note the hemoglobin absorption in the 420-nm and 540-580 nm ranges in the 
(Tissue - Water)/Teflon spectrum. 
86 
In summary, the portable DSOS device was completed in April 2009 and its 
operating characteristics matched expectations. It is 14" x 8" x 10" in size, 14 pounds in 
weight, and easily transportable. It has a spectral resolution of 8 nm, a signal-to-noise 
ratio of 250 for a typical measurement of healthy oral mucosa, a measurement time of 
5 seconds, and real-time analysis software that generates fully processed spectra and a 
diagnostic prediction a few seconds after the measurement is completed. 
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8. CLINICAL STUDY OF A PORTABLE DEVICE FOR DEPTH-SENSITIVE 
OPTICAL SPECTROSCOPY 
8.1 Introduction 
This chapter presents clinical studies of the portable DSOS device as outlined in Specific 
Aim 2. Similarities and differences in diagnostic performance between the portable 
DSOS device (described in Chapter 7) and the earlier DSOS instrument (described in 
Chapters 4-6) are discussed. Results of in vivo measurements of 47 subjects, including 
16 oral cancer patients, 11 high-risk subjects, and 20 healthy volunteers, are presented. 
8.2 Materials and methods 
This study was conducted at the University of Texas M. D. Anderson Cancer Center 
(MDACC), the University of Texas Dental Branch (UTDB), and Rice University. The 
study was approved by the Institutional Review Board at each institution. Patients with 
lesions of the oral mucosa and healthy volunteers 18 years or older were recruited to 
participate. Subjects measured at MDACC were patients with oral lesions suspicious for 
dysplasia or cancer (a high prevalence population); subjects measured at UTDB had a 
variety of benign oral lesions (a high risk population); and subjects at Rice University 
were healthy volunteers (a screening population). Written informed consent was 
obtained from all subjects. 
Procedures for spectroscopic measurements were identical to those described in 
Chapter 5. The portable DSOS device described in Chapter 7 was used for all 
measurements. Instrument calibration and data processing were performed as described 
in Chapter 7. At MDACC, an average of five sites were measured per patient (including 
several abnormal sites and at least one normal-appearing site), and biopsies were 
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typically taken at two of the measured sites. At UTDB, an average of three sites were 
measured per subject and no biopsies were taken. At Rice University, an average of 
seven sites were measured per healthy volunteer and no biopsies were collected. 
Spectra measured using the portable DSOS device were compared with spectra 
collected using the original DSOS instrument. The quantitative spectral features 
described in Chapter 5 were extracted from the measured data for use as input to the 
diagnostic algorithm. Variations of the diagnostic algorithm for nonkeratinized tissue 
developed in Chapter 5 were applied as described in the next section to generate an 
automated diagnostic prediction, which was available approximately 8 seconds after each 
measurement. The diagnostic prediction was provided to the clinician either immediately 
after the measurement was completed, or after the completion of all measurements for the 
patient, according to the clinician's preference. 
The portable DSOS diagnostic prediction (Normal/Abnormal) for each site was 
compared to the gold standard to evaluate diagnostic performance. For sites in patients at 
MDACC for which a corresponding biopsy was available, histopathology was used as the 
gold standard. As in Chapter 5, a binary diagnosis of Normal to Mild Dysplasia 
(negative) vs. Moderate Dysplasia to Cancer (positive) was used. For sites in patients at 
MDACC for which no corresponding biopsy was available, and for all sites in subjects at 
UTDB, expert clinical impression was used as the gold standard. A binary diagnosis of 
Normal to Abnormal Low Risk (negative) vs. Abnormal High Risk to Cancer (positive) 
was used. All sites measured in healthy volunteers at Rice University were assigned a 
negative gold standard diagnosis. 
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8.3 Results 
Table 11 summarizes the numbers of subjects, oral sites, and spectroscopic measurements 
involved in this study of the portable DSOS device. During the 6-month period from 
October 2009 to March 2010, a total of 485 in vivo measurements of oral tissue were 
collected from 242 sites in 47 subjects. Subjects included 16 oral cancer patients at 
MDACC, 11 high-risk subjects at UTDB, and 20 healthy volunteers at Rice University. 
All measurements passed the quality control check and all were included in the analysis. 
The final data set consisted of 485 measurements from 242 sites in 47 subjects. 
Table 11. Oral Tissue Measurements In Vivo: Portable Depth-Sensitive Optical Spectroscopy Device 
MDACC UTDB Rice Univ. 
Oral Cancer High Risk Healthy 
Patients Subjects Volunteers Total 
Data set 
Subset: 
Nonkeratinized tissue 
Subset: 
Keratinized tissue 
Subjects 
Sites 
Measurements 
Subjects represented* 
Sites 
Measurements 
Subjects represented* 
Sites 
Measurements 
16 
79 
158 
12 
58 
116 
5 
21 
42 
* Some subjects are represented in both the keratinized subset and 
11 
31 
63 
10 
29 
58 
1 
2 
5 
20 
132 
264 
20 
85 
170 
20 
47 
94 
a nonkeratinized subset. 
47 
242 
485 
42 
172 
344 
26 
70 
141 
Table 12 shows the anatomic location of sites in the data set. There were 172 
sites at anatomic locations categorized as nonkeratinized, including buccal mucosa, 
tongue (mostly lateral, some ventral), floor of mouth, lip, and soft palate. There were 70 
sites at anatomic locations categorized as keratinized, including gingiva and hard palate. 
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Table 12. Number of Sites per Anatomic Location 
Data set 
Nonkeratinized subset 
Keratinized subset 
Buccal 
mucosa 
74 
74 
0 
Tongue 
87 
87 
0 
Floor of 
mouth 
7 
7 
0 
Lip 
2 
2 
0 
Soft 
Palate 
2 
2 
0 
Gingiva 
45 
0 
45 
Hard 
palate 
25 
0 
25 
Total 
242 
172 
70 
Table 13 shows the expert clinical diagnosis and the histopathologic diagnosis, 
where available, for sites in the data set. Histopathology results were available for 30 
sites in patients at MDACC. Of the 79 sites in patients at MDACC, 43 were considered 
positive by the gold standard (13 by pathology and 30 by clinical impression), and 36 
were considered negative by the gold standard (17 by pathology and 19 by clinical 
impression). The 31 sites in subjects at UTDB were all considered negative (11 Normal, 
20 Abnormal Low Risk) based on clinical impression. The 132 sites in healthy 
volunteers at Rice University were all assigned a negative gold standard diagnosis, 
including two sites described as Abnormal Low Risk due to inflammation. 
Table 13. Histopathology (if available) and Clinical Diagnosis of Sites in the Data Set 
Data Subset 
Expert clinical impression 
Histopathology 
diagnosis 
Abnormal Abnormal 
Normal low risk high risk Cancer Total 
MDACC sites with 
pathology 
Normal / benign 
Mild dysplasia 
Mod/severe dysplasia 
Cancer 
Subtotal 
MDACC sites, no path. N/A 
UTDB patient sites N/A 
Healthy volunteer sites N/A 
9 
4 
0 
0 
13 
17 
11 
130 
1 
0 
0 
1 
2 
2 
20 
2 
2 
0 
0 
0 
2 
5 
0 
0 
0 
1 
2 
10 
13 
25 
0 
0 
12 
5 
2 
11 
30 
49 
31 
132 
Total 171 26 38 242 
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The diagnostic performance of expert clinical impression can only be evaluated in 
the subset of 30 sites in patients at MDACC for which histopathology results are 
available. Referring to Table 13, with clinical impression categories grouped as Normal 
to Abnormal Low Risk vs. Abnormal High Risk to Cancer, and histopathologic 
categories grouped as Normal to Mild Dysplasia vs. Moderate Dysplasia to Cancer, 
expert clinical diagnosis correlated with pathologic diagnosis with a sensitivity of 92% 
and a specificity of 82% in that subset of 30 sites. 
The clinical impression category "Abnormal Low Risk" is of particular interest 
because a wide variety of benign lesions are seen in patients at UTDB. Table 14 
indicates the specific diagnosis of the 26 sites categorized as Abnormal Low Risk by 
clinical impression in the data set. 
Table 14. Specific Diagnosis of Sites with Clinical Impression Abnormal Low Risk. 
Data subset # of sites Specific diagnosis Notes 
MDACC patients 4 Lichen planus/inflammation 4 sites all in same patient 
UTDB patients 9 Lichen planus (red or white) 9 sites in 6 different patients 
3 Pemphigus vulgaris/inflammation 
2 Mild erythema/mucositis 
2 Red & white patch/inflammation Submucous fibrosis (prev. biopsy) 
2 Smokeless tobacco keratosis 
1 Geographic tongue (Erythema vulgaris) 
1 Brown pigmented lesion (Melanotic macule) 
Healthy volunteers 2 Inflammation 
Figure 29 shows an example of the real-time display of fully processed spectral 
data obtained immediately following a single measurement of a lateral tongue site in a 
healthy volunteer. The display shows two fluorescence spectra (385 nm excitation: 
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medium depth and shallow depth channels) and two reflectance ratio spectra (white light 
illumination: medium depth and shallow depth channels). The spectra of the current 
measurement are shown along with average spectra for nonkeratinized sites measured 
using the previous DSOS instrument (Chapter 5), broken down by diagnostic category, 
for comparison. The diagnostic prediction for the measurement shown in Figure 29 was 
Normal (posterior probability < 0.01 using analysis Method 1; posterior probability = 
0.14 using analysis Method 2, described further below). 
As the example shown in Figure 29 illustrates, the Fluorescence Medium spectra, 
Fluorescence Shallow spectra, and Reflectance Shallow spectra measured using the 
portable DSOS device are consistent with average spectra measured using the previous 
device. However, the Reflectance Medium spectrum is shifted to higher values with 
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respect to previous data. Two likely causes of this instrument-dependent shift were 
investigated and two corresponding methods for correcting for it were explored. The first 
possible cause is variation from one probe to another in back reflections from the ball 
lens surfaces within the probe tip, as described previously in Chapter 7. This possibility 
was addressed as indicated in Chapter 7 by reprocessing all previous and current data 
using the (Tissue - Water)/Teflon method, instead of the Tissue/Teflon method, for 
analyzing reflectance spectra. The second possible cause of the shift is intensity 
variations in the Teflon spectra (used to generate the average Teflon spectrum used in the 
reflectance ratio) that were measured using the previous DSOS instrument. The Teflon 
measurements in the previous data set were known to be more variable in intensity 
because those standards measurements were done in a clinical setting in which it was 
difficult to perform well controlled measurements. This second possibility was addressed 
by applying an empirical correction factor to the Reflectance Medium spectra. This 
wavelength-dependent correction factor was derived by taking the ratio of the average 
nonkeratinized spectra for normal volunteers in the previous data set to the average 
nonkeratinized spectra for normal volunteers in the portable DSOS data. 
Figures 30-41 show a series of comparisons of average spectra measured using 
the previous DSOS instrument and the portable DSOS device. 
Figures 30-33 show average data with the reflectance ratio calculated in the usual 
manner, as Tissue/Teflon. Figure 30 shows average nonkeratinized spectra measured 
using the previous instrument; this is the data set that was used to develop the diagnostic 
algorithm for nonkeratinized tissue. Figure 31 shows average nonkeratinized spectra 
measured using the portable DSOS device. The shift in the Reflectance Medium spectra 
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is clearly visible, while the other three spectra agree well with previous data. Figure 32 
shows average keratinized spectra measured using the previous instrument, and Figure 33 
shows average keratinized spectra measured using the portable DSOS device. These 
spectra show that the separation between normal and abnormal categories is less 
pronounced in keratinized tissue, making diagnostic classification more difficult. 
Figures 34-37 show average data with the reflectance ratio calculated as (Tissue-
Water)/Teflon. Figure 34 shows nonkeratinized data collected with the previous 
instrument and Figure 35 shows nonkeratinized data collected with the portable device. 
Figure 36 shows keratinized data collected with the previous instrument and Figure 37 
shows keratinized data collected with the portable device. As the plots indicate, this 
analysis method does not bring the Reflectance Medium spectra into full agreement. The 
Reflectance Medium spectra for both devices are shifted downward by similar amounts, 
still leaving a discrepancy. The Reflectance Shallow spectra for the portable device are 
shifted slightly downward as well, while the Reflectance Shallow spectra for the previous 
instrument are unaffected (there was negligible internal probe reflectance in this channel). 
Figures 38-41 show average data with the reflectance ratio calculated as 
Tissue/Teflon, but with an empirical correction factor applied to the Reflectance Medium 
spectra for the portable device. Figure 38 shows nonkeratinized data collected with the 
previous instrument and Figure 39 shows nonkeratinized data collected with the portable 
device. Figure 40 shows keratinized data collected with the previous instrument and 
Figure 41 shows keratinized data collected with the portable device. The empirical 
correction factor brings the average nonkeratinized Reflectance Medium spectra into 
good agreement, as expected. 
95 
5 
I 4 
CO I 3 
o 
o, 
S- 2 
'55 
c 
1 1 
0.8 
.g 
"5 
^ 0.6 
o c 
CD 
8 0.4 
% 
a. 
0.2 
x 1Q4 Fluorescence Medium 
^W_ f: 
450 500 550 600 650 
Wavelength (nm) 
Reflectance Medium 
^ 
0.8 
I . . 
-
0.2 
x io4 Fluorescence Shallow 
f £ ^ _ 
450 500 550 600 650 
Wavelength (nm) 
Reflectance Shallow 
=^-'^!!zr^~ Z -j^szzz 
zf 
450 500 550 600 650 450 500 550 600 650 
Wavelength (nm) Wavelength (nm) 
Fig. 30. Average nonkeratinized spectra collected using the previous DSOS instrument. Normal = 
solid blue traces; Mild Dysplasia = dashed blue traces; Moderate/Severe Dysplasia = dashed red traces; 
Cancer = solid red traces. This is the data set that was used to develop the diagnostic algorithm for 
nonkeratinized tissue in Chapter 5. 
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Fig. 31. Average nonkeratinized spectra collected using the portable DSOS instrument. Normal = 
solid blue traces; Mild Dysplasia or Abnormal Low Risk = dashed blue traces; Moderate/Severe 
Dysplasia or Abnormal High Risk = dashed red traces; Cancer = solid red traces. 
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Fig. 32. Average keratinized spectra collected using the previous DSOS instrument. Normal = solid 
blue traces; Mild Dysplasia = dashed blue traces; Moderate/Severe Dysplasia = dashed red traces; 
Cancer = solid red traces. 
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Fig. 33. Average keratinized spectra collected using the portable DSOS instrument. Normal = solid 
blue traces; Mild Dysplasia or Abnormal Low Risk = dashed blue traces; Moderate/Severe Dysplasia or 
Abnormal High Risk = dashed red traces; Cancer = solid red traces. 
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Fig. 34. Average nonkeratinized spectra collected using the previous DSOS instrument, with 
reflectance ratio calculated as (Tissue-Water)/Teflon. Normal = solid blue traces; Mild Dysplasia = 
dashed blue traces; Moderate/Severe Dysplasia = dashed red traces; Cancer = solid red traces. 
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Fig. 35. Average nonkeratinized spectra collected using the portable DSOS instrument, with 
reflectance ratio calculated as (Tissue-Water)/Teflon. Normal = solid blue traces; Mild Dysplasia or 
Abnormal Low Risk = dashed blue traces; Moderate/Severe Dysplasia or Abnormal High Risk = 
dashed red traces; Cancer = solid red traces. 
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Fig. 36. Average keratinized spectra collected using the previous DSOS instrument, with reflectance 
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Fig. 38. Average nonkeratinized spectra collected using the previous DSOS instrument. Normal = 
solid blue traces; Mild Dysplasia = dashed blue traces; Moderate/Severe Dysplasia = dashed red traces; 
Cancer = solid red traces. This figure is identical to Fig. 30 and is shown for comparison with Fig. 39 
below. 
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Fig. 39. Average nonkeratinized spectra collected using the portable DSOS instrument, with an 
empirical correction factor applied to Reflectance Medium spectra. Normal = solid blue traces; Mild 
Dysplasia or Abnormal Low Risk = dashed blue traces; Moderate/Severe Dysplasia or Abnormal High 
Risk = dashed red traces; Cancer = solid red traces. 
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Fig. 40. Average keratinized spectra collected using the previous DSOS instrument. Normal = solid 
blue traces; Mild Dysplasia = dashed blue traces; Moderate/Severe Dysplasia = dashed red traces; 
Cancer = solid red traces. This figure is identical to Fig. 32 and is shown for comparison with Fig. 41 
below. 
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Fig. 41. Average keratinized spectra collected using the portable DSOS instrument, with an 
empirical correction factor applied to Reflectance Medium spectra. Normal = solid blue traces; Mild 
Dysplasia or Abnormal Low Risk = dashed blue traces; Moderate/Severe Dysplasia or Abnormal High 
Risk = dashed red traces; Cancer = solid red traces. 
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Four variations of the nonkeratinized diagnostic algorithm developed in Chapter 5 
were tried for classifying sites measured using the portable DSOS device. Table 15 lists 
the four methods and Table 16 summarizes the diagnostic performance of each method. 
In Table 16, for Methods 2 and 4, performance is further broken down by patient group 
and keratinization. 
Table 15. Analysis methods applied to the portable DSOS data. 
Method Description 
1 Nonkeratinized algorithm with original 6 parameters 
2 Nonkeratinized algorithm with only parameter #1 (Fluor. 385ex/472em, medium depth) 
3 Retrain nonker algo on training set (Ti-Wa)/Tf; apply to portable DSOS data (Ti-Wa)/Tf 
4 Nonker algo with original 6 parameters, applied to new data with Refl Med correction factor 
In Method 1, the nonkeratinized algorithm was applied directly without 
modification. The original six parameters and the original threshold (0.5533) described 
in Chapter 5 were used. This method produced a very low sensitivity (33%) and high 
specificity (100%) due to the presence of an uncorrected shift in the Reflectance Medium 
spectra. If the threshold were allowed to vary to compensate, a sensitivity of 80% and 
specificity of 73% could be achieved by setting the threshold to an extremely low value 
(< 0.01); however, this was not considered a workable solution for ongoing analysis. 
In Method 2, only the first parameter of the nonkeratinized algorithm 
(fluorescence, 380-385 nm excitation/472 nm emission, medium depth) was used. This 
method avoids the problem of the shift in the Reflectance Medium spectra by excluding 
those spectra from the algorithm. Method 2 was used as an interim real-time analysis 
procedure in clinical measurements from November 2009 to March 2010. This method 
produced an overall sensitivity of 84% and specificity of 63%. Diagnostic performance 
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was better in nonkeratinized tissue (sensitivity = 85%, specificity = 73%) than in 
keratinized tissue (sensitivity = 80%, specificity = 40%). Specificity was particularly low 
for keratinized sites in healthy volunteers. 
Table 16. Diagnostic performance of the portable DSOS device. Se: Sensitivity. Sp: 
Overall Nonkeratinized 
Method Subject group # sites Se Sp Se Sp 
Specificity. 
Keratinized 
Se Sp 
1 
2 
3 
4 
All subjects 
All subjects 
MDACC patients 
UTDB subjects 
Healthy vols 
Sites w/ pathology 
All subjects 
All subjects 
MDACC patients 
UTDB subjects 
Healthy vols 
Sites w/ pathology 
242 
242 
79 
31 
132 
30 
242 
242 
79 
31 
132 
30 
33% 
84% 
84% 
— 
-
85% 
37% 
8 1 % 
81% 
~ 
~ 
85% 
100% 
63% 
75% 
58% 
61% 
65% 
98% 
78% 
75% 
68% 
81% 
65% 
85% 
85% 
— 
~ 
80% 
82% 
82% 
~ 
~ 
80% 
73% 
80% 
59% 
75% 
67% 
83% 
80% 
69% 
89% 
67% 
80% 
80% 
. . 
-
100% 
80% 
80% 
--
-
100% 
40% 
64% 
50% 
34% 
60% 
65% 
64% 
50% 
66% 
60% 
In Method 3, the nonkeratinized algorithm was retrained on its original training 
set with reflectance in the form (Tissue-Water)/Teflon instead of Tissue/Teflon. A new 
set of six parameters was selected using stepwise feature selection to maximize the area 
under the ROC curve, and the retrained algorithm was applied to portable DSOS data 
with reflectance in the form (Tissue-Water)/Teflon. The set of six new parameters was 
found to be similar to the previous set; the new parameters included features #1 and #3 
from Table 4 in Chapter 5 as well as the shallow-depth equivalents to those same features 
#1 and #3. Similar to Method 1, this method produced a very low sensitivity (37%) and 
high specificity (98%) due to the shift in the Reflectance Medium spectra that was not 
fully corrected by the (Tissue-Water)/Teflon procedure. Again, the threshold could be 
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adjusted to an extremely low value (< 0.02) to compensate, resulting in a sensitivity of 
77% and specificity of 81%; but this was not considered ideal for ongoing analysis. 
In Method 4, the original nonkeratinized algorithm was applied directly without 
modification, using the original six parameters, to portable DSOS data with an empirical 
correction factor applied to Reflectance Medium spectra. The original threshold of 
0.5533 was used for nonkeratinized sites. A new threshold of 0.89 was established for 
keratinized sites. Method 4 produced an overall sensitivity of 81%> and specificity of 
78%. Again, performance was higher in nonkeratinized tissue (sensitivity = 82%, 
specificity = 83%) and somewhat lower in keratinized tissue (sensitivity = 80%, 
specificity = 65%). This method provided the best performance of the four variations of 
the original nonkeratinized algorithm. 
Figures 42-47 show ROC curves and scatter plots. In each scatter plot, sites are 
numbered chronologically (healthy volunteers were measured first). Figure 42 shows an 
ROC curve and scatter plot of posterior probability for analysis Method 1. In this scatter 
plot, about half of the abnormal sites (red markers) separate very well from the normal 
sites (blue markers); however, many abnormal sites remain with a low posterior 
probability, so sensitivity is poor unless the threshold is set extremely low. Figure 43 
displays the ROC curve and scatter plot for analysis Method 2. This method moves most 
of the abnormal sites to a high posterior probability, but they are accompanied by a 
significant fraction of normal sites so specificity is decreased. Figure 44 shows the ROC 
curve and scatter plot for analysis Method 3. Figures 45-47 show ROC curves and scatter 
plots for Method 4, which achieved the best performance: overall results in Fig. 45, 
nonkeratinized sites only in Fig. 46, and keratinized sites only in Fig. 47. 
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Fig. 42. Analysis method 1: Nonkeratinized algorithm with original 6 parameters. Top: ROC curve. 
Bottom: scatter plot of posterior probability vs. site number. Blue marker: Negative by gold standard. 
Red marker: Positive by gold standard. Triangular marker indicates clinical impression was incorrect 
with respect to gold standard. 
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Fig. 43. Analysis method 2: Nonkeratinized algorithm with only parameter #1. Top: ROC curve. 
Bottom: scatter plot of posterior probability vs. site number. Blue marker: Negative by gold standard. 
Red marker: Positive by gold standard. Triangular marker indicates clinical impression was incorrect 
with respect to gold standard. 
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1-Specificity 
Fig. 44. Analysis method 3: Nonkeratinized algorithm retrained on its training set in the form (Ti-
Wa)/Tf, applied to portable DSOS data in the form (Ti-Wa)/Tf. Top: ROC curve. Bottom: scatter plot 
of posterior probability vs. site number. Blue marker: Negative by gold standard. Red marker: 
Positive by gold standard. Triangular marker indicates clinical impression was incorrect with respect to 
gold standard. 
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Fig. 46. Analysis method 4: Nonkeratinized algorithm with original 6 parameters, applied to 
nonkeratinized portable DSOS data with empirical correction factor applied to Reflectance Medium 
spectra. Top: ROC curve. Bottom: scatter plot of posterior probability vs. site number. Blue marker: 
Negative by gold standard. Red marker: Positive by gold standard. Triangular marker indicates 
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Fig. 47. Analysis method 4: Nonkeratinized algorithm with original 6 parameters, applied to 
keratinized portable DSOS data with empirical correction factor applied to Reflectance Medium 
spectra. Top: ROC curve. Bottom: scatter plot of posterior probability vs. site number. Blue marker: 
Negative by gold standard. Red marker: Positive by gold standard. Triangular marker indicates 
clinical impression was incorrect with respect to gold standard. 
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8.4 Discussion 
The goal in the analysis of the portable DSOS data was to implement the previously 
developed diagnostic algorithm as closely as possible, and to minimize retraining on the 
new data set. This goal was dependent on obtaining well-matched clinical data using two 
very different devices with different types of light sources, different types of 
spectrographs, different detectors, different filter sets, different illumination power, 
different exposure times, and different sets of correction factors. The outcome was that 
three of the four spectra measured by the portable DSOS instrument were well matched 
to previous data; a correction factor was applied to the Reflectance Medium spectrum so 
that the original diagnostic algorithm could be implemented appropriately. 
The current data confirm previous results indicating differences between 
nonkeratinized and keratinized tissue. In nonkeratinized tissue, the portable DSOS data 
show the expected trend of decreasing fluorescence and lower reflectance ratio with 
dysplastic progression (compare Fig. 38 and Fig. 39). In keratinized tissue, disease 
progression is more difficult to correlate with spectral changes; yet the portable DSOS 
spectra are strikingly similar to previous results (compare Fig. 40 and Fig. 41). 
Diagnostic performance in the 26 sites with a clinical impression of Abnormal 
Low Risk was mixed. The portable device (using Method 4) correctly classified 15 of 
these 26 sites. There were 11 false positives: 7 lichen planus, 3 pemphigus vulgaris, and 
1 geographic tongue. There were 14 true negatives: 5 lichen planus, 2 mild 
erythema/mucositis, 2 red and white patch/inflammation (submucous fibrosis), 2 
smokeless tobacco keratosis, 1 pigmented lesion, and 2 inflammation. There was 1 true 
I l l 
positive: a lichen planus, found by histopathology to be dysplasia/cancer in a background 
of lichen planus. 
The current data provide an indication of the variations in fluorescence and 
reflectance spectra that may be observed in benign lesions. Figures 48-53 display 
examples of lesions measured at UTDB with a clinical impression of Abnormal Low 
Risk, along with the corresponding measured spectra (with correction factor applied to 
Reflectance Medium spectra). Figures 48-50 show examples of sites that were correctly 
classified (true negative): white lichen planus (Figure 48), smokeless tobacco keratosis 
(Figure 49), and red & white patch/inflammation/submucous fibrosis (Figure 50). 
Figures 51-53 show examples of sites that were misclassified (false positive): red lichen 
planus (Figure 51), pemphigus vulgaris/inflammation (Figure 52), and geographic tongue 
(Figure 53). 
It is evident from the data that lesion appearance and spectral characteristics may 
vary considerably even within a single diagnosis such as lichen planus. In this small set 
of sites, for example, red lichen planus was more likely to be misclassified as positive 
than white lichen planus. The clinical description "inflammation" did not appear to 
strongly affect classification; the set of true negative sites and the set of false positive 
sites measured at UTDB both included sites described as having inflammation. The 
geographic tongue fluorescence spectra in Figure 53 are particularly interesting because 
the fluorescence peak displays a pronounced shift to the left with respect to previous data. 
This shift is strongly reminiscent of the fluorescence spectrum measured from a 
fingernail (Figure 54). This most likely indicates the presence of a highly keratinized 
layer of tissue at this oral site, which is consistent with the clinical diagnosis. 
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Fig. 48. White lichen planus, lateral tongue, classified correctly (true negative). Top: arrow indicates 
site of spectroscopic measurement. Bottom: Measured spectra. Posterior probability per Method 4: 
0.24. 
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Fig. 49. Smokeless tobacco keratosis, mandibular buccal sulcus, classified correctly (true negative). 
Top: arrow indicates site of spectroscopic measurement. Bottom: Measured spectra. Posterior 
probability per Method 4: 0.16. 
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Fig. 50. Red & white patch with inflammation (submucous fibrosis per previous biopsy), lower buccal 
mucosa, classified correctly (true negative). Top: arrow indicates site of spectroscopic measurement. 
Bottom: Measured spectra. Posterior probability per Method 4: 0.05. 
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Fig. 51. Red lichen planus, anterior lateral tongue, misclassified (false positive). Top: arrow indicates 
site of spectroscopic measurement. Bottom: Measured spectra. Posterior probability per Method 4: 
0.99. 
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Fig. 52. Pemphigus vulgaris/inflammation, buccal mucosa, misclassified (false positive). Top: arrow 
indicates site of spectroscopic measurement. Bottom: Measured spectra. Posterior probability per 
Method 4: 0.98. 
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Fig. 53. Geographic tongue, lateral tongue, misclassified (false positive). Top: arrow indicates site of 
spectroscopic measurement. Bottom: Measured spectra. Posterior probability per Method 4: 0.81. 
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In summary, the diagnostic performance of a portable depth-sensitive spectroscopy 
device was evaluated in a clinical study involving 47 subjects, including 16 oral cancer 
patients, 11 high risk subjects, and 20 healthy volunteers. Measured spectra were 
compared to previous data. Variations in the spectra of different types of benign lesions 
were explored. A previously developed diagnostic algorithm was implemented with 
minor modifications to classify measured sites. Sensitivity and specificity were 82% and 
83%, respectively, for nonkeratinized sites and 80% and 65%, respectively, for 
keratinized sites. 
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9. COMBINATION OF IMAGING AND SPECTROSCOPIC MODALITIES FOR 
OPTICAL DIAGNOSIS OF ORAL PRECANCER*1 
dThe contents of this chapter are being prepared for submission to the journal Photochemistry and 
Photobiology with the following author list: Schwarz RA, Roblyer DM, Stepanek V, Weber CR, Gao W, 
Le TT, Gillenwater AM, Richards-Kortum R (2010). D. M. Roblyer performed widefield imaging 
measurements. Widefield images and independent analysis of widefield image data are courtesy of D. M. 
Roblyer. 
Abstract: The development and progression of dysplasia and cancer in the oral 
cavity alter the optical properties of oral mucosa, producing measurable changes 
in tissue autofluorescence, scattering, and absorption. Widefield imaging and 
point spectroscopy are two complementary optical techniques for noninvasive 
diagnosis of oral precancer and cancer based on these changes. Measurements of 
46 sites in 29 oral cancer patients using both widefield multispectral imaging and 
depth-sensitive point spectroscopy are reported. Differences between the two 
techniques are examined, including illumination and collection parameters, data 
analysis methods, and clinical considerations. The diagnostic performance of 
each technique is reported relative to histopathology. Methods of combining 
diagnostic information from widefield multispectral imaging and depth-sensitive 
point spectroscopy are analyzed. Using fixed thresholds previously established in 
the respective training sets, optimum performance is obtained by averaging the 
posterior probabilities obtained by the two modalities, with sensitivity = 94% and 
specificity = 69%. The data suggest that the overall performance of noninvasive 
optical diagnostic methods may be enhanced through the use of platforms that 
combine both imaging and spectroscopic modalities. 
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9.1 Introduction 
Cancer causes about 20% of all deaths in high income countries and 10% of all deaths in 
low income countries (5). Oral cancer forms a significant part of this global burden, 
ranking as the eleventh most common cancer worldwide with 390,000 new cases each 
year (1). Major advances have been made in the management of oral cancer through the 
combined use of surgery, radiotherapy and chemotherapy, resulting in significant 
improvements in quality of life; however, there has been little improvement in the five-
year overall survival rate for patients with oral cancer (7). Early detection of symptoms 
remains a key determinant of patient outcomes. Low-cost screening methods that can be 
sustained in low-resource settings are under evaluation, and population studies on the 
predictive value of oral cancer screening are needed (5). 
A number of noninvasive optical techniques have been investigated for early 
detection and diagnosis of oral cancer based on measurements of tissue autofluorescence 
and reflectance (31, 94, 96, 97). These include widefield imaging (38, 62, 63, 82, 85), in 
which a region of tissue is viewed or imaged under specialized illumination conditions; 
and point spectroscopy (47, 56, 59, 68, 75, 76, 78, 128), in which spectra are measured at 
a specific tissue site using a fiber optic probe. Both methods are based on the same 
fundamental principle: alterations in tissue autofluorescence, scattering, and absorption 
that occur with the development of dysplasia and cancer can be measured noninvasively 
and used for evaluation and diagnosis. 
Sources of native autofluorescence in oral mucosa include the amino acids 
tryptophan, tyrosine, and phenylalanine; structural proteins including collagen, collagen 
crosslinks, and elastin; the coenzymes reduced nicotinamide adenine dinucleotide 
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(NADH) and flavin adenine dinucleotide (FAD); keratin; and porphyrins (38, 42, 133, 
134). The spatial distribution of these fluorophores varies with depth. A keratin layer 
may be present at the tissue surface; NADH and FAD are primarily localized in the 
cytoplasm of metabolically active cells in the epithelium; and collagen fibers, collagen 
crosslinks, and elastin fibers are located in the stroma and produce a strong stromal 
fluorescence signal (51). Oxyhemoglobin and deoxyhemoglobin, primarily present in 
blood vessels in the stroma, have strong absorption maxima in the visible wavelength 
region. Light scattering from cell nuclei, mitochondria, and other organelles also affects 
the measured signal (77). As precancer develops the epithelium may display increased 
metabolic activity, increased thickness, increased nuclear size, and pleomorphism, while 
changes in the stroma may include microvascularization and breakdown of collagen 
crosslinks. These alterations are typically associated with an overall reduction in blue-
green fluorescence intensity (38) and sometimes an increase in red fluorescence due to 
increased accumulation of porphyrins (134). 
A number of research groups have explored the combined use of widefield 
imaging and point spectroscopy for multimodal optical diagnosis of oral precancer (52, 
65, 91). The use of a multimodal platform of this type offers several advantages. 
Widefield imaging may be used to detect suspicious regions and guide the placement of 
the point probe. Imaging and spectroscopy may be employed sequentially, with 
thresholds chosen such that the imaging step has a relatively high sensitivity and the 
spectroscopy step has a relatively high specificity. Quantitative information from the 
two different modalities may be combined to enhance diagnostic performance. Finally, 
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multimodal approaches may provide a means of minimizing false positive results due to 
inflammation and other benign conditions. 
Here we report measurements of 46 sites in 29 oral cancer patients using both 
widefield multispectral imaging and depth-sensitive point spectroscopy. The diagnostic 
performance of each method is compared with histopathology. Methods of combining 
data from the two methods to improve diagnostic performance are explored. 
9.2 Materials and methods 
Instrumentation. The widefield multispectral imaging device used in this study has been 
described in detail elsewhere (87). It consists of a commercial dental microscope (Zeiss 
OPMI Pico) fitted with a mercury arc lamp, excitation and emission filters, and CCD 
cameras (Figure 55a). The instrument collects a sequence of images under different 
illumination conditions, including reflectance imaging with white light illumination and 
autofluorescence imaging with several illumination wavelengths including 405 nm. 
The depth-sensitive 
point spectroscopy device 
used in this study has also 
been described previously 
(125). It consists of a xenon 
arc lamp, excitation and 
emission filters, fiber optic 
probe, spectrograph, and 
CCD detector (Figure 55b). 
The probe is 4 mm in 
Fig. 55. (a) Widefield imaging device and (b) depth-sensitive 
optical spectroscopy device used in the joint study of optical 
imaging and spectroscopy. 
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diameter and contains four sets of illumination and collection fibers, referred to as depth 
channels, which allow targeting of different measurement depths. Two depth channels 
are coupled through a sapphire ball lens located at the distal tip of the probe, enabling 
preferential targeting of shallow depths (epithelium) and medium depths (basal 
epithelium and shallow stroma). The other two depth channels consist of fibers directly 
in contact with the tissue, which interrogate deeper tissue regions (stroma). The device 
measures auto fluorescence spectra at twelve excitation wavelengths in the range 300-
470 nm and diffuse reflectance spectra using white light illumination. 
Several key differences between the imaging instrument and the spectroscopic 
instrument should be noted. The imaging device is a noncontact instrument which is 
positioned approximately 25 cm from the tissue site, whereas the spectroscopic probe is 
placed gently in contact with the site. The field of view of the imaging device ranges 
from 1 cm to 4 cm depending on the magnification setting; each depth channel of the 
spectroscopic probe interrogates a region approximately 1 mm in diameter. The imaging 
device collects images with < 50 urn transverse spatial resolution and coarse spectral 
resolution; the spectroscopy device collects spectra from the entire 1-ram diameter 
interrogated region with < 1 nm spectral resolution. The imaging modality interrogates 
deeper regions in the tissue than the shallow and medium depth channels of the 
spectroscopic probe, which are specifically designed to target the epithelium and shallow 
stroma. 
Human subjects. The study was performed at the University of Texas M. D. 
Anderson Cancer Center (MDACC) and was approved by the Institutional Review 
Boards at MDACC and Rice University. Patients 18 years or older with known or 
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suspected precancerous or cancerous lesions of the oral mucosa were recruited to 
participate in the study. Patients may have had previous surgical, radiation, or 
chemotherapeutic treatments. Written informed consent was obtained from all subjects. 
Measurement procedure. Multimodal measurements were performed at MDACC 
in the operating room prior to surgery, or in the clinic. The oral cavity was first inspected 
visually and apparent oral lesions were identified (Fig. 56a). The widefield imaging 
device was then used to measure one or more lesions (Fig. 56b), as well as adjacent 
and/or contralateral normal-appearing regions. Next the spectroscopic point probe device 
was used to measure one or more of the lesion sites (Fig. 56c) and normal-appearing 
sites. The clinical appearance of each measured site, as judged by a single expert 
observer, was recorded and categorized as Normal, Abnormal Low Risk, Abnormal High 
Risk, or Cancer. All optical measurements were performed in a darkened room to 
minimize the effects of ambient light. Following the optical measurements, tissue 
specimens were collected from the measured sites for histopathologic evaluation. In 
most cases the tissue specimens were 4-mm punch biopsies; in other cases, measured 
sites within a region of tissue to be resected were marked for later identification on the 
Fig. 56. (a) Oral lesion; (b) widefield autofluorescence image of the lesion; (c) spectroscopic point 
probe measurement of the lesion. 
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resected specimen. The pathology diagnosis for each site was categorized as 
Normal/Benign, Mild Dysplasia, Moderate/Severe Dysplasia, or Cancer. The category 
Normal/Benign included normal, hyperkeratosis, hyperplasia, and/or inflammation 
without dysplasia or with only focal mild dysplasia; there were no benign tumors in the 
study. 
Independent data analysis. Procedures for instrument calibration, data 
acquisition, selection of regions of interest within images, data processing, data analysis, 
and histopathologic correlation for each independent device were identical to those 
reported previously in Roblyer et al (88) and Schwarz et al (135). The diagnostic 
classification algorithms and thresholds previously developed using the training sets in 
those studies were directly applied here to calculate the diagnostic performance of each 
instrument alone. Both the imaging algorithm and the spectroscopy algorithm are linear 
two-class classifiers trained to optimize the area under the receiver operating 
characteristic curve (ROC) in the training set. Each algorithm generates a posterior 
probability that a given site is abnormal and applies a threshold value to determine a 
diagnostic prediction. For both the imaging algorithm and the spectroscopy algorithm, 
the threshold value previously established in the training set was used without 
modification, to reduce the risk of overtraining in the relatively small joint data set. 
The imaging algorithm uses one quantitative feature as the basis for classification: 
the red-to-green fluorescence intensity ratio at 405 nm excitation within the region of 
interest, normalized with respect to a clinically normal region within the same image 
(88). The spectroscopy algorithm uses six quantitative spectral features as the basis for 
classification; the six features are associated with fluorescence at 380 nm excitation and 
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reflectance with white light illumination in the medium and shallow depth channels 
(135). The pathology diagnosis was used as the gold standard, with "Normal/Benign" 
considered a negative result and "Mild Dysplasia", "Moderate/Severe Dysplasia", and 
"Cancer" considered positive results. Note that the convention of Roblyer et al (88) was 
used in which mild dysplasia is considered a positive result. 
Combined data analysis. Five different approaches were used to combine the 
results of the imaging and spectroscopy data to produce a consensus diagnosis, as 
follows: 1) maximum posterior probability; 2) minimum posterior probability; 3) mean 
posterior probability; 4) posterior probability for imaging used as prior probability for 
spectroscopy; and 5) a two-step procedure in which only sites determined positive by 
imaging were evaluated by spectroscopy. Each method is described further below. 
Maximum posterior probability. Imaging and spectroscopy algorithms were 
applied independently to all sites. The higher of the two posterior probability values was 
selected as the final posterior probability. The higher of the two threshold values was 
selected as the final threshold value. 
Minimum posterior probability. Imaging and spectroscopy algorithms were 
applied independently to all sites. The lower of the two posterior probability values was 
selected as the final posterior probability. The lower of the two threshold values was 
selected as the final threshold value. 
Mean posterior probability. Imaging and spectroscopy algorithms were applied 
independently to all sites. The mean of the two posterior probability values was selected 
as the final posterior probability. The mean of the two threshold values was selected as 
the final threshold value. 
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Posterior probability for imaging used as prior probability for spectroscopy. The 
imaging algorithm was applied independently to all sites. The resulting posterior 
probability was used as the prior probability for the spectroscopy algorithm, which was 
then applied to all sites. The resulting posterior probability from spectroscopy was used 
as the final posterior probability. The threshold value for spectroscopy was used as the 
final threshold value. 
Two-step procedure with imaging followed by spectroscopy. The imaging 
algorithm was applied independently to all sites. Sites determined to be negative by 
imaging were considered negative and were not evaluated further. Sites determined to be 
positive by imaging were evaluated using the spectroscopy algorithm. The resulting 
posterior probability from spectroscopy was used as the final posterior probability. The 
threshold value for spectroscopy was used as the final threshold value. 
In addition to the combined analysis methods described above, a new single 
classifier was developed using the combined parameters from both modalities, retrained 
on the current data set. This new single classifier was used only to determine the 
performance that could be obtained in the given data set through retraining using the 
selected parameters; it is not considered a fair estimate of diagnostic performance 
because it involves retraining on a relatively small joint data set. 
9.3 Results 
During the 29-month period from June 2006 to October 2008, multimodal measurements 
using the widefield imaging device and the depth-sensitive optical spectroscopy device 
were performed on a total of 40 patients. The data were reviewed and 61 distinct 
measurement sites were identified at which an imaged region of interest corresponded to 
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a location measured with the spectroscopic point probe. Six of these sites were excluded 
because pathology results for the site were unavailable or inconclusive. Five sites were 
excluded because incomplete spectral data were available for the site. Four sites were 
excluded because the measurement site (and therefore the biopsy site) spanned an 
apparent margin between regions described clinically as "normal" and "cancerous", 
which would require different procedures to account for two potentially distinct disease 
states in both the measured data and the tissue sample. The resulting final data set for 
combined analysis consisted of 46 sites in 29 patients. 
The combined imaging/spectroscopy data set includes some sites for which 
independent imaging results or independent spectroscopy results have previously been 
reported. Of the 46 sites in the combined data set, 23 sites were in the widefield imaging 
training set and 12 were in the widefield imaging validation set (88); while 7 sites were in 
the spectroscopy training set and 7 were in the spectroscopy validation set (135). 
Table 17 shows the expert clinical impression vs. histopathology result recorded 
for each site. According to histopathology (the gold standard), 13 sites were negative for 
disease (Normal/Benign) and 33 sites were positive for disease (Mild Dysplasia, 
Moderate/Severe Dysplasia, or Cancer). Using the binary clinical impression categories 
"Normal to Abnormal Low Risk" vs. "Abnormal High Risk to Cancer", expert clinical 
impression had a sensitivity of 94% and a specificity of 85%. Clinical impression 
misclassified two Normal/Benign sites as Abnormal High Risk and misclassified two 
Mild Dysplasia sites as Normal or Abnormal Low Risk. 
Table 18 shows the anatomic location vs. histopathology diagnosis of each site. 
Lateral tongue and buccal mucosa were the most frequent anatomic locations, together 
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accounting for two-thirds of the sites measured. Other sites included floor of mouth, lip, 
soft palate, retromolar trigone, and hard palate. Eight of the 46 sites were found by 
histology to have no inflammation; 22 had mild to moderate inflammation; and 1 had 
severe inflammation. Information about inflammation was not available from histology 
for 15 sites. 
Table 17. Histopathology vs. Clinical Diagnosis of Oral Sites in the Imaging/Spectroscopy Data Set 
Histopathology diagnosis 
Expert clinical impression 
Abnormal Abnormal 
Normal low risk high risk Cancer Total 
Normal / benign 
Mild dysplasia 
Moderate or severe dysplasia 
Cancer 
Total 
11 
1 
0 
0 
12 
0 
1 
0 
0 
1 
2 
3 
5 
0 
10 
0 
2 
4 
17 
23 
13 
7 
9 
17 
46 
Table 18. Histopathology vs. Anatomic Location of Oral Sites in the Imaging/Spectroscopy Data Set 
Histopathology 
diagnosis 
Normal / benign 
Mild dysplasia 
Moderate/severe dyspl. 
Cancer 
Total 
Buccal 
mucosa 
5 
1 
2 
2 
10 
Tongue 
6 
4 
2 
8 
20 
Anatomic Location 
Floor of 
Mouth 
1 
1 
1 
0 
3 
Lip 
0 
0 
0 
3 
3 
Soft 
Palate 
0 
1 
2 
1 
4 
Retromolar 
trigone 
1 
0 
1 
2 
4 
Hard 
palate 
0 
0 
1 
1 
2 
Total 
13 
7 
9 
17 
46 
Figures 57-66 show sample images and spectra from 10 selected sites. Each 
figure shows an image of the site under white light illumination; an autofluorescence 
widefield image at 405 nm excitation; an image with the region of interest circled 
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(corresponding to the site where the point probe was placed); an image with the clinically 
normal region circled which was used for normalization in the imaging algorithm; an 
auto fluorescence spectrum at 390 nm excitation; and a reflectance spectrum with white 
light illumination. Figures 57-59 are sites that were correctly classified as True Negative 
by imaging and by spectroscopy. Figures 60-62 are sites that were correctly classified as 
True Positive by imaging and by spectroscopy. Figure 63 is a site that was True Positive 
by imaging, but False Negative by spectroscopy. Figure 64 is a site that was False 
Negative by imaging, but True Positive by spectroscopy. Figures 65-66 are sites that 
were False Positive by imaging and by spectroscopy. 
(a) White light i (b) Autofluorescence, 405 nm excitation 
(c) Region of interest (ROI) (d) Clinically normal site for normalization 
, x 1 0 
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Wavelength (nm) 
600 650 450 500 550 
Wavelength (nm) 
600 650 
(e) Fluorescence spectrum at ROI, 390 nm ex (f) Reflectance spectrum at ROI 
Fig. 57. Lateral tongue site classified as True Negative by imaging (posterior probability = 0.24) 
and True Negative by spectroscopy (posterior probability = 0.18). Clinical impression: Normal. 
Histopathology: Hyperkeratosis, (a) White light image, (b) Autofluorescence image at 405 nm 
excitation, (c) Region of interest circled; corresponds to location of point probe measurement, (d) 
Clinically normal region circled; used for normalization in imaging algorithm. (e) 
Autofluorescence spectrum at the region of interest at 390 nm excitation, (f) Reflectance ratio 
spectrum at the region of interest under white light illumination. 
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Fig. 58. Lateral tongue site classified as True Negative by imaging (posterior probability = 0.24) 
and True Negative by spectroscopy (posterior probability = 0.19). Clinical impression: Normal. 
Histopathology: Benign squamous mucosa, (a) White light image, (b) Autofluorescence image at 
405 nm excitation, (c) Region of interest circled; corresponds to location of point probe 
measurement, (d) Clinically normal region circled; used for normalization in imaging algorithm, 
(e) Autofluorescence spectrum at the region of interest at 390 nm excitation, (f) Reflectance ratio 
spectrum at the region of interest under white light illumination. 
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Fig. 59. Buccal site classified as True Negative by imaging (posterior probability = 0.25) and True 
Negative by spectroscopy (posterior probability = 0.06). Clinical impression: Normal. 
Histopathology: Hyperplastic squamous mucosa, (a) White light image, (b) Autofluorescence 
image at 405 nm excitation, (c) Region of interest circled; corresponds to location of point probe 
measurement, (d) Clinically normal region circled; used for normalization in imaging algorithm, 
(e) Autofluorescence spectrum at the region of interest at 390 nm excitation (fluorescence peak 
extends above scale shown), (f) Reflectance ratio spectrum at the region of interest under white 
light illumination. 
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Fig. 60. Lateral tongue site classified as True Positive by imaging (posterior probability = 0.998) 
and True Positive by spectroscopy (posterior probability = 0.97). Clinical impression: Cancer. 
Histopathology: Extensive carcinoma in situ, (a) White light image, (b) Autofluorescence image 
at 405 nm excitation, (c) Region of interest circled; corresponds to location of point probe 
measurement, (d) Clinically normal region circled; used for normalization in imaging algorithm, 
(e) Autofluorescence spectrum at the region of interest at 390 nm excitation, (f) Reflectance ratio 
spectrum at the region of interest under white light illumination. 
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Fig. 61. Ventral tongue site classified as True Positive by imaging (posterior probability = 0.65) 
and True Positive by spectroscopy (posterior probability = 0.97). Clinical impression: Cancer. 
Histopathology: Invasive squamous carcinoma, moderately differentiated, (a) White light image, 
(b) Autofluorescence image at 405 nm excitation, (c) Region of interest circled; corresponds to 
location of point probe measurement, (d) Clinically normal region circled; used for normalization 
in imaging algorithm, (e) Autofluorescence spectrum at the region of interest at 390 nm excitation, 
(f) Reflectance ratio spectrum at the region of interest under white light illumination. 
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Fig. 62. Lateral tongue site classified as True Positive by imaging (posterior probability = 0.88) 
and True Positive by spectroscopy (posterior probability = 0.995). Clinical impression: On margin 
between dysplasia and cancer. Histopathology: Mixed dysplasia and cancer, poorly differentiated, 
(a) White light image, (b) Autofluorescence image at 405 nm excitation, (c) Region of interest 
circled; corresponds to location of point probe measurement, (d) Clinically normal region circled; 
used for normalization in imaging algorithm, (e) Autofluorescence spectrum at the region of 
interest at 390 nm excitation, (f) Reflectance ratio spectrum at the region of interest under white 
light illumination. 
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Fig. 63. Lateral tongue site classified as True Positive by imaging (posterior probability = 0.59), 
but False Negative by spectroscopy (posterior probability = 0.30). Clinical impression: 
Erythroplasia. Histopathology: Moderate dysplasia, focal ulceration and chronic inflammation, (a) 
White light image, (b) Autofluorescence image at 405 nm excitation, (c) Region of interest 
circled; corresponds to location of point probe measurement, (d) Clinically normal region circled; 
used for normalization in imaging algorithm, (e) Autofluorescence spectrum at the region of 
interest at 390 nm excitation, (f) Reflectance ratio spectrum at the region of interest under white 
light illumination. 
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Fig. 64, Soft palate site classified as False Negative by imaging (posterior probability = 0.26), but 
True Positive by spectroscopy (posterior probability = 0.91). Clinical impression: Abnormal high 
risk. Histopathology: Focally ulcerated mucosa with dysplasia, (a) White light image, 
(b) Autofluorescence image at 405 nm excitation, (c) Region of interest circled; corresponds to 
location of point probe measurement, (d) Clinically normal region circled; used for normalization 
in imaging algorithm, (e) Autofluorescence spectrum at the region of interest at 390 nm excitation, 
(f) Reflectance ratio spectrum at the region of interest under white light illumination. 
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Fig. 65. Lateral tongue site (outside clinical border of lesion) classified as False Positive by 
imaging (posterior probability = 0.47) and False Positive by spectroscopy (posterior probability = 
0.99). Clinical impression: Normal. Histopathology: Hyperkeratosis, (a) White light image, 
(b) Autofluorescence image at 405 nm excitation, (c) Region of interest circled; corresponds to 
location of point probe measurement, (d) Clinically normal region circled; used for normalization 
in imaging algorithm, (e) Autofluorescence spectrum at the region of interest at 390 nm excitation, 
(f) Reflectance ratio spectrum at the region of interest under white light illumination. 
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Fig. 66. Lateral tongue site (outside clinical border of lesion) classified as False Positive by 
imaging (posterior probability = 0.38) and False Positive by spectroscopy (posterior probability = 
0.86). Clinical impression: Normal. Histopathology: Focal mild dysplasia (grouped with Normal 
in this analysis), (a) White light image, (b) Autofluorescence image at 405 nm excitation, (c) 
Region of interest circled; corresponds to location of point probe measurement, (d) Clinically 
normal region circled; used for normalization in imaging algorithm, (e) Autofluorescence 
spectrum at the region of interest at 390 nm excitation, (f) Reflectance ratio spectrum at the region 
of interest under white light illumination. 
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Figure 67 shows scatter plots of selected parameters that were used in diagnostic 
classification. The single parameter that was used in the widefield imaging classification 
algorithm, normalized red-to-green fluorescence intensity ratio at 405 nm excitation, is 
shown in Fig. 67 (top). Parameter #1 used in the spectroscopic classification algorithm, 
fluorescence intensity at 380 nm excitation and 472 nm emission (the parameter found to 
be most important for diagnosis), is shown in Fig. 67 (bottom). 
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Fig. 67. Top: Scatter plot of widefield imaging parameter: normalized red-to-green fluorescence 
intensity at 405 nm excitation. Bottom: Scatter plot of spectroscopy parameter #1: fluorescence 
intensity at 380 nm excitation and 472 nm emission. Sites are grouped by histopathology diagnosis. 
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Figure 68 shows scatter plots of the posterior probabilies generated by each 
independent diagnostic algorithm. Posterior probabilities generated by the widefield 
imaging algorithm alone appear in Fig. 68 (top). Using the fixed threshold established 
previously in the training set (0.3585, indicated by the horizontal line), widefield imaging 
alone has a sensitivity of 94% and a specificity of 54% in this data set for distinguishing 
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Fig. 68. Top: Scatter plot of posterior probabilities generated by the widefield imaging algorithm alone. 
With threshold previously established in the training set (0.3585), sensitivity = 94% and specificity = 
54% in this data set for distinguishing Normal from Mild Dysplasia-Cancer. Bottom: Scatter plot of 
posterior probabilities generated by the spectroscopy algorithm alone. With threshold previously 
established in the training set (0.5533), sensitivity = 91% and specificity = 69% in this data set for 
distinguishing Normal from Mild Dysplasia-Cancer. Sites are grouped by histopathology diagnosis. 
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Normal from Mild Dysplasia-Cancer. Posterior probabilities generated by the 
spectroscopy algorithm alone appear in Fig. 68 (bottom). Using the fixed threshold 
established previously in the training set (0.5533, indicated by the horizontal line), 
spectroscopy alone has a sensitivity of 91% and a specificity of 69% in this data set for 
distinguishing Normal from Mild Dysplasia-Cancer. 
Table 19 summarizes the diagnostic performance of expert clinical impression, 
imaging alone, spectroscopy alone, and various multimodal combinations of imaging and 
spectroscopy. The best multimodal diagnostic performance was obtained either by taking 
the mean of the posterior probabilities generated by imaging and spectroscopy, or by 
using the imaging posterior probability as the spectroscopy prior probability. Both 
methods gave a sensitivity of 94% and a specificity of 69%, which are essentially the 
sensitivity of the widefield imaging algorithm coupled with the specificity of the 
spectroscopy algorithm. This result matched the sensitivity of expert clinical impression 
(94%), but not its specificity (85%); the multimodal algorithm generated 4 false positives 
out of 13 normal sites, compared to 2 false positives for expert clinical impression. 
For purposes of comparison the classifier was retrained on the current data set 
using data from both imaging and spectroscopy, and the threshold was reoptimized. As 
indicated in Table 19, this is not considered a valid estimate of performance due to the 
risk of overtraining on a small joint data set; however, it gives an idea of the best possible 
performance that could ideally be obtained in this data set using the specified features. In 
this data set, the retrained classifier was the only method that produced diagnostic results 
that matched or exceeded the performance of expert clinical impression (sensitivity = 
91%, specificity = 92%). 
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Table 19. Diagnostic performance relative to histopathology. 
Method Threshold Sensitivity Specificity 
Expert clinical impression 
Widefield imaging alone 
Spectroscopy alone 
Maximum posterior probability 
Minimum posterior probability 
Mean posterior probability 
Imaging post prob as spectroscopy prior prob 
Two step, imaging followed by spectroscopy 
Retrain classifier on current data set 
(for comparison only; not considered a fair 
estimate of performance) 
N/A 
Established in training set 
Established in training set 
Maximum of 2 thresholds 
Minimum of 2 thresholds 
Mean of 2 thresholds 
Spectroscopy threshold 
Spectroscopy threshold 
94% 
94% 
91% 
100% 
85% 
94% 
94% 
85% 
85% 
54% 
69% 
62% 
69% 
69% 
69% 
69% 
Optimized in current data set 91% 92% 
9.4 Discussion 
Widefield autofluorescence imaging has a high sensitivity for detecting oral lesions, but 
may have difficulty in distinguishing precancer from benign lesions such as 
inflammation. The use of depth-sensitive optical spectroscopy in combination with 
widefield imaging provides the ability to target the epithelium (where early precancerous 
changes occur) and minimize the signal from the stroma (which is more affected by 
inflammation). This raises the possibility of a combined measurement procedure in 
which imaging is used to identify suspicious lesions and guide the placement of the probe 
for spectroscopic measurements. 
In the current data set of 46 sites, widefield imaging alone was found to have a 
sensitivity and specificity of 94% and 54%, respectively. This can be compared to the 
widefield imaging training set of 102 sites, in which a sensitivity and specificity of 96% 
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and 96%, respectively, were obtained (88). The lower specificity here is primarily due to 
the fact that the threshold established in the training set was used without modification. 
As an inspection of Figure 68 indicates, if the threshold were optimized in the current 
data set by increasing it from 0.3585 to 0.47, a sensitivity of 94% and a specificity of 
85% could be obtained. This hints at a pattern that may be characteristic of the widefield 
imaging approach: it provides valuable information with the potential for excellent 
diagnostic performance, but may be limited by the difficulty of establishing a reliable 
threshold for the identification of disease. 
In the current data set, spectroscopy was found to have a sensitivity and 
specificity of 91% and 69%), respectively. This can be compared to the spectroscopy 
training set of 191 sites, in which a sensitivity and specificity of 94% and 90%, 
respectively, were obtained. The lower specificity here is primarily due to the fact that 
the training set included both patients and healthy volunteers, while the current data set 
includes only patients. In the subset of the training set containing only sites in patients 
(70 sites), sensitivity and specificity were 94% and 63%, respectively, which represents 
similar performance to that observed in the current patient-only data set. 
The optimal methods of combining the imaging and spectroscopy results (mean 
posterior probability, and imaging posterior as spectroscopy prior probability) gave a 
sensitivity of 94% and a specificity of 69%. This indicates that an appropriate 
multimodal measurement approach can indeed achieve the high sensitivity of widefield 
imaging along with the improved specificity of depth-sensitive optical spectroscopy. 
However, in this data set multimodal diagnostic performance approached but did not 
match the performance of expert clinical impression. Interestingly, the two-step 
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procedure in which imaging was used to identify sites to be measured by spectroscopy 
did not perform as well as directly combining posterior probabilities from both methods 
for all sites. 
It is useful to compare how individual sites were classified by imaging and by 
spectroscopy. It can be seen from Figures 57 through 66 that the imaging algorithm tends 
to classify as positive sites that have significant red porphyrin fluorescence in the region 
of interest compared to the region used for normalization. For these sites in which red 
fluorescence is visible in the image, the spectroscopic data typically also display a red 
fluorescence peak around 635 nm. Regardless of the presence of porphyrin fluorescence, 
however, the spectroscopy algorithm tends to classify as positive sites that have low 
autofluorescence in the blue-green spectral region. 
Of the 33 positive sites in the data set, 28 were correctly classified by both 
imaging and spectroscopy; 3 were correctly classified by imaging but misclassified by 
spectroscopy; and 2 were correctly classified by spectroscopy but misclassified by 
imaging. Of the 13 negative sites in the data set, 7 were correctly classified by both 
imaging and spectroscopy; 2 were correctly classified by spectroscopy but misclassified 
by imaging; and 4 were misclassified by both imaging and spectroscopy. The four sites 
that were misclassified as false positive by both imaging and spectroscopy are of 
particular interest. These four sites included three sites with a normal clinical appearance 
that were located outside the margin of a clinically apparent lesion; and one site with an 
abnormal clinical appearance that was determined by histology to be squamous mucosa 
with a submucosal hemorrhage. It may be significant that none of these four false 
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positive sites was a completely unremarkable normal site; each was either near a clinical 
margin or had an unusual histology result. 
The effects of inflammation were not conclusive in this data set. For the 31 sites 
for which inflammation data were available, no clear relationship was observed between 
inflammation status and posterior probability. It is notable that the two sites that were 
false positive by imaging but true negative by spectroscopy both had mild/moderate 
inflammation; this suggests that depth-sensitive spectroscopy may be less sensitive than 
widefield imaging to the effects of inflammation, as anticipated. Of the four sites that 
were false positive by both imaging and spectroscopy, three had no inflammation and one 
had no data available regarding inflammation. 
Based on our experience with these multimodal measurements, several 
observations can be made about the use of widefield imaging and spectroscopy in the 
clinical setting. In general, widefield imaging can either be implemented in a mode in 
which the viewer makes direct observations and interprets them subjectively, or in a 
mode in which images are collected and analyzed quantitatively. Either way, the 
determination of the threshold for diagnosis of disease is critical. In the case of 
subjective observation, inter-observer variability, observer training, and reproducibility in 
making a diagnosis are of high importance. In the case of image collection for 
quantitative analysis, the selection of regions of interest and the consistency and quality 
of images are of high importance, especially given the difficulty in establishing a reliable 
fixed threshold value for identifying disease. In practice, the time required in a clinical 
setting to consistently collect high-quality images that are suitable for quantitative 
analysis should not be underestimated. On the other hand, point probe measurements 
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only interrogate a single site at a time, but they can be performed quite rapidly in a 
clinical setting. One key issue with point probe measurements is the problem of 
recording and identifying the location of measured sites; this can be quite challenging if 
more than a few sites are measured in a single subject. 
When combining data from imaging and spectroscopy, attention must be paid to 
registration of regions of interest within the widefield image and sites measured 
spectroscopically. It is helpful if the measurement procedure includes the collection of 
images of the probe placed on the measurement site. Comparisons with histopathology 
require careful selection of the appropriate gold standard; in some cases there may be one 
pathology diagnosis associated with a specific biopsy site (corresponding to a point 
measurement or a specific location in an image) and another pathology diagnosis 
associated with a resected tissue specimen (corresponding to a region of interest within 
an image) which contains the biopsy site. 
In summary, 46 sites in 29 oral cancer patients were measured using both 
widefield imaging and depth-sensitive optical spectroscopy. Diagnostic algorithms and 
thresholds previously established in the training sets were applied without modification. 
Widefield imaging was found to have a sensitivity and specificity of 94% and 54%, 
respectively. Spectroscopy was found to have a sensitivity and specificity of 91% and 
69%, respectively. Methods for combining the imaging and spectroscopy results were 
explored, and the optimum multimodal combination produced a sensitivity of 94% and a 
specificity of 69%. These results suggest that the overall performance of noninvasive 
optical diagnostic methods may be enhanced through the use of platforms that combine 
both imaging and spectroscopic modalities. 
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10. COMBINATION OF OPTICAL CONTRAST AGENTS AND SPECTROSCOPY 
FOR OPTICAL DIAGNOSIS OF ORAL PRECANCER6 
eK. J. Rosbach prepared and applied contrast agents as described in Materials and Methods. Contrast agent 
procedures, images of resected tissue and pathology results are courtesy of K. J. Rosbach. 
10.1 Introduction 
Molecular specific imaging has emerged as an important tool for early diagnosis of 
cancer. The identification and cataloguing of a variety of molecular biomarkers 
associated with carcinogenesis have led to the development of an array of targeted 
exogenous contrast agents for diagnostic imaging and research. The most widely used 
molecular imaging technique for cancer is positron emission tomography (PET) imaging 
1 ft 
using the contrast agent F-FDG (fluorodeoxyglucose), which is a routine procedure for 
staging and assessment of treatment response (136). Optical molecular specific imaging 
shows great promise as well, offering a potential combination of high spatial resolution, 
nonradioactive contrast agents, ease of synthesis, and topical application. 
While optical contrast agents are typically used in the context of imaging, optical 
spectroscopy can be a valuable asset for measuring and quantifying contrast agents in a 
clinical setting. When imaging instruments (either widefield or high spatial resolution) 
are used to image tissue to which contrast agents have been applied, some basic questions 
tend to arise: Is the contrast agent present at the site being imaged? How much is present 
relative to other nearby areas? If there are difficulties in obtaining images with suitable 
contrast, is it due to problems with contrast agent delivery or to problems with the 
imaging conditions? Did the contrast agent penetrate into the tissue, and how deeply? 
What are the spectral characteristics and the magnitude of the measured signal from the 
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contrast agent? What is the relative contribution to the measured signal from multiple 
contrast agents that may be present? 
These questions can all be addressed by depth-sensitive optical spectroscopy 
(DSOS). Point-probe spectroscopic measurements of contrast agents at tissue sites of 
interest, with spectra displayed in real time, can be used to rapidly characterize the 
distribution and effectiveness of contrast agent delivery. Spectroscopy can also be used 
with contrast agents as a multimodal diagnostic combination in its own right, with the 
advantages of high spectral resolution and high dynamic range to compensate for its lack 
of high spatial resolution. 
The purpose of this pilot study was to evaluate the diagnostic potential of DSOS 
in combination with exogenous contrast agents targeted for specific biomarkers of 
neoplastic progression. Freshly resected human oral tissue samples were obtained and 
contrast agents were applied topically. Spectroscopic measurements were performed 
before and after contrast agent application. 
Three exogenous contrast agents were used. The first was 2-(N-(7-nitrobenz-2-
oxa-l,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG), a fluorescent analog to 18F-FDG. 
2-NBDG preferentially accumulates in cells which have increased rates of glucose 
metabolism, including cancer cells which tend have high metabolic rates and to 
overexpress glucose transporters. 2-NBDG has a fluorescence excitation peak at 
approximately 475 nm and an emission peak at approximately 550 run. The second 
contrast agent was epidermal growth factor (EGF) conjugated to Alexa Fluor 647 dye. 
EGF-Alexa 647 targets the epidermal growth factor receptor (EGFR) which is 
overexpressed in many oral precancers and cancers. EGF-Alexa 647 has a fluorescence 
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excitation peak at approximately 650 nm and an emission peak at approximately 670 nm. 
The third contrast agent was proflavine, a vital stain that highlights changes in nuclear 
morphology. Proflavine has a fluorescence excitation peak at approximately 450 nm and 
an emission peak at approximately 505 nm. Histopathology was used as the diagnostic 
gold standard. 
10.2 Materials and methods 
2-NBDG (Invitrogen, Carlsbad, CA) was diluted to a concentration of 0.16 mM in sterile 
IX phosphate buffered saline (PBS). Purified human-derived recombinant EGF peptide 
(Calbiochem, San Diego, CA) was conjugated to AlexaFluor 647-carboxylic ester 
(Invitrogen, Carlsbad, CA). Excess free dye was removed by size exclusion 
chromatography followed by dialysis. The resulting EGF-Alexa 647 contrast agent was 
diluted to a final concentration of 0.025 mg/mL in sterile IX PBS with 10% dimethyl 
sulfoxide (DMSO) as a permeation enhancer. A 0.01% solution of proflavine was 
produced by dissolving proflavine hydrochloride (Sigma, St. Louis, MO) in IX PBS. 
Freshly resected specimens of human oral tissue were obtained from patients 
undergoing surgery at M. D. Anderson Cancer Center. Written informed consent was 
obtained from all participants in the study. Tissue specimens were obtained immediately 
following surgical resection. Contrast agents were applied and specimens were imaged 
(imaging results are not reported here) and measured spectroscopically. The 
spectroscopy device described in Chapter 4 was used. Measurement and data processing 
procedures were as described in Chapter 4, except that only shallow and medium depth 
channels of the probe were used and excitation wavelengths were 430 nm, 470 nm, and 
615 nm. 
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Excitation wavelengths selected to interrogate each contrast agent were as 
follows: 470 nm excitation to interrogate 2-NBDG; 615 nm excitation to interrogate 
EGF-Alexa 647; and 430 nm excitation to interrogate proflavine. Two measurements 
were performed at each site for each excitation wavelength. Baseline (precontraast) 
autofluorescence measurements were taken at selected sites prior to the application of 
contrast agents, using 470 nm excitation, 615 nm excitation, and 430 nm excitation. 
After precontrast autofluorescence measurements, 2-NBDG solution was topically 
applied to the epithelial surface of the resected oral tissue and placed in an incubator set 
at 37 °C for 20 minutes. Following incubation with 2-NBDG, the tissue was briefly 
washed in sterile IX PBS to remove any excess unbound contrast agent. The tissue was 
measured at the same sites using all excitation wavelengths. Next, EGF-Alexa 647 in 
10% DMSO was topically applied to the epithelial surface of the tissue and incubated for 
20 minutes at 37 °C. The tissue was briefly washed with sterile IX PBS and measured 
using all excitation wavelengths. Finally, proflavine was topically applied for 10 
seconds, washed, and measured at the same sites. 
After measurements were completed, the tissue specimen was returned to the 
Pathology Department at M. D. Anderson Cancer Center and processed following 
standard procedures (sliced and placed into cassettes for H&E staining). Slicing was 
monitored and the portion of the tissue that was placed into each cassette was recorded to 
allow for correlation to pathology. Neither 2-NBDG, EGF-Alexa 647, nor proflavine 
affects histopathology processing or staining. 
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10.3 Results 
During the 10-month period from April 2008 to January 2009, multimodal measurements 
using contrast agents in combination with the depth-sensitive optical spectroscopy device 
were performed at 80 distinct sites in resected tissue specimens from 18 patients. Data 
from three patients were excluded from the analysis because histopathology results were 
unavailable. The final data set for combined analysis consisted of 64 distinct sites in 
resected tissue specimens from 15 patients. 
Table 20. Histopathology Diagnosis of Sites in the Contrast Agent/Spectroscopy Data Set 
Histopathology diagnosis Number of sites 
Normal / benign 
Mild dysplasia 
Moderate or severe dysplasia 
Cancer 
Total 
23 
11 
13 
17 
64 
Table 20 shows the histopathology result recorded for each of the 64 sites in the 
data set. According to histopathology (the gold standard), 23 sites were negative for 
disease (Normal/Benign), 11 sites 
contained Mild Dysplasia, 13 sites 
contained Moderate or Severe 
Dysplasia, and 17 sites contained 
Cancer. Of the 15 resected 
specimens, 4 were from the tongue; 
4 from tongue/floor of mouth; 1 
Fig. 69. Example of a resected specimen measured in the 
study (lateral tongue, 2.1 x 2.1 x 0.7 cm in size). 
154 
from floor of mouth; 1 from buccal mucosa/retromolar trigone/maxillary gingiva; 1 from 
mandible/pharynx/tongue; 1 from mandible/buccal mucosa/lip; 1 from gingiva/lip; 1 
from palate/buccal mucosa; and 1 from retromolar trigone/mandible. Figure 69 shows a 
photograph of a typical resected specimen measured in the study (lateral tongue, 2.1 cm x 
2.1 cm x 0.7 cm in size). 
Figure 70 shows typical 
spectra measured in sequence to 
interrogate each contrast agent. 
Figure 70a shows 470 nm 
excitation: precontrast and post 2-
NBDG application. Figure 70b 
shows 615 nm excitation: 
precontrast, post 2-NBDG 
application, and post-EGF-Alexa 
647 application. Figure 70c shows 
430 nm excitation: precontrast, 
post 2-NBDG application, post-
EGF-Alexa 647 application, and 
post-proflavine application. The 
spectra for 470 nm excitation and 
615 nm excitation are cut off on the 
left (at 498 nm and 665 nm, 
respectively) due to longpass 
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Fig. 70. Sample spectra measured in sequence to 
interrogate (a) NBDG at 470 nm excitation; (b) EGF at 615 
nm excitation; and (c) proflavine at 430 nm excitation. 
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emission filters; in the case of 615 nm excitation, only a narrow region of the emission 
spectrum from 665-680 nm is sampled. 
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Fig. 71. Complete set of spectra measured from a single site (same site as in Fig. 2): (a) 430 nm 
excitation, shallow channel; (b) 430 nm excitation, medium channel; (c) 470 nm excitation, shallow 
channel; (d) 470 nm excitation, medium channel; (e) 615 nm excitation, shallow channel; (f) 615 nm 
excitation, medium channel. 
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Figure 71 shows an example of a complete set of spectra collected from a single 
site. Measurements at 430 nm, 470 nm, and 615 nm excitation are shown for precontrast, 
post-2-NBDG, post-EGF-Alexa 647, and post-proflavine conditions. Twelve specific 
spectral features were selected for further analysis, as shown in Table 21. 
Table 21. Spectral Features Selected for Analysis of Contrast Agent/Spectroscopy Data 
Feature # 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Feature Description 
Precontrast, Shallow Depth 
Precontrast, Medium Depth 
Post NBDG - Precontrast, Shallow Depth 
Post NBDG - Precontrast, Medium Depth 
Post EGF - Precontrast, Shallow Depth 
Post EGF - Precontrast, Medium Depth 
Post Proflavine - Precontrast, Shallow Depth 
Post Proflavine - Precontrast, Medium Depth 
Post EGF - Post NBDG, Shallow Depth 
Post EGF - Post NBDG, Medium Depth 
Post Proflavine - Post EGF, Shallow Depth 
Post Proflavine - Post EGF, Medium Depth 
Excitation /Emission 
430nm/490nm 
430nm/490nm 
470 nm / 545 nm 
470 nm / 545 nm 
615 run/672 nm 
615 nm/672 nm 
430 nm / 505 nm 
430nm/505nm 
615 nm/672 nm 
615 nm/672 nm 
430nm/505nm 
430 nm / 505 nm 
Features #1-2 in Table 21 represent the precontrast fluorescence intensity. 
Features #3-8 are the difference between the fluorescence intensity following application 
of the contrast agent and the precontrast fluorescence intensity. Features #9-12 are the 
difference between the fluorescence intensity following application of the contrast agent 
of interest and the fluorescence intensity prior to application of that contrast agent. In 
cases in which two successive measurements were taken at the same site in identical 
conditions, the intensity values were averaged. 
The twelve features in Table 21 were examined to determine whether they varied 
with the disease state of the tissue. Figures 72-83 show box and whisker plots of the 
twelve features as a function of histopathology diagnosis of the site measured. 
Precontrast, 430ex/490em, Shal 
3f ' ' I 
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Fig. 72. Precontrast fluorescence intensity vs. histopathology diagnosis. Excitation 
430 nm; emission 490 nm; shallow depth channel. 
Precontrast, 430ex/490em, Med 
Normal Mild Dysp Mod/Sev Dysp Cancer 
Fig. 73. Precontrast fluorescence intensity vs. histopathology diagnosis. Excitation 
430 nm; emission 490 nm; medium depth channel. 
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Fig. 74. Post NBDG - Precontrast fluorescence intensity vs. histopathology 
diagnosis. Excitation 470 nm; emission 545 nm; shallow depth channel. 
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Fig. 75. Post NBDG - Precontrast fluorescence intensity vs. histopathology 
diagnosis. Excitation 470 nm; emission 545 nm; medium depth channel. 
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Fig. 76. Post EGF - Precontrast fluorescence intensity vs. histopathology diagnosis. 
Excitation 615 nm; emission 672 nm; shallow depth channel. 
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Fig. 77. Post EGF - Precontrast fluorescence intensity vs. histopathology diagnosis. 
Excitation 615 nm; emission 672 nm; medium depth channel. 
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Fig. 78. Post proflavine - Precontrast fluorescence intensity vs. histopathology 
diagnosis. Excitation 430 nm; emission 505 nm; shallow depth channel. 
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Fig. 79. Post proflavine - Precontrast fluorescence intensity vs. histopathology 
diagnosis. Excitation 430 nm; emission 505 nm; medium depth channel. 
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Fig. 80. Post EGF - Post NBDG fluorescence intensity vs. histopathology diagnosis. 
Excitation 615 nm; emission 672 nm; shallow depth channel. 
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Fig. 81. Post EGF - Post NBDG fluorescence intensity vs. histopathology diagnosis. 
Excitation 615 nm; emission 672 nm; medium depth channel. 
Post Proflavine - Post EGF, 430ex/505em, Shal 
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Fig. 82. Post proflavine - Post EGF fluorescence intensity vs. histopathology 
diagnosis. Excitation 430 nm; emission 505 nm; shallow depth channel. 
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Normal Mild Dysp Mod/SevDysp Cancer 
Fig. 83. Post proflavine - Post EGF fluorescence intensity vs. histopathology 
diagnosis. Excitation 430 nm; emission 505 nm; medium depth channel. 
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In the box and whisker plots, notches do not overlap if the median values are 
statistically different at the 5% significance level. The plots suggest that 2-NBDG and 
EGF-Alexa 647 do provide significantly improved contrast between healthy tissue and 
neoplastic tissue, as measured using depth-sensitive optical spectroscopy. This trend is 
not seen in the precontrast data or the proflavine data. 
10.4 Discussion 
As Figures 70 and 71 indicate, optical spectroscopy provides a useful and rapid way to 
track the presence and relative intensity contributions of different contrast agents that are 
applied to tissue. The spectral resolution, dynamic range, and quantitative nature of this 
method provide information that may not be immediately apparent in widefield or high 
resolution images of the same tissue regions. Spectroscopy can therefore be a useful tool 
for guiding and monitoring the use of contrast agents for molecular imaging. 
The combined use of depth-sensitive optical spectroscopy and contrast agents for 
direct diagnostic purposes shows considerable potential. Both 2-NBDG and EGF-Alexa 
647 produced greater increases in fluorescence intensity in neoplastic tissue than in 
healthy tissue when applied to resected oral specimens, due to overexpression of glucose 
transporters and epidermal growth factor receptor, respectively, in the diseased tissue. 
Proflavine, on the other hand, increased the overall fluorescence intensity, but had a 
similar effect in both neoplastic tissue and healthy tissue. This may be because 
proflavine is not targeted to a specific biomarker that is overexpressed in neoplastic 
tissue, but is rather used highlight changes in nuclear structure that are detectable using 
high-resolution imaging. 
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This pilot study demonstrated the diagnostic potential of depth-sensitive optical 
spectroscopy in combination with molecular specific contrast agents. Spectroscopy 
provides a useful way to rapidly and effectively track the presence of multiple contrast 
agents applied to tissue specimens. The use of this multimodal technique in vivo will be 
of great interest in future work. 
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11. CONCLUSION 
In summary, a series of clinical studies were performed to evaluate the performance of 
depth-sensitive optical spectroscopy (DSOS), alone and in combination with other 
techniques, for noninvasive in vivo diagnosis of oral neoplasia. A study of DSOS in 124 
subjects resulted in sensitivity and specificity values of 94% and 90% in the training set 
for nonkeratinized tissue, 82% and 87% in the validation set for nonkeratinized tissue, 
and 79% and 80% in the cross-validation set for keratinized tissue. A followup study in 
33 subjects using a limited set of excitation wavelengths resulted in sensitivity and 
specificity values of 91% and 89% in a second validation set for nonkeratinized tissue 
and 67% and 75% for keratinized tissue. Based on the diagnostic algorithms and results 
from these studies, a compact, portable DSOS device was constructed to provide rapid, 
automated diagnostic capability in real time. A clinical study of the portable DSOS 
device in 47 subjects resulted in sensitivity and specificity values of 82% and 83% in 
nonkeratinized tissue and 80% and 65% in keratinized tissue. In a separate pilot study of 
29 subjects, the combination of DSOS with widefield imaging was explored. The 
combination of the two methods performed slightly better than each method alone, 
resulting in a sensitivity of 94% and specificity of 69%. Finally, in a pilot study of 
resected specimens from 15 subjects, the use of DSOS in combination with molecular 
targeted contrast agents was investigated. Improved contrast between healthy and 
abnormal tissue was observed using DSOS in combination with 2-NBDG and EGF-Alexa 
647, and spectroscopy was found to be a useful tool for guiding and monitoring the use of 
contrast agents in molecular imaging. 
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The results reported here confirm that DSOS can be a useful tool for noninvasive 
evaluation of oral lesions. Based on the diagnostic results achieved to date, its most 
immediate utility is for evaluating nonkeratinized oral sites in a patient population with a 
relatively high prevalence of disease. In such a clinical setting DSOS is a rapid, simple 
measurement technique that can be used by the clinician to help characterize oral lesions, 
determine their extent, and determine optimal sites for biopsy. Challenges that remain 
for implementation of DSOS in a more general screening setting include improving 
specificity in keratinized tissue and improving specificity in certain types of benign oral 
lesions, particularly those with ulceration or thick superficial keratinization. These 
challenges are most likely to be effectively addressed through the use of multimodal 
diagnostic methods that incorporate DSOS and other diagnostic approaches such as 
widefield imaging, molecular targeted contrast agents, and high resolution imaging. 
Based on this series of clinical studies, two general observations can be made 
regarding the clinical utility of DSOS (and point probe spectroscopy in general). First, a 
drawback of DSOS is that the spectra and quantitative diagnostic information it produces 
are not as visually compelling and immediately recognizable as images of tissue. 
However, reliable quantitative information, particularly regarding absolute intensity 
levels, is often exactly what is missing from imaging data. In the limited time available 
in the clinical setting, imaging methods (whether widefield or high resolution) must 
necessarily concentrate on obtaining proper focus, appropriate alignment, and suitable 
detected intensity levels from the desired region of interest. Manipulating the instrument 
and the patient to achieve the ideal imaging configuration can be a time-consuming 
process, and variations in imaging orientation and lighting can make it difficult to 
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maintain quantitative standards. By contrast, a point probe can be rapidly placed on a site 
and quantitatively meaningful data can be collected with minimal preparation and 
minimal concerns regarding orientation and lighting. For this reason it makes sense to 
pair spectroscopy and imaging methods. 
Second, the capability to provide real-time information in the clinical setting is 
extremely important, not only for the clinician but also for the development of the 
diagnostic method itself. The implementation of real-time display and diagnostic 
software in the portable DSOS system changed the nature of these clinical studies, 
enabling the clinician to measure different types of sites and margins in real time, see the 
results almost immediately, and develop a sense of the response characteristics of the 
automated system. This information was highly valuable in instrumentation 
development, algorithm adjustment, and interpretation of results. The next important step 
in the development of the portable DSOS system will be to make the measurement and 
display "live", eliminating the brief delay of 5-8 seconds between the measurement and 
the display of results. It is also possible to envision redesigning the probe tip to be 
smoothly curved so that it slides gently across the tissue surface, enabling the clinician to 
perform measurements across margins by sliding the probe along the surface and 
observing the changes in the spectra in real time. 
A standard model in multimodal optical diagnostics is the use of widefield 
imaging to identify specific regions of interest, which are then interrogated using a high 
resolution probe (either a high spatial resolution imaging probe or a high spectral 
resolution spectroscopy probe). The experience gained in these clinical studies suggests 
a different possible multimodal combination: the use of a "live", real-time DSOS point 
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probe to assist the clinician in identifying specific regions of interest, which are then 
interrogated by a high resolution imaging probe. DSOS and high resolution imaging 
could both be implemented using a single common probe, and the combined system 
could easily be made compact and portable with an integrated user interface and display. 
Implementation of this multimodal combination of depth-sensitive optical spectroscopy 
and high resolution imaging is one very promising future direction in the further 
development of noninvasive optical techniques for diagnosis of oral neoplasia. 
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13. APPENDIX 
This Appendix contains additional plots of the data set described in Chapter 5 
(clinical study of depth-sensitive optical spectroscopy in 124 subjects). 
Figures A-l through A-18 show average measured spectra for all excitation 
wavelengths and all depth channels, broken down by gold standard diagnosis (normal, 
mild dysplasia, moderate/severe dysplasia, or cancer) and by tissue type (nonkeratinized 
or keratinized). 
Figures A-19 through A-24 show plots of posterior probability vs. parameter 
value for each parameter in the classification algorithm for nonkeratinized tissue 
developed in Chapter 5. In each plot, only the parameter of interest is varied while the 
other five parameters are held at a neutral value that does not affect the posterior 
probability. Prior probability is set to 0.50. 
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Fig. A-l. Average fluorescence spectra, nonkeratinized sites, shallow depth channel, excitation 
wavelengths 300, 310, 330, 350, 370, 380 nm; broken down by diagnosis (Normal, Mild Dysplasia, 
Moderate/Severe Dysplasia, Cancer). Numbers in parentheses indicate number of measurements 
represented in the average. Data set is from Chapter 5. The slight ripple in the 380ex spectra is an 
artifact due to filter leakage. 
183 
2.5 
2 
1.5 
1 
0.5 
K IO* Nonker Shallow 390ex 
/ ^ \ \ 
/ / \ \ 
/ \ \ 
^ /'N \ \ 
f/VS\ \ 
X^x ^ 1 % ^ ^ ^ > 
Nonker Shallow 400ex 
500 550 600 
Wavelength (nm) 
Nonker Shallow 450ex 
^ 8000 
Norm (281) 
MiDy (37) 
— — Mo/SvOy(29) 
^ ^ ™ Cancer (61) 2 
1,5 
(co
un
t 
* 
500 550 GOO 650 
Wavelength (nm) 
Nonker Shallow 410ex 
/ ,-^^ \ 
' / \ \ 
7 \ \ 
/ ^ \ \ 
/ ^ ^ < > x \ 
r ^ c \ 
^ f c \ \ 
* " » « 
-Norm (281) 
- MiDy (37) 
i Mo/S\Oy (29) 
• Cancer (61) 
-Norm (281) 
- MIDy (37) 
Mo/SvOy (29) 
• Cancer (61) 
/^"A 1
 \ \ 
KZZ>^ x \ y 1 ^ ^ x \ 
' x ^ \ \ 
^ & ^^v ^ ^ f c ^ N 
^ " O 
-Norm (281) 
-MiDy (37) 
Mo/S\Oy(29) 
• Cancer (61) 
500 550 600 
Wavelength (nm) 
Nonker Shallow 430ex 
-Norm (281) 
- MiDy (37) 
' Mo/SvOy (29) 
•Cancer (61) 
550 600 
Wavelength (nm) 
Nonker Shallow 470ex 
8000 
7000 
6000 
1 5000 
J. 4000 
| 3000 
2000 
1000 
/ 
( 
+*~ 
r 
^ \ 
\ \ \ \ \ \ \ 
**v \ \ 
—-^  V x \ 
^*vN,\\ 
^^£> V \ ' 
^ * ^ 
-Norm (281) 
- MiDy (37) 
MolSvOy (29) 
•Cancer (61) 
550 600 
Wavelength (nm) 
550 600 
Wavelength (nm) 
Fig. A-2. Average fluorescence spectra, nonkeratinized sites, shallow depth channel, excitation 
wavelengths 390, 400, 410, 430, 450, 470 nm; broken down by diagnosis (Normal, Mild Dysplasia, 
Moderate/Severe Dysplasia, Cancer). Numbers in parentheses indicate number of measurements 
represented in the average. Data set is from Chapter 5. 
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Fig. A-3. Average fluorescence spectra, nonkeratinized sites, medium depth channel, excitation 
wavelengths 300, 310, 330, 350, 370, 380 nm; broken down by diagnosis (Normal, Mild Dysplasia, 
Moderate/Severe Dysplasia, Cancer). Numbers in parentheses indicate number of measurements 
represented in the average. Data set is from Chapter 5. The slight ripple in the 380ex spectra is an 
artifact due to filter leakage. 
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Fig. A-4. Average fluorescence spectra, nonkeratinized sites, medium depth channel, excitation 
wavelengths 390, 400, 410, 430, 450, 470 nm; broken down by diagnosis (Normal, Mild Dysplasia, 
Moderate/Severe Dysplasia, Cancer). Numbers in parentheses indicate number of measurements 
represented in the average. Data set is from Chapter 5. 
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Fig. A-5. Average fluorescence spectra, nonkeratinized sites, deep channel #1, excitation 
wavelengths 300, 310, 330, 350, 370, 380 nm; broken down by diagnosis (Normal, Mild Dysplasia, 
Moderate/Severe Dysplasia, Cancer). Numbers in parentheses indicate number of measurements 
represented in the average. Data set is from Chapter 5. The slight ripple in the 380ex spectra is an 
artifact due to filter leakage. 
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Fig. A-6. Average fluorescence spectra, nonkeratinized sites, deep channel #1, excitation 
wavelengths 390, 400, 410, 430, 450, 470 nm; broken down by diagnosis (Normal, Mild Dysplasia, 
Moderate/Severe Dysplasia, Cancer). Numbers in parentheses indicate number of measurements 
represented in the average. Data set is from Chapter 5. 
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Fig. A-7. Average fluorescence spectra, nonkeratinized sites, deep channel #2, excitation 
wavelengths 300, 310, 330, 350, 370, 380 nm; broken down by diagnosis (Normal, Mild Dysplasia, 
Moderate/Severe Dysplasia, Cancer). Numbers in parentheses indicate number of measurements 
represented in the average. Data set is from Chapter 5. The slight ripple in the 380ex spectra is an 
artifact due to filter leakage. 
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Fig. A-8. Average fluorescence spectra, nonkeratinized sites, deep channel #2, excitation 
wavelengths 390, 400, 410, 430, 450, 470 nm; broken down by diagnosis (Normal, Mild Dysplasia, 
Moderate/Severe Dysplasia, Cancer). Numbers in parentheses indicate number of measurements 
represented in the average. Data set is from Chapter 5. 
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Fig. A-10. Average fluorescence spectra, keratinized sites, shallow depth channel, excitation 
wavelengths 300, 310, 330, 350, 370, 380 nm; broken down by diagnosis (Normal, Mild Dysplasia, 
Moderate/Severe Dysplasia, Cancer). Numbers in parentheses indicate number of measurements 
represented in the average. Data set is from Chapter 5. The slight ripple in the 380ex spectra is an 
artifact due to filter leakage. 
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Fig. A-ll . Average fluorescence spectra, keratinized sites, shallow depth channel, excitation 
wavelengths 390, 400, 410, 430, 450, 470 nm; broken down by diagnosis (Normal, Mild Dysplasia, 
Moderate/Severe Dysplasia, Cancer). Numbers in parentheses indicate number of measurements 
represented in the average. Data set is from Chapter 5. 
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Fig. A-14. Average fluorescence spectra, keratinized sites, deep channel #1, excitation wavelengths 
300, 310, 330, 350, 370, 380 nm; broken down by diagnosis (Normal, Mild Dysplasia, 
Moderate/Severe Dysplasia, Cancer). Numbers in parentheses indicate number of measurements 
represented in the average. Data set is from Chapter 5. The slight ripple in the 380ex spectra is an 
artifact due to filter leakage. 
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Fig. A-15. Average fluorescence spectra, keratinized sites, deep channel #1, excitation wavelengths 
390, 400, 410, 430, 450, 470 nm; broken down by diagnosis (Normal, Mild Dysplasia, 
Moderate/Severe Dysplasia, Cancer). Numbers in parentheses indicate number of measurements 
represented in the average. Data set is from Chapter 5. 
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Fig. A-16. Average fluorescence spectra, keratinized sites, deep channel #2, excitation wavelengths 
300, 310, 330, 350, 370, 380 nm; broken down by diagnosis (Normal, Mild Dysplasia, 
Moderate/Severe Dysplasia, Cancer). Numbers in parentheses indicate number of measurements 
represented in the average. Data set is from Chapter 5. The slight ripple in the 380ex spectra is an 
artifact due to filter leakage. 
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Fig. A-18. Average reflectance spectra (Tissue/Teflon), keratinized sites, broken down by depth 
channel and by diagnosis (Normal, Mild Dysplasia, Moderate/Severe Dysplasia, Cancer). Numbers 
in parentheses indicate number of measurements represented in the average. Data set is from 
Chapter 5. 
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Fig. A-23. Posterior probability vs. parameter #5 (Fluor 380ex 478em/458em ratio, medium depth) 
in the classification algorithm for nonkeratinized tissue. All other parameters are held at a neutral 
value. Prior probability is set to 0.50. Parameters are listed in Table 4, Chapter 5. 
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Fig. A-24. Posterior probability vs. parameter #6 (Refl 420 intensity, shallow depth) in the 
classification algorithm for nonkeratinized tissue. All other parameters are held at a neutral value. 
Prior probability is set to 0.50. Parameters are listed in Table 4, Chapter 5. 
